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 Summary 
Background: Cardiovascular disease (CVD) remains a significant cause of mortality globally, with a 
reduction in free sugars consumption a public health target for decreasing disease burden. 
Fructose raises post-prandial triacylglycerol (TAG) concentrations (risk factor for CVD), relative to 
glucose or sucrose, possibly due disrupted intestinal TAG metabolism.        
Aims: Determine whether effects of high-fructose consumption on plasma TAG concentration are 
explained by intestinal and/or hepatic TAG lipoprotein kinetics, as well as de novo lipogenesis 
(DNL), in humans and an in vitro model. 
Methods: Five overweight males consumed drinks containing 30% energy as fructose or complex 
carbohydrate hourly for 11h on two separate occasions, in a randomised cross-over design (4 
week washout). Stable isotopes were given to measure DNL, chylomicron (CM)-TAG and VLDL-TAG 
kinetics. CM and VLDL were separated according to their apolipoprotein B (apoB) content (Sf>20 
fraction). Caco-2 cells were treated (96h) with different fructose and glucose concentrations, or a 
mixture of sugars (“Mix”), and stable isotopes tracers ([13C6]-fructose; [13C6]-glucose). TAG 
enrichments were measured by gas chromatography-mass spectrometry. 
Results: Fructose consumption in comparison to the complex CHO had no effect on either 
intestinal or hepatic DNL. Intestinal and hepatic DNL were correlated in the fasted (P<0.0001) and 
fed state (P≤0.004). Plasma TAG (P<0.005) and VLDL-TAG (P=0.003) were greater, and CM-TAG 
production rate (PR, P=0.046) and fractional catabolic rate (FCR, P=0.073) lower, when fructose 
was consumed, with no differences in VLDL-TAG kinetics. Insulin was lower (P=0.005) and apoB48 
(P=0.039), apoB100 (P=0.013) and plasma NEFA (P=0.013) higher in response to fructose. Caco-2 
cells utilised fructose and glucose for TAG-palmitate and TAG-glycerol synthesis dose-dependently, 
with more palmitate derived from glucose after “Mix” treatment (P<0.05). 
Conclusions: Fructose increased post-prandial TAG concentrations, possibly due to less insulin-
mediated lipoprotein metabolism. DNL was unaffected by fructose consumption. This study 
supports public strategies to restrict dietary free sugars.  
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Chapter 1 Introduction 
1.1 Free sugars and cardiometabolic health 
Reducing the amount of free sugars consumed in the diet has become a key public health 
target, both within the UK and internationally. The consumption of a high proportion of 
dietary calories as free sugars is attributed to an increased risk of obesity (weight gain), as well 
as type 2 diabetes mellitus (Prentice 2015). Excess free sugars in the diet may also promote 
dyslipidaemia (e.g. raised triacylglycerol [TAG] and low-density lipoprotein [LDL] cholesterol 
concentrations), which increases the risk of cardiovascular disease (see section 1.2.10) 
(Stanhope 2016). Concerns regarding the deleterious health effects of free sugars have 
prompted the UK Scientific Advisory Committee on Nutrition to recommend that no more 
than 5 % of dietary energy is obtained from free sugars (Prentice 2015). This guideline is also 
reflected in the World Health Organization’s advice to reduce free sugar intake to less than 10 
% of dietary energy, with recognition of additional potential benefits if further reduced to 
below 5 % of energy (WHO 2015). 
Fructose has gained particular attention in relation to free sugars, with some evidence that it 
exacerbates fasting and post-prandial TAG concentrations in comparison to glucose (Bantle et 
al. 2000, Teff et al. 2004, Teff et al. 2009, Silbernagel et al. 2011). This specific effect of fructose 
is thought to arise from its differential metabolism, relative to glucose (see section 1.5), which 
may favour the synthesis of new fatty acids via de novo lipogenesis (Taskinen et al. 2017, 
Beysen et al. 2018). While there is currently controversy as to whether these effects of 
fructose may be due to the provision of excess dietary calories (Tappy et al. 2010), the existing 
evidence has highlighted the need for a greater understanding of the potential mechanisms 
by which fructose may augment plasma TAG levels.      
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1.2 Triacylglycerol metabolism 
1.2.1 Triacylglycerol (TAG) structure 
Approximately 95% of the lipid in the human diet is in the form of triacylglycerol (TAG), as well 
as phospholipid (PL: ~4.5%) and cholesterol ester (CE: ~0.5%) (Wang et al. 2013). Each TAG 
molecule is composed of a glycerol ‘backbone’ (Figure 1.1), esterified to three fatty acids (FA) 
which may be saturated or unsaturated, and vary in their length. Therefore, the structure of 
individual TAG molecules may vary widely according to the composition and distribution of FA 
at each stereospecific position (sn-1 to sn-3). However, the source of TAG may largely 
determine its structure. For example, TAG molecules from the adipose (fat) tissue of animals 
typically have a saturated fatty acid (SFA) at the sn-1 position and an unsaturated fatty acid 
(UFA) at the sn-2 position, with the sn-3 position being more variable (Karupaiah et al. 2007).         
 
 
Figure 1.1. Generalised structure of a triacylglycerol (TAG) molecule. 
Fatty acyl chains (denoted R1, R2, R3) vary in their length and degree of desaturation at each of the 
three stereospecific positions (sn-1, sn-2, sn-3) of glycerol.  
 
 
1.2.2 TAG digestion and absorption 
Figure 1.2 summarises the digestion and absorption of dietary TAG, its re-esterification within 
intestinal enterocytes and export into the circulation via the lymphatic system within 
chylomicron (CM) lipoprotein particles. Digestion begins in the mouth, where the enzyme 
lingual lipase initiates hydrolysis of TAG to yield free fatty acids (FFA) and diacylglycerol (DAG) 
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(Kulkarni et al. 2014). On entering the stomach, both gastric and lingual lipases continue TAG 
hydrolysis, as well as mechanical emulsification. In the small intestine, liver-derived bile acids 
emulsify lipids to form small mixed micelles 4-8 nm in diameter. Pancreatic lipase, in the 
presence of a colipase activator, digests TAG and DAG to form 2-monoacylglycerol (2-MAG), 
FFA and glycerol.  
MAG and FFA are absorbed across the brush border membrane of enterocyte cells of the 
intestine via passive diffusion when lumenal concentrations are high. Absorption can also 
occur against a concentration gradient, which is mediated by several classes of protein. These 
include plasma membrane fatty acid transport protein (FABPpm), which may couple uptake 
to FA oxidation, as well as fatty acid transport proteins (FATPs) and cluster determinant 36 
(CD36), which is thought to act in the proximal small intestine as a high-affinity receptor and 
transporter for long chain FA (LCFA) (Pan et al. 2012).   
 
 
Figure 1.2. Summary of the digestion, absorption and re-synthesis of dietary triacylglycerol (TAG). 
Dietary TAG is digested by lipase enzymes to yield 2-monoacylglycerol (2-MAG) and free fatty acids 
(FFA), which are absorbed across the intestinal epithelium. Within enterocyte cells, most TAG (80 %) 
is re-synthesised from 2-MAG and FFA via the action of acyl coenzyme A:monoacylglycerol 
acyltransferase (MGAT) and acyl coenzyme A:diacylglycerol acyltransferase (DGAT), with a smaller 
amount produced by the slower glycerol-3-phosphate (G-3-P) pathway. Re-synthesised TAG is 
packaged into chylomicron particles by microsomal triglyceride transfer protein (MTP), which then 
enter the circulation via the lymphatic system. 
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Once absorbed into enterocytes, FFA and MAG are directed to the endoplasmic reticulum (ER) 
and used to re-synthesise TAG via two routes: the glycerol-3-phosphate (G-3-P) and 2-
monoacylglycerol (2-MAG) pathways (Figure 1.3). Data obtained from humans and animals 
indicated that approximately 80 % of TAG re-synthesis within human enterocytes occurs via 
the 2-MAG pathway (Clark et al. 1961, Fred et al. 1965, Kayden et al. 1967). Dietary 2-MAG 
and FFA are utilised to produce DAG, and subsequently TAG, via the sequential actions of the 
enzymes acyl coenzyme A:monoacylglycerol acyltransferase (MGAT) and acyl coenzyme 
A:diacylglycerol acyltransferase (DGAT) (Yen et al. 2015). The G-3-P pathway is present in most 
cell types and is the predominant route for TAG synthesis in the liver. This is a slower process 
producing DAG from glucose (providing G-3-P) and FFA, which is further metabolised to TAG 
by DGAT (Pan et al. 2012). The final step of TAG synthesis for both pathways converges on the 
action of DGAT (Yen et al. 2008). 
 
 
Figure 1.3. The glycerol-3-phosphate (G-3-P) and 2-monoacylglycerol (2-MAG) pathways of TAG 
synthesis. 
The faster 2-MAG pathway predominates in the small intestine, whereas the G-3-P pathway is the 
main route for hepatic TAG synthesis. The two pathways converge at diacylglycerol before the final 
step is catalysed by acyl coenzyme A:diacylglycerol acyltransferase (DGAT). AGPAT, 1-acyl-sn-
glycerol-3-phosphate acyltransferase (AGPAT); FA-CoA, fatty acyl coenzyme A; GPAT, glycerol-3-
phosphate acyltransferase; MGAT, acyl coenzyme A:monoacylglycerol acyltransferase; PAP, 
phosphatidate phosphohydrolase.     
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Re-synthesised TAG may be either transiently stored in intracellular lipid droplets (LDs) 
(section 1.2.8), or packaged into chylomicron (CM) lipoproteins for exocytosis and absorption 
into the lymphatic system, and subsequently the general circulation (section 1.2.5).  
 
1.2.3 Lipoprotein structure 
Due to their hydrophobic nature, lipids require specialised mechanisms to allow transport in 
the blood. Non-esterified fatty acids (NEFA) bind to the protein albumin, which has a plasma 
concentration of approximately 640 μmol/L and possesses 7 binding sites for FA. Due to this 
moderate to high affinity binding to albumin, the concentration of NEFA in plasma is 
approximately 0.3 mmol/L (van der Vusse 2009). TAG, cholesteryl ester (CE) and non-esterified 
‘free’ cholesterol (FC), however, are transported within complex macromolecules called 
lipoproteins (Figure 1.4). Each lipoprotein particle is composed of a core of hydrophobic TAG 
and CE, which is surrounded by an amphipathic monolayer of phosphoplipids (PL) and small 
amounts of FC. Lipoproteins also feature apolipoprotein (apo) components, which may help 
to stabilise the structure of the particle (e.g. apoB48), or act as ligands to direct the 
metabolism of particles and their removal from the circulation (e.g. apoE).  
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Figure 1.4. General structure of a lipoprotein particle. 
Each particle features a hydrophobic core of triacylglycerol (TAG) and cholesteryl ester (CE) 
surrounded by an amphipathic monolayer of phospholipids (PL) and non-esterified ‘free’ cholesterol 
(FC). Apolipoproteins are either structural or help to direct the metabolism and removal of particles 
from the circulation. 
 
1.2.4 Major lipoprotein classes 
Lipoproteins are a heterogeneous group of particles, which differ in their lipid and 
apolipoprotein content. They are classified according to density, as determined by their 
flotation rate during ultracentrifugation. The density and size of lipoproteins are inversely 
related, as shown in Figure 1.5.  
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Figure 1.5. Particle density and size distribution of the major lipoprotein classes. 
Lipoproteins are classified according to their density (g/mL), which is inversely related to the particle 
size (nm). CM, chylomicron; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, 
low-density lipoprotein; VLDL, very low-density lipoprotein.   
 
Different lipoprotein types serve different metabolic functions. Very low-density lipoprotein 
(VLDL) and chylomicrons (CM) are collectively referred to as TAG-rich lipoproteins (TRL) and 
are chiefly responsible for the transport of dietary TAG from the small intestine (CM) and from 
the liver (VLDL), mainly to skeletal muscle and adipose tissue, for either energy generation or 
storage (sections 1.2.5 and 1.2.8). The smaller intermediate- (IDL) and low-density 
lipoproteins (LDL), derived from the catabolism and shrinking of VLDL within the circulation, 
are relatively TAG-poor and cholesterol-rich. While LDL functions to deliver cholesterol to 
tissues, high-density lipoprotein (HDL) is involved in cholesterol transport from peripheral 
tissues to the liver (section 1.2.9).       
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Table 1.1. Composition of the major classes of lipoprotein 
Lipoprotein Density (g/mL) 
Diameter 
(nm) 
Major 
apolipoproteins 
Composition (% by weight) 
Protein TAG Cholesterol PL 
CM < 0.950 80 – 1000 B48, A-I, A-IV, C, E 1 90 5 4 
VLDL 0.950 -1.006 30 – 80 B100, C, E 10 65 13 13 
LDL 1.019 – 1.063 20 – 25 B100 20 10 45 23 
HDL 1.063 – 1.210 9 – 15   A-I, A-II, C, E 50 2 18 30 
The major lipoprotein classes are shown, with the exception of intermediate-density lipoprotein 
(IDL), which has a low concentration and short half-life. The composition is approximate and may 
vary within each major class. Apolipoprotein C includes types C-I, C-II and C-III, which usually found 
together. CM, chylomicron; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PL, 
phospholipid; TAG, triacylglycerol; VLDL, very low-density lipoprotein. Information from (Frayn 2010). 
 
 
 
1.2.5 Assembly and secretion of CM and VLDL 
Both CM and VLDL lipoproteins are synthesised via a common intracellular pathway, prior to 
their secretion into the circulation. The metabolism of CM and VLDL particles is discussed in 
sections 1.2.6 and 1.2.8. The assembly of apoB-containing lipoproteins (B-Lp) begins with the 
synthesis of either apolipoprotein B100 (apoB100) or B48 (apoB48) in the lumen of the 
endoplasmic reticulum (ER), for incorporation into VLDL (liver) or CM (intestine), respectively. 
While VLDL contains the full APOB gene product (4536 residues), the CM-specific apoB48 
contains only the N-terminal 2152 residues. This truncated form of the protein arises from 
mRNA editing in the intestine, involving the deamination of a cytidine residue to a uracil, thus 
introducing a stop codon (Davidson et al. 2000). Synthesis of ApoB is believed to be 
constitutive, although in the absence of sufficient lipid in the ER lumen, such as in the fasted 
state, apoB is degraded (Hussain 2014). If lipids are present in the ER lumen then the formation 
of “primordial” B-Lp, with a density similar to HDL, may occur. Although this process is not 
precisely understood, microsomal triglyceride transfer protein (MTP) is known to be essential. 
The exact function of MTP remains unclear, but it may facilitate trafficking of lipids to the ER 
membrane in order to initiate particle formation. The absence of MTP has been shown to 
cause apoB degradation, as has the inhibition of protein-protein interactions between the two 
(Bakillah et al. 2000). Ionic interactions between MTP and the N-terminus of apoB are 
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implicated in B-Lp assembly, and these are reduced as apoB grows and becomes increasingly 
lipidated (Hussain et al. 1997). Such interactions may aid development of the correct apoB 
conformation, to allow further lipid accumulation in nascent particles. 
The second stage of B-Lp formation is that of “core expansion”. In this stage, small HDL-sized 
B-Lps fuse with pre-formed ER lumenal LD that do not contain apoB48, resulting in a dramatic 
increase in size and lipid content. These LD may be those contained in the ER or recruitment 
of cytosolic LD (CLD). Eventually, primordial B-Lps dissociate from the ER membrane, which 
may occur in response to termination of apoB translation, dissociation of MTP or other 
mechanisms that dislodge particles from the membrane (Sirwi et al. 2018).   
Newly-synthesised B-Lps are transported to the cis-Golgi via specialised vesicles, known as 
pre-chylomicron (or pre-VLDL) transport vesicles (PCTVs or VTVs). These are formed when the 
‘coatamer’ protein COPII interacts with the ER membrane, selecting B-Lps as its transport 
cargo. This process may also involve COPII interaction with the cytosolic C-terminal 70 kDa of 
apoB48 (Mansbach et al. 2016) for PCTV formation. Although the two vesicles perform the 
same function, there are several differences between PCTVs and VTVs, including the proteins 
required for their budding from the ER and fusion with the cis-Golgi, as well as their density 
and size (Tiwari et al. 2012). Following transport to the cis-Golgi, B-Lps mature further through 
glycosylation of apoB and addition of apoA-I to CM particles (Hussain 2014) and VLDL (Tiwari 
et al. 2012).  Mature B-Lps are secreted from cells by reverse exocytosis, with VLDL entering 
the circulation directly. CM gain access to the bloodstream via the lamina propria and the 
mesenteric lymph, eventually entering the circulation at the thoracic duct (Mansbach et al. 
2016).   
           
1.2.6 Cytosolic lipid droplets 
To avoid the cytotoxic effects of excess free lipids within cells, these are converted into neutral 
lipids such as TAG and sterol esters (SE) and deposited in cytosolic lipid droplets (CLD). For a 
long time, CLD were thought to be inert intracellular lipid stores, although recent advances in 
proteomics, lipidomics and imaging techniques have revealed them to be highly dynamic cell 
organelles, which are involved in many cellular processes, including protein degradation and 
sequestration of transcription factors (Onal et al. 2017).  
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Within enterocytes, the absorbed products of dietary lipid digestion may be directed towards 
CM synthesis and secretion, as discussed in section 1.2.5, or the formation of CLD. CLD feature 
a core of TAG and CE surrounded by a phospholipid monolayer, and contain a diverse array of 
proteins which interact with other cellular compartments (Demignot et al. 2014). The 
proteome of mouse CLD following an oral fat challenge contains over 180 proteins, including 
37 known to participate in lipid related metabolic pathways, such as perilipin 3 (PLIN3), apoA-
IV and acyl-CoA synthetase long chain family member 5 (D’Aquila et al. 2015). CLD synthesis 
most likely occurs through budding of excess TAG from the smooth ER membrane, with 
subsequent expansion through localised TAG synthesis at the CLD surface, as well as fusion 
with other CLD (D'Aquila et al. 2016). The mechanism for control of de novo TAG partitioning 
between CM and CLD is not yet understood, although may involve the differential expression 
of DGAT1 and DGAT2 within the ER, both of which catalyse the final committed step of TAG 
synthesis (see Figure 1.3), yet do not share genetic or structural homology (Hung et al. 2017). 
Mouse enterocytes rapidly store TAG within CLD of varying size (15-1000 nm diameter) in 
response to an oral fat load, with the amount of cytosolic TAG shown to vary in real time (Zhu 
et al. 2009, Soayfane et al. 2016). The transient storage of dietary TAG in CLD has also been 
demonstrated in humans, with rapid mobilisation of these stores in response to a secondary 
meal (Jackson et al. 2002, Robertson et al. 2003). Storage of TAG from an evening meal within 
intra-enterocyte stores can extend at least 16 h, following a breakfast meal on the subsequent 
day (Chavez-Jauregui et al. 2010). Therefore, the formation and mobilisation of CLD for CM 
synthesis, appears to be important in influencing the magnitude and duration of the post-
prandial plasma TAG response following a meal (Demignot et al. 2014, Hussain 2014). The role 
of CLD may be to smooth the magnitude of this response, particularly after a high-fat meal, 
when the ability of the ER to synthesise CM may become overloaded, subsequently releasing 
TAG and other lipids during the inter-prandial and fasted periods (Beilstein et al. 2016).       
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1.2.7 Exogenous lipoprotein pathway: CM metabolism 
Upon entering the circulation via the thoracic duct, CM have a very short half-life of only 4.5 
to 10 min in healthy individuals (Grundy et al. 1976, Wang et al. 2013). They firstly acquire 
apoC-II and apoE from circulating HDL to form mature CM (Figure 1.6). As these particles 
circulate through capillaries, apoC-II on their surface acts as a cofactor to activate the enzyme 
lipoprotein lipase (LPL), which is found anchored to the surface of endothelial cells within 
adipose, heart and muscle tissues, and is differentially expressed in the fasting and fed states 
(Goldberg 1996). LPL hydrolyses TAG within the hydrophobic core of CM, therefore releasing 
FFA and glycerol, which are absorbed by tissues for energy generation (muscle) or storage 
(adipose tissue), with some minor escape into the circulation. The delipidation of CM leads to 
a decreased particle size, as well as the loss of FC, PL and apoC-II, which are transferred to 
HDL, resulting in the formation CM remnants (CMR). Due to the loss of apoC-II, the ability of 
LPL to hydrolyse CMR is reduced. Remnant particles are eventually taken up by the liver, in a 
process involving binding of the surface ligand apoE to the LDL receptor (LDLR) (Wang et al. 
2013). The LDL receptor-related protein (LRP) and cell surface heparin sulphate proteoglycans 
(HSPG) have also been shown to assist in CMR uptake (Mahley et al. 1999). The surface protein 
apoA-V may play a role in two stages of CM metabolism; promotion of LPL-mediated lipolysis 
through facilitating lipoprotein and LPL interaction (Merkel et al. 2005), as well as 
enhancement of CMR clearance by mediation of particle interaction with LRP to allow uptake 
by the liver (Ress et al. 2011).    
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Figure 1.6. The exogenous lipid transport pathway. 
Dietary lipids are packaged into nascent CM, which enter the circulation via the thoracic duct and 
accept apoC-II and apoE from circulating HDL to form mature particles. The apoC-II component of CM 
acts a cofactor for LPL, located on the endothelial surface of adipose tissue, heart and skeletal muscle, 
which hydrolyses TAG in the hydrophobic core of CM, releasing FFA, which are either taken up by 
tissues, or escape into plasma. TAG hydrolysis by LPL may also be promoted by apoA-V. As particles 
lose TAG they shrink to form CMR, while also losing PL, FC and apoC-II from their surface, which are 
exchanged with HDL. CMR are cleared from the circulation by the liver, which removes CMR through 
an endocytosis step mediated by LDLR and LRP. Apo, apolipoprotein; CM, chylomicron; CMR, 
chylomicron remnant; FC, free cholesterol; FFA, free fatty acids; HDL, high-density lipoprotein; LDLR, 
low-density lipoprotein receptor; LPL, lipoprotein lipase; LRP, low-density lipoprotein related protein; 
PL, phospholipid; TAG, triacylglycerol.     
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1.2.8 Endogenous lipoprotein pathway: VLDL metabolism 
Hepatic lipids are packaged into VLDL and secreted into the circulation via a similar 
intracellular pathway as CM (section 1.2.5), although VLDL particles contain the full length 
structural apoB100 protein. The intra-hepatic availability of lipids is the primary determinant 
of the VLDL synthesis rate. Besides exogenous lipids derived from the diet, the liver also 
utilises existing hepatic TAG stores, newly-synthesised FFA produced via de novo lipogenesis 
(DNL) (see section 1.5.1) and plasma FFA into secreted VLDL particles, depending on the 
energy status of the body (Julius 2003).  
VLDL metabolism in the circulation is initially similar to that of CM (Figure 1.7), with 
competition between CM and VLDL for hydrolysis by LPL in the fed state. However, kinetic 
studies in humans have shown that CM appear to be the preferential substrate for LPL (Adiels 
et al. 2012). Metabolism of VLDL reduces the particle size and leads to the formation of IDL. 
Approximately 50 % of IDL is taken up by the liver via apoE interaction with the LDLR, while 
the remaining 50 % is subject to further lipolysis by hepatic lipase (HL) and remodelling 
through loss of apolipoproteins, thus yielding LDL (Bhagavan et al. 2011). Larger IDL are more 
susceptible to clearance by the liver, while smaller IDL are more likely to transition to become 
LDL (Daniels et al. 2009). LDL have a long half-life in the circulation of approximately 3 days 
(Langer et al. 1972), which may be due to their lack of lipase activating apolipoproteins, or the 
stability of their CE-rich core.  
The majority of LDL (~70 %) is cleared from the circulation by the liver, through LDLR binding 
to apoB100, while the remainder is taken up by extrahepatic tissues through the same 
mechanism (Feingold KR 2018). While apoB100 is the primary ligand for the LDLR, with 
residues 3,300-3,600 known to be essential for binding (Milne et al. 1989), the LDLR also 
recognises apoE within CMR, VLDL and IDL. Discovered in the 1970s as a result of the 
pioneering work of Goldstein and Brown, the LDLR is now known to consist of three principal 
extracellular domains; a ligand-binding domain with seven cysteine-rich repeats (~40 amino 
acids each); an epidermal growth factor homology domain; a C-terminal domain enriched with 
O-linked oligosaccharides (Nikolic et al. 2018). LDLR are located within ‘coated pits’ of the cell 
membrane, which are rich in the protein clathrin and make up about 2 % of the total cell 
surface (Mangiapane et al. 2001).      
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Following ligand binding, LDLR are endocytosed and the resulting acidic pH within endosomes 
dissociates LDLR from its apolipoprotein ligand, allowing LDLR recycling back to the cell 
membrane. However, this process is not 100 % efficient and thus requires synthesis of new 
LDLR to replace those that are lost (Mangiapane et al. 2001). Intracellular lysosomes degrade 
apolipoprotein by proteases and convert CE to FC to be utilised within the cell.  
Two mechanisms are currently recognised as controlling the number of LDLR available in the 
cell membrane of hepatocytes, and thus the capacity of the liver to clear LDL (and CMR) from 
the circulation. One of these molecular processes was only elucidated relatively recently 
(2003), following the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This 
is a hepatic protease that binds to the epidermal growth factor-like domain of the LDLR, 
preventing the receptor from forming a closed conformation, making it more susceptible to 
intracellular lysosomal degradation (Page et al. 2018). As a result, fewer LDLR are recycled to 
the cell membrane, decreasing the number of membrane bound receptors available for 
binding of LDL particles. Therefore, the expression and release of PCSK9 into the circulation 
elicits a net increase in plasma LDL cholesterol concentrations. Since the recognition of this 
crucial role of PCSK9, monoclonal antibodies (mAb) capable of binding circulating PCSK9 and 
preventing its association with LDLR have been developed. Two mAb PCSK9 inhibitors for 
lowering of LDL-C were approved by the American Federal Drug Administration in 2015 
(alirocumab and evolocumab), and may prove extremely effective therapies for the lowering 
of plasma LDL-C levels and subsequent risk of atherosclerotic cardiovascular disease (see 
section 1.2.10) (Baum et al. 2018).     
Membrane levels of LDLR are also mediated by the intracellular cholesterol content. A 
decrease in cholesterol concentration activates preformed sterol regulatory element binding 
proteins (SREBPs), which reside dormant in the ER, causing their translocation to the Golgi, 
wherein they are cleaved by proteolytic enzymes to their active form (Feingold KR 2018). Over 
30 genes involved in lipid synthesis, transport and uptake are known to contain functional 
sterol regulatory elements (SREs), which are bound by SREBPs (Horton et al. 2003). These 
include the gene encoding HMG-CoA reductase, the rate-limiting enzyme in cholesterol 
synthesis, as well as the gene for PCSK9. The SREBP family has three key members. While 
SREBP1a is a potent activator of all SREBP-responsive genes for cholesterol, FA and TAG 
synthesis, SREBP1c preferentially regulates FA synthesis genes, with SREBP2 targeting genes 
for cholesterol synthesis (Horton et al. 2002).  
 35 
 
 
Figure 1.7. The endogenous lipid transport pathway. 
VLDL particles are secreted by the liver and acquire apoC-II and apoE from circulating HDL. Within 
capillaries of heart, muscle and adipose tissue, LPL hydrolyses VLDL to release FFA for uptake by the 
tissues. As VLDL shrink and lose apolipoproteins they form IDL, 50 % of which is cleared by the liver via 
the LDLR, while the remaining 50 % is further hydrolysed and remodelled by hepatic lipase to yield LDL, 
which contains only apoB100. Approximately 70 % of LDL is cleared by the liver through apoB100 
binding to LDLR, while the remainder is taken up by extracellular tissues via the same mechanism. Apo, 
apolipoprotein; FC, free cholesterol; FFA, free fatty acids; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; LDLR, LDL receptor; LPL, lipoprotein lipase; PL, phospholipid; TAG, triacylglycerol; 
VLDL, very low-density lipoprotein.     
    
 
1.2.9 Reverse cholesterol transport 
Cholesterol is a key component of cell membranes and a precursor for the synthesis of bile 
acids, steroid hormones and vitamin D (Cerqueira et al. 2016). Cholesterol that is not 
synthesised de novo within cells, may be delivered to extra-hepatic tissues by B-Lps (CM, VLDL 
and LDL) via the exogenous and endogenous lipid transport pathways, described in sections 
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1.2.7 and 1.2.8, by a process collectively referred to as forward cholesterol transport. 
Cholesterol may also be recycled back to the liver through a third pathway, termed reverse 
cholesterol transport (RCT), after which it may be metabolised or excreted as bile acids during 
digestion.   
As shown in Figure 1.8, the primary transporter for RCT is HDL, which includes the four sub-
classes HDL1 (αHDL), HDL2, HDL3 and pre-β HDL, in increasing order of density and decreasing 
order of size (Brunham et al. 2015). The formation of pre-β HDL begins with the secretion of 
apoA-I into the circulation by the liver and intestine, which then acquires FC and PL from the 
liver, intestine and other tissues. This efflux of FC and PL from cells occurs through the action 
of ATP-binding cassette transporters (ABC) A1 and G1, as well as passively via scavenger 
receptor B1 (SR-B1) and aqueous diffusion (Pizzini et al. 2017). The resulting discoidal pre-β 
HDL particles further develop into mature spherical HDL through esterification of FC into CE, 
which then migrates into the lipoprotein core. This step is catalysed by the enzyme lecithin-
cholesterol acyl transferase (LCAT), which is activated by apoA-I (Feingold KR 2018). Growing 
HDL also obtain PL from other lipoproteins via the action of phospholipid transfer protein 
(PLTP). Larger, mature HDL particles may transfer some of their CE content to B-Lps (CM, VLDL, 
LDL) in exchange for TAG, in a mechanism mediated by cholesteryl ester transfer protein 
(CETP). These TAG-enriched HDL particles may then be metabolised by hepatic lipase (HL), 
which also liberates PL from HDL, to yield smaller HDL particles (Hill et al. 1997). However, 
most of the CE carried within HDL is delivered to the liver, where SR-B1 binds HDL and accepts 
CE without internalising the particle itself. Smaller, cholesterol-depleted HDL are then 
released back into the circulation. Delivery of cholesterol to the liver via the RCT pathway may 
therefore occur directly through HDL binding to SR-B1, or indirectly via CE transfer to LDL and 
other B-Lps (von Eckardstein 2012) and their eventual uptake via the LDLR.          
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Figure 1.8. The process of reverse cholesterol transport. 
The liver and intestine secrete apoA-I, which acquires FC and PL following efflux from liver, intestine 
and extrahepatic tissues via ABCA1 and ABCG1, as well as SR-B1 and diffusion. The resulting pre-β-
HDL particles convert FC into CE through the action of LCAT, and acquire PL through the action of 
PLTP. Mature, spherical HDL particles may exchange CE for TAG with circulating CM, VLDL and LDL, 
yielding TAG-enriched HDL that are metabolised by liver HL. The delivery of CE within HDL to the liver 
occurs via the SR-B1 receptor, after which particles are released back into the circulation. The CE 
taken up by the liver may be utilised for synthesis of hormones or bile acids. ABCA1 and ABCG1, ATP-
cassette binding transporter (ABC) A1 and G1; apoA-I, apolipoprotein A-I; B-Lp, apolipoprotein B 
containing lipoprotein; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; CM, 
chylomicron; FC, free cholesterol; HDL, high-density lipoprotein; HL, hepatic lipase; LCAT, lecithin-
cholesterol acyltransferase; LDL, low-density lipoprotein; LDLR, LDL receptor; PL, phospholipid; PLTP, 
PL transfer protein; SR-B1, scavenger receptor B1; TAG, triacylglycerol; VLDL, very low-density 
lipoprotein.     
 
1.2.10 TRL remnants and atherosclerosis  
1.2.10.1 Atherosclerosis and its risk factors 
Atherosclerosis is the principal underlying cause of CVDs, including CHD, stroke and peripheral 
arterial disease (PAD). This term was first used in 1904 to describe the lipid-rich deposits noted 
in arteriosclerosis, the scarring and calcification of post-mortem arteries (Mangiapane et al. 
2001). Several ‘traditional’ risk factors are involved in the initiation and progression of 
atherosclerosis, including raised total and LDL cholesterol (LDL-C), low HDL cholesterol (HDL-
C), as well as smoking and hypertension. More recently, other ‘novel’ risk factors have also 
emerged, including elevated fasting glucose, as well as hypertriacylglycerolaemia (hyperTAG) 
 38 
and an increased TRL remnant concentration, in both the fasting and fed states (Fruchart et 
al. 2004). A brief overview of the most broadly-accepted hypothesis for initiation and 
progression of atherosclerotic lesions, involving accumulation of oxidised LDL (oxLDL), is 
provided here, with subsequent discussion of the more-recently recognised role of TRL 
remnants in this process. 
The development of advanced atherosclerotic lesions is a complex process, but may be 
described in four stages: early fatty streak development; formation of early fibroatheroma; 
formation of thin-cap fibroatheroma susceptible to rupture; complex lesion development 
(Insull 2009). The process of fatty streak development begins with the migration of LDL into 
the subendothelial space of the artery wall, where it becomes trapped and forms oxLDL, in 
response to oxidative species released by the endothelium (Navab et al. 1995). The retention 
of oxLDL is dependent on extracellular matrix (ECM) molecules, in particular proteoglycans, 
with the modification of retained oxLDL triggering a maladaptive inflammatory response 
(Tabas et al. 2007). This inflammatory response leads to the recruitment of monocyte cells, 
which enter the intimal space and differentiate into macrophages. Chemically-modified oxLDL 
is internalised by macrophages in an uncontrolled manner via scavenger receptors, leading to 
cholesterol-loaded ‘foam cells’, which collectively form a ‘fatty streak’ (Berliner et al. 1995). 
Plaque development is thought to proceed via the further recruitment and differentiation of 
monocytes, as well as T-lymphocytes, which drives foam cell formation and cell death, giving 
rise to lesions with a lipid-rich necrotic core covered by a fibrous cap of vascular smooth 
muscle cells (SMC) and ECM (Fan et al. 2003). Atherosclerotic plaques may be regarded as 
either ‘stable’, with a small lipid core and thick fibromuscular cap, or ‘vulnerable’, containing 
a large lipid core and thin cap featuring a high number of inflammatory cells (van der Wal et 
al. 1999). Vulnerable plaques are more susceptible to rupture and/or erosion, which exposes 
the necrotic core to the circulation, triggering the blood coagulation cascade and thrombosis 
formation (Sakakura et al. 2013). The rupture and subsequent repair of thin-capped plaques, 
with SMC and collagen fibres, may occur up to four times prior to a clinical event such as 
myocardial infarction (MI) or stroke (Burke et al. 2001).  
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1.2.10.2 Evidence for a role of TRL remnants in atherosclerosis  
The assertion that retention of apoB-containing lipoproteins within the arterial intima was the 
central initiating event in atherosclerosis was only made approximately 20 years ago, in what 
is known as the ‘response-to-retention’ hypothesis (Williams et al. 1995). The retention of LDL 
particles within the arterial wall, at sites prone to the formation of lesions, leads to an 
increased likelihood of particles becoming chemically modified, including peroxidation of the 
apoB100 component of LDL, leading to a loss of normal functioning. The resulting oxLDL are 
recognised by the scavenger receptor of macrophages, which readily engulf particles, but are 
unable to degrade their cholesterol content, thus forming lipid-loaded ‘foam cells’. 
Accumulation of foam cells within the artery wall leads to the formation small yellowish spots, 
or ‘fatty streaks’, which are the first visible sign of atherosclerotic plaque formation (Frayn et 
al. 2019).    
Increasing levels of LDL, and its associated cholesterol (LDL-C), are strongly associated with 
the risk of developing atherosclerotic CVD (ASCVD) in a dose-dependent manner, as evidenced 
by the combined results from over 200 epidemiological studies involving more than 2 million 
participants (Ference et al. 2017). In the same report, pooled data from over 30 randomised 
trials aimed at lowering LDL-C, comprising greater than 200,000 participants (>30,000 ASCVD 
events), consistently demonstrated that a reduction in plasma LDL-C concentrations lowers 
the risk of an ASCVD event in a proportional manner.      
Although LDL-C is widely accepted as having a causal relationship with the development and 
progression of ASCVD, several advancements in the last two decades have implicated TRL 
remnants of intestinal origin (CMR), as well as plasma TAG concentrations, in the pathogenesis 
of atherosclerosis. For example, it has been noted that therapies targeted at reducing LDL-C, 
as well as blood pressure and thrombotic events, fail to ‘normalise’ risk in individuals at high 
risk of CVD, as determined by the percentage of CVD death and events post-treatment, 
indicating the importance of factors other than LDL-C (Chapman et al. 2011). An elevated TAG 
level is one of these factors, as demonstrated in the PROVE IT-TIMI 22 trial, in which the risk 
of recurrent CHD events in over 4,000 patients, hospitalised after an acute coronary syndrome 
(ACS), was reduced independently of LDL-C, when on-treatment TAG levels were <150 mg/dL 
(1.7 mmol/L) (Miller et al. 2008).  
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High plasma TAG levels may serve as a marker for an atherogenic lipoprotein profile, involving 
raised LDL-C, low HDL cholesterol [HDL-C] and accumulation of CMR and partially metabolised 
VLDL particles, which is found to be common in insulin-resistant patients with type 2 diabetes 
mellitus and metabolic syndrome (MetS) (Talayero et al. 2011). There is an association 
between raised plasma TAG and an increased production of VLDL lipoproteins with an altered 
lipoprotein content (less apoE and more apoC-III), leading to a reduced rate of VLDL 
catabolism by LPL in the circulation and an impaired clearance by the liver (Zheng et al. 2010). 
An impaired clearance of CMR has also been reported in the post-prandial state for men with 
metabolic syndrome, in comparison to lean controls (Shojaee-Moradie et al. 2013). Prolonged 
residency of both CMR and VLDL remnants in the circulation promotes the formation of 
particles enriched in CE, due to exchange with HDL through the action of CETP (see Figure 1.8) 
(Talayero et al. 2011). At the same time, this effect reduces HDL-C concentrations, leading to 
a net transfer of cholesterol from ‘anti-atherogenic’ HDL to ‘pro-atherogenic’ B-Lps, 
unfavourably altering the HDL-C to LDL-C ratio (Barter et al. 2003). 
Evidence for an atherogenic effect of CMR in the aetiology of coronary artery disease (CAD) 
dates back as far as 1987. In a case-control study of 82 subjects with CAD, the 
apoB48/apoB100 ratio in the Svedberg flotation (Sf) rate > 60 range (TRL fraction), taken as a 
relative measure of CM and CMR presence, was found to be higher in cases than for controls, 
with this ratio being predictive of CAD presence in a ‘dose-response’ fashion (Simons et al. 
1987). A subsequent three-year case-control study, involving a similar number of 
normolipidaemic CAD patients (n=85), demonstrated an impaired clearance of CM in cases 
versus controls, following a fat-loading test, indicating that delayed CMR clearance may be 
key component of CVD risk (Weintraub et al. 1996). Additionally, the post-prandial levels of 
small CMR (Sf 20-60) in 32 post-infarction patients were found to be strongly correlated to the 
rate of coronary lesion progression at five years post-event, as determined by angiography, 
implicating small CMR in the progression of CAD (Karpe et al. 1994). 
Evidence from laboratory studies also supports a role for CMR in the aetiology of 
atherosclerosis. The first visual evidence for this was reported by Proctor and colleagues, who 
showed the rapid penetration of fluorescent-labelled CMR into arterial tissue, and their 
subsequent retention and accumulation within the subendothelial space (Proctor et al. 1998). 
The same group subsequently identified both apoB100- and apoB48-containing lipoproteins 
in human femoral and carotid plaques removed via endarterectomy. The relative proportion 
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of intestinal (apoB48) to hepatic (apoB100) lipoproteins was considered much greater than 
their relative plasma concentrations and degree of arterial exposure (Pal et al. 2003). 
Entrapment of apoB48-containing lipoproteins also occurs in Watanabe rabbits, a model of 
human hypercholesterolaemia, with 3D confocal microscopy of fluorescent lipoproteins 
revealing an almost two-fold greater retention of cholesterol from CMR than from LDL, 
following carotid artery infusion (Proctor et al. 2003).  
The uptake of CMR by macrophages in vitro has been well documented. This was initially 
thought to be mediated by the LDLR, following investigation using cultured J774 and P388D1 
cell lines (Ellsworth et al. 1987). However, studies of peritoneal macrophages from normal and 
gene knockout (KO) mice suggested that uptake may occur via several mechanisms, including 
LDLR, LRP or another non-LDL receptor family mechanism in the absence of apoE within CMR 
(Fujioka et al. 1998). Incubation of macrophages with CMR also appears to alter the expression 
of key genes involved in lipoprotein uptake and cholesterol efflux. CM-like particles (CMR-LP) 
have been observed to downregulate mRNA levels of ABCA1 and to upregulate expression of 
LRP (Batt et al. 2004). The cytotoxicity of CMR on human monocyte-derived macrophages has 
also been reported to be time- and dose-dependent, resulting in reduced macrophage viability 
following CMR uptake, due to free radical production (Yu et al. 2000). The fatty acid 
composition of CMR may be more important than particle oxidation in determining effects on 
foam cell formation. A similar induction of TAG accumulation in J774 macrophages was 
reported in response to both normal and oxidised particles, although particles rich in n-6 
polyunsaturated FA (PUFA) stimulated greater TAG synthesis than for n-3 PUFA rich remnants 
(Napolitano et al. 2003). Macrophage cell death in response to CMR uptake may be due to the 
rapid accumulation of free cholesterol, which is abundant in the surface of CMR, leading to 
the destabilisation of intracellular lysosomes (Wakita et al. 2015). Taken together, these 
studies strongly support a role for CMR in the induction of foam cell formation. 
The growing body of evidence from clinical, in vivo and in vitro studies, as discussed above, 
clearly implicates TRL remnants in the development of atherosclerosis. TRL remnants may act 
via both direct mechanisms, including foam cell formation and SMC proliferation, as well as 
indirect mechanisms, such as increasing the formation of highly-atherogenic ‘small dense’ LDL 
(sdLDL) (Botham et al. 2013). Recently, the European Atherosclerosis Society Consensus Panel, 
composed of 25 international experts, determined there to be unequivocal evidence that LDL 
causes atherosclerotic CVD, based on mechanistic, genetic and epidemiological studies 
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(Ference et al. 2017). However, challenges remain in the translation of research findings into 
benefits within clinical practice (Libby et al. 2011). Modifiable lifestyle factors that reduce 
fasting and post-prandial TAG levels, such as dietary changes, may be the most effective as a 
‘first-line’ approach, due to a relative lack of high quality evidence on the benefits of TAG-
lowering drugs (Boren et al. 2014). 
 
1.3 Fructose – dietary sources, absorption and metabolism 
1.3.1 Fructose chemical structure 
Fructose is a six-carbon hexose sugar, which has the same chemical formula (C6H12O6) and 
molecular mass (180.16 g/mol) as glucose. It is the most water soluble monosaccharide (3750 
g/L) and dissolves in exceedingly small amounts of water. Both fructose and glucose may exist 
as an open linear chain, a five-membered cyclical furanose or a six-membered cyclical 
pyranose molecule (Figure 1.9). Fructose in aqueous solution exists as an equilibrium of 70 % 
pyranose and 22 % furanose, in addition to other forms, although it is most commonly 
represented as a β-D-fructofuranose molecule (American Chemical Society 2017). This is the 
molecular form in which it is able to bond to α-D-glucopyranose to form sucrose, via an α1-2 
glycosidic linkage.  
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Figure 1.9. Chemical structures of fructose and sucrose. 
In aqueous solution (top) the β-D-fructopyranose form predominates (70 %) over β-D-fructofuranose 
(22%) and the linear form of fructose. Sucrose (bottom) is formed from an α 1-2 glycosidic linkage 
between α-D-glucopyranose and β-D-fructofuranose.  
 
 
1.3.2 Dietary intake of free sugars and fructose 
Many fruits are naturally-occurring sources of fructose, such as dates, raisins and figs (>10 % 
by weight), as well as grapes, apples and blueberries (>5 %) (Bray 2007). Honey is also a well-
known source of fructose and may provide over 40 g per 100 g as a free monosaccharide 
(Raatz et al. 2015). However, fructose is typically co-ingested with glucose, either within the 
disaccharide sucrose, or as free monosaccharides in high-fructose corn syrup (HFCS), which is 
chiefly consumed in North America.  
Table 1.2 shows data from the National Diet and Nutrition Survey (NDNS) for the total amount 
of free sugars consumed in the UK population during the period 2014-2016, as well as the 
amount of fructose (2008-2012). As a percentage of total energy, girls and boys aged 11 to 18 
years consumed more free sugars than children aged 4 to 10 years or adults aged 19 to 64 
years (Roberts 2018). The proportion of free sugars specifically obtained from fructose was 
similar across ages and genders, although slightly higher for children aged 11 to 18 years (17 
– 20 g/day). The main dietary source of free sugars for children aged 4 to 10 years was ‘cereal 
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and cereal products’ (33 %), while for children aged 11 to 18 years this was ‘non-alcoholic 
beverages’ (33 %), with 22 % contributed by soft drinks (not low calorie) and 10 % coming 
from fruit juices. For adults, ‘Sugar, preserves and confectionery’ accounted for the largest 
proportion of free sugar consumption (25 %), with 21 % from ‘non-alcoholic beverages’.   
 
Table 1.2. Average daily intake of free sugars and fructose in UK population. 
 NDNS Age Groups (years) 
 4 – 10 11 – 18 19 – 64 
 Boys Girls Boys Girls Men Women 
Free sugars b 
(g/day) 
54.5 49.9 71.6 62.4 64.3 50.0 
Free sugars b  
(% TE) 
13.6 13.4 13.9 14.4 11.1 11.2 
Fructose a 
(g/day) 
16 - 17 17 – 20 15 – 18 
Data from the National Diet and Nutrition Survey (NDNS) for years 1-4 (2008-2012)a and years 7-8 
(2014-2016)b of the rolling programme. TE, total energy.   
 
In the United States, the mean consumption of fructose is estimated at 54.7 g/day, although 
this is higher amongst adolescents aged 12 to 18 years (72.8 g/day) and accounts for 10.2 % 
of total energy intake, with the largest source of fructose (30 %) being sugar-sweetened 
beverages (SSB) (Vos et al. 2008). Between 1978 and 2004, the availability of the sweetener 
HFCS, which provides fructose and glucose as free monosaccharides (55% fructose and 41% 
glucose; or 42% fructose and 52% glucose) increased by 60.8 %, with a concomitant decrease 
in sucrose availability of 32.7 %, indicating a shift in the sources of added free sugars in the 
diet (Marriott et al. 2009).  
The consumption of total added sugars in the United States reduced from 100.1 g/day in 1999 
to 76.7 g/day in 2008, for both children and adults aged < 35 years (Welsh et al. 2011). A 
similar decrease in the percentage of total energy from free sugars also occurred in the UK 
population between 2008 and 2016, for both boys and girls aged 4 to 10 years and 11 to 18 
years, as well as adults aged 19 to 64 years. However, the contribution of added sugars to total 
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dietary energy remains at 13 % in the United States, and that of free sugars at 11.1-13.6 % in 
the UK, which both exceed the current government recommendations of 10 % (USDA 2015) 
and 5 % (Prentice 2015), respectively.       
 
1.3.3 Fructose digestion and absorption 
Fructose may be obtained from the diet as a free monosaccharide or as part of the 
disaccharide sucrose.  During digestion, the α 1-2 glycosidic bond in sucrose is hydrolysed by 
the enzyme sucrase-isomaltase (SI), which is a hetero-dimeric glucosidase found anchored to 
the apical brush border of intestinal enterocyte cells, thus yielding free monosaccharides 
which may be absorbed (Cohen 2016). The main processes involved in the intestinal 
absorption of fructose, as well as glucose and galactose, are summarised in Figure 1.10. Two 
different types of transport protein are responsible for the absorption of these 
monosaccharides. The sodium-glucose linked transporter-1, or sodium-glucose cotransporter 
(SGLT1), is the main route for the absorption of glucose, which can occur against a glucose 
concentration gradient, and involves cotransport of sodium ions in the same direction 
(symport). A favourable sodium concentration gradient is maintained by the sodium-
potassium adenosine triphosphatase (Na+K+ ATPase), located in the basolateral membrane, to 
provide a source of chemical potential (Poulsen et al. 2015). The SGLT1 transporter is 
expressed in the brush border membrane of enterocytes in the upper third of the small 
intestine and is also the principal transporter for galactose absorption (Kiela et al. 2016).  
The second type of transport protein is the facilitated diffusion glucose transporter (GLUT) 
family, which includes GLUT5 and GLUT2. Fructose is primarily absorbed across the apical 
membrane via an energy-independent mechanism which requires GLUT5, and its absorption 
is increased in response to dietary fructose availability (Thorens et al. 2010). The transport of 
fructose across the basolateral membrane and into the circulation occurs via GLUT2, which 
has a low-affinity and high-capacity for fructose, and also facilitates the basolateral transport 
of glucose and galactose (Leturque et al. 2005). The GLUT2 transporter may also be recruited 
to the apical membrane in response to high luminal concentrations of mono- and 
disaccharides to aid the absorption of fructose, glucose and galactose (Kellett et al. 2005). 
However, this potential role of GLUT2 in the apical transport of glucose has more recently 
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been challenged, although both SGLT1 and GLUT2 are still considered to play a role in the 
apical sensing of glucose (Röder et al. 2014).       
The essential role of GLUT5 in fructose absorption has been reported in rodents, with GLUT5 
knockout (GLUT5-KO) mice fed a high fructose diet (60%) exhibiting a 75 % reduction in 
fructose absorption in the jejunum of the intestine, which was not seen when a high glucose 
diet (60 %) was fed (Barone et al. 2009). More recently, Patel and colleagues also 
demonstrated a lack of facilitated diffusion in GLUT5-KO mice, despite their having normal 
levels of GLUT2. Western blot analysis revealed a six-fold increase in GLUT5 expression in 
response to fructose feeding in wild type mice, with only half the increase in heterozygous 
animals and none at all in GLUT5-KO mice (Patel et al. 2015a). Thus, it was concluded that 
GLUT5 is the primary fructose transporter in rodents, and that its regulation specifically 
requires fructose uptake and GLUT5 trafficking to the apical membrane.   
 
Figure 1.10. Intestinal absorption of fructose, glucose and galactose. 
The absorption of fructose across the apical membrane requires glucose transporter 5 (GLUT5), 
whereas glucose and galactose are absorbed via sodium-glucose linked transporter-1 (SGLT1). 
Sodium-potassium ATPase (Na+ K+ ATPase) maintains a favourable sodium concentration gradient 
for SGLT1 functioning. Fructose, glucose and galactose are absorbed across the basolateral 
membrane and into the circulation via the low-affinity, high-capacity GLUT2 transporter, which may 
also function at the apical membrane in response to high lumenal mono- and disaccharide 
concentrations.   
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1.4 Fructose and cardiovascular disease risk 
Cardiovascular disease (CVD) is a term that describes a group of related disorders of the heart 
and blood vessels, including coronary heart disease (CHD), cerebrovascular disease, peripheral 
arterial disease, rheumatic and congenital heart diseases, as well as venous thromboembolism 
(Stewart et al. 2017). Many of these disorders result from atherosclerosis, the process 
whereby arteries become occluded over the life course due to lipid deposits within the arterial 
wall (see section 1.2.10). Globally, CVDs are the primary cause of death from non-
communicable diseases (31 %), accounting for an estimated 17.7 million deaths in 2015, of 
which 7.4 million were attributable to CHD and 6.7 million due to stroke (WHO 2017). Despite 
recent decreases in CVD mortality in Europe, this remains the primary cause of death among 
both men (40 %) and women (49 %) (Townsend et al. 2016), with an estimated cost to the EU 
economy of €196 billion per year (Nichols M 2012). 
An abnormally raised plasma triacylglycerol (TAG) level, referred to as 
hypertriacylglycerolaemia (hyperTAG), is considered a risk factor for CVD, both in the fasting 
and post-prandial (fed) states (Eberly et al. 2003). However, non-fasting TAG levels may be of 
greater relevance, as those consuming a typical ‘Western’ diet may spend up to 18 hours per 
day in the fed state (Sharrett et al. 2001). A raised plasma TAG concentration may result from 
either an increased production, or an impaired clearance, of TAG-rich lipoproteins (TRL), and 
their associated remnant particles (Boren et al. 2014), in the circulation (see sections 1.2.7 
and 1.2.8).  
Diet is an important modifiable risk factor for CVD (Dhingra et al. 2007, Maersk et al. 2012). 
Consumption of the monosaccharide fructose (section 1.3), specifically, has attracted much 
attention, due to reports that it raises both fasting (Bantle et al. 2000, Silbernagel et al. 2011) 
and post-prandial TAG levels (Teff et al. 2004, Teff et al. 2009, Ngo Sock et al. 2010, Stanhope 
et al. 2011). Several human and animal studies have focussed on the effect of fructose on 
VLDL, one of the principal TAG-carrying particles within the circulation, as a determinant of an 
overall increased TAG concentration (Zavaroni et al. 1982, Le et al. 2006, Le et al. 2009). 
Indeed, the oxidation of smaller LDL, which result from the metabolism of VLDL (see section 
1.2.8), have long been implicated in the pathogenesis of atherosclerosis (Berliner et al. 1995).  
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However, there is also evidence that fructose-induced hyperTAG is partly due to an increased 
production of CM lipoproteins, which are produced in the small intestine to transport dietary 
TAG (section 1.2.5). This has been demonstrated in a hamster model of insulin resistance 
(Haidari et al. 2002), as well as in men with the metabolic syndrome (Shojaee-Moradie et al. 
2013). Both in vivo and in vitro evidence suggests that smaller CM remnants (CMR), arising 
from CM metabolism, also contribute to atherosclerotic plaque formation (Pal et al. 2003, 
Elsegood et al. 2006, Nakano et al. 2008), and that this process may occur independent of 
CMR oxidation (Napolitano et al. 2003).  
The current project aims to further develop knowledge of the effects of fructose consumption 
on post-prandial TAG metabolism, with a specific focus on the role of intestinal CM production 
and metabolism. The findings may further support recent UK and US government 
recommendations to limit the consumption of free sugars to no more than 5% and 10% of 
total dietary calories, respectively (Prentice 2015, USDA 2015). 
 
1.5 Fructose metabolism 
Three main cell types express all of the fructose-metabolising enzymes; hepatocytes, 
enterocytes and kidney tubular cells (Campos et al. 2016). The principal metabolic pathways 
of fructose, as well as glucose, are summarised in Figure 1.11. The majority of fructose 
absorbed by intestinal enterocytes is believed to enter the circulation across the basolateral 
membrane via the GLUT2 transporter, and is subsequently delivered to the liver.  
Within cells, fructose is rapidly converted into fructose-1-phosphate (fructose-1-P) by the 
enzyme fructokinase, which is also known as ketohexokinase (KHK). This enzyme has two 
isoforms, KHK-A and KHK-C, although the KHK-C form has a ten-fold higher affinity for fructose 
(Km = 0.8 mM) and is therefore responsible for most fructose metabolism (Asipu et al. 2003). 
Fructose-1-phosphate is cleaved into the three-carbon intermediates dihydroxyacetone 
phosphate (DHAP) and glyceraldehyde (GA) by the action of Aldolase B. These compounds 
may be channelled into the glycolysis pathway and converted into glyceraldehyde-3-
phosphate (G-3-P), followed by pyruvate and acetyl-CoA (Ac-CoA), which may then be utilised 
for energy generation via the tricarboxylic acid (TCA) cycle. Fructose carbons may also be 
directed towards glucose formation (gluconeogenesis), via lactate, or the formation of 
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glycerol-3-phosphate (glyceroneogenesis), which may be utilised for TAG synthesis. One 
further potential pathway is the conversion of Ac-CoA, via malonyl-CoA, into new fatty acids 
through the process of de novo lipogenesis (DNL), which is further discussed in section 1.5.1.  
One of the most detailed overviews of the quantitative metabolism of fructose was provided 
by Sun et al (2012), using the results of 34 studies where the metabolic fate of fructose was 
traced using stable isotope techniques (see section 1.6). Following the ingestion of fructose, 
both with and without glucose or sucrose, it was concluded that oxidation (31-62 %), 
gluconeogenesis (29-54 %) and lactate formation (~28 %) were the predominant pathways, 
with only a minor amount of fructose (<1 %) directed towards DNL (Sun et al. 2012). The 
authors were unable to provide an estimate of the relative contributions of glycogen 
formation (glycogenesis) and glyceroneogenesis. 
Following absorption of fructose from the intestinal lumen, the majority is transported to the 
liver via the portal vein, whereby hepatic uptake occurs via GLUT2, followed by rapid 
conversion to GA, G-3-P and DHAP through the action of KHK and Aldolase B (Tappy et al. 
2010). These enzymes act specifically on fructose and fructose-1-P and are not regulated by 
ADP, citrate or insulin, as for hexokinase and phosphofructokinase (Figure 1.11), which act 
upon glucose (Tappy 2012). This lack of regulation of fructose metabolism may therefore 
provide a large pool of three-carbon intermediates within hepatocytes, driving the formation 
of glucose, lactate and hepatic glycogen, in addition to oxidation, as well as DNL (Tappy et al. 
2010).  
 
 50 
 
Figure 1.11. Intracellular metabolism of fructose and glucose. 
Fructose phosphorylation (enzymes 1 and 2) is not subject to regulation by ADP and citrate, as with 
the glycolytic enzymes (enzymes 3 and 4) which phosphorylate glucose. The main metabolic end 
products of fructose and glucose catabolism are glycogen (glycogenesis), CO2 (oxidation), lactate, 
glucose (gluconeogenesis) and fatty acids (de novo lipogenesis). Key enzymes are numbered: (1) 
fructokinase/ketohexokinase; (2) aldolase B; (3) hexokinase/glucokinase; (4) phosphofructokinase. 
Ac-CoA, acetyl-CoA; DHAP, dihydroxyacetone-phosphate; DNL, de novo lipogenesis; Mal-CoA, 
malonyl-CoA; MG, methylglyoxal; -P/-diP, phosphate/diphosphate; TAG, triacylglycerol. Adapted 
from (Steenson et al. 2017). Reproduced under the Creative Commons Attribution License. 
 
Although the liver has long been considered the primary organ responsible for fructose 
metabolism, intestinal enterocytes in both the guinea pig (Ginsburg et al. 1960) and rat 
(Mavrias et al. 1973) are also known to strongly express KHK and Aldolase B. Importantly, 
there have been few studies to date to accurately determine portal vein fructose 
concentrations following ingestion of a fructose load (Patel et al. 2015b), and to therefore 
confirm the assumption that fructose is predominantly delivered to the liver, rather than being 
metabolised within enterocytes.  
Patel et al. estimated that as much as 10-30 % of an absorbed fructose load may be catabolised 
within enterocytes (Patel et al. 2015b). The same group subsequently undertook a detailed 
investigation of the effects of fructose ingestion on fructose and glucose concentrations in the 
portal and systemic circulation of both wild type mice, as well as mice lacking an active form 
of the KHK enzyme (KHK-/-). They reported portal fructose concentrations for mice consuming 
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a diet containing 20 % fructose (10 % sucrose, 0 % glucose) of 0.06 mM during fasting and 0.18 
mM, measured 8 h after feeding (Patel et al. 2015c). Unexpectedly, this diet also resulted in 
significantly higher portal glucose concentrations (12.5-19 mM) than when feeding an 
equivalent 20 % glucose (10 % sucrose, 0 % fructose) diet (9-14 mM), suggesting significant 
gluconeogenesis of fructose within enterocytes. In addition, feeding the same 20 % fructose 
diet to KHK-/- mice did not stimulate hyperglycaemia in the portal circulation, but instead 
resulted in a marked hyperfructosaemia (> 1mM), in both portal and systemic blood. These 
observations indicate the potential importance of intestinal KHK activity in the metabolism of 
an ingested fructose load. When the fructose content of the diet was increased to 40 %, a 
greater fructose-induced hyperglycaemia was noted in wild type animals, as well as an 
increased hyperfructosaemia in KHK-/- animals.    
The significance of enterocyte fructose metabolism was further confirmed this year (2018) by 
the work of Jang and colleagues. Through an extensive series of experiments using both wild 
type and KHK-/- mice, as well as stable isotope-labelled [13C]-fructose, [13C]-glucose and [13C]-
sucrose, it was shown that the majority of a fructose load is in fact metabolised within the 
small intestine, rather than the liver (Jang et al. 2018). Following feeding of either 0.5 g/kg of 
fructose and glucose (1 g/kg total), or 1 g/kg sucrose, approximately 90 % of the fructose load 
was cleared by the small intestine. The principal metabolic products of fructose metabolism 
appearing in the circulation were glycerate, glucose and organic acids. It was also shown that 
the concentration of fructose-derived glucose in the portal circulation quickly exceeded that 
of fructose itself after feeding, indicating a significant degree of intestinal gluconeogenesis. 
The authors also reported that in wild type mice fed sucrose comprised of [13C]-fructose and 
[12C]-glucose, there was a large 13C-labelled glucose excursion in portal blood (up to 0.8 mM), 
demonstrating direct conversion of fructose into glucose (via gluconeogenesis) in the 
intestine. In support of the work of Patel et al., no such increase in 13C-labelled glucose was 
observed in the portal circulation of KHK-/- animals, again highlighting the importance of this 
enzyme for intestinal fructose metabolism.   
 Through differential [13C]-labelling of either carbons 1, 2 and 3, versus carbons 4, 5 and 6 of 
fructose, it was revealed that portal vein glucose was predominantly obtained from the 
cleavage of fructose to three-carbon intermediates and their subsequent combination with 
other three-carbon compounds to form glucose. These ground-breaking findings, although 
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observed in rodents, have emphasised the importance of enterocyte fructose metabolism 
with regards to the overall metabolic impact of sucrose, and fructose, consumption.   
 
1.5.1 Fructose and de novo lipogenesis (DNL) 
1.5.1.1 The process of DNL and its regulation 
De novo lipogenesis (DNL) refers to the endogenous production of newly-synthesised fatty 
acids (FA) from other dietary substrates. It may be considered a three-step process involving 
FA synthesis, elongation and/or desaturation, and assembly of de novo FA into triacylglycerol 
(see section 1.2.1). The three-carbon intermediates (G-3-P and DHAP) from the breakdown of 
glucose and fructose are metabolised into pyruvate, which may then enter mitochondria and 
be converted to Ac-CoA and utilised for energy generation via the TCA cycle. However, during 
periods of sufficient cellular energy status, citrate may be transported into the cytosol by the 
mitochondrial tricarboxylate transport system (Kaplan et al. 1990), therefore making it 
available for DNL (Figure 1.12). Citrate is converted to Ac-CoA via the action of ATP citrate 
lyase (ACL), which is further metabolised to into malonyl-CoA by Acetyl-CoA carboxylase (ACC) 
(Softic et al. 2016). Fatty acid synthase (FAS) then sequentially adds two-carbon units from Ac-
CoA, thus extending the acyl chain into a sixteen-carbon palmitate molecule. Palmitate 
molecules (16:0) may then be further lenthened by elongase enzymes, including those of the 
Elovl (elongation-of-very-long-chain-fatty acids) family, which consists of at least 6 members, 
thought to act in a substrate-specific manner on FA of different lengths and degrees of 
desaturation (Jakobsson et al. 2006). Palmitate is considered the major product of DNL in 
humans (Hudgins et al. 1996). However, both palmitate and stearate (18:0) are commonly 
desaturated via the action of stearoyl-CoA desaturase (SCD), also known as Δ9-desaturase, to 
form the more soluble FA palmitoleate (16:1, n-7) and oleate (18:1, n-9) (Ntambi 1999). 
The products of DNL may be directed towards phospholipid or TAG synthesis. The resulting 
TAG may contribute to intracellular stores or be incorporated into lipoprotein particles for 
secretion (section 1.2.5). The main rate-limiting step during endogenous lipid synthesis is the 
action of ACC. The expression of ACC is controlled by several transcription factors including 
sterol regulatory element binding proteins (SREBP1a and SREBP1c) and carbohydrate 
response element binding protein (ChREBP). While ACC may be considered the rate-limiting 
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enzyme for DNL, SREBP1 transcription factors also regulate the expression of other genes 
essential for the functioning of this pathway, including FAS and SCD.   
Both transcription factors may be induced by a high-carbohydrate diet, although SREBP1c 
requires insulin signalling, while ChREBP may induce expression of lipogenic enzymes 
independently of insulin (Tong 2005). The activity of ACC is allosterically activated by citrate 
and inhibited by increased cytosolic palmitate levels. The induction of cyclic adenosine 
monophosphate (AMP) mediated phosphorylation by glucagon, as well as AMP-activated 
protein kinase activity, also inhibit the functioning of ACC (Softic et al. 2016).       
 
 
Figure 1.12. The process of de novo lipogenesis (DNL) in humans. 
Citrate exiting the tricarboxylic acid cycle in mitochondria is transported into the cytosol, where it is 
converted into acetyl-CoA. Palmitate is the major product of DNL, which may be further elongated 
and desaturated to form other fatty acids. Numbers refer to enzymes or enzyme groups: (1) ATP 
citrate lyase; (2) acetyl-CoA carboxylase; (3) fatty acid synthase; (4) fatty acid elongases; (5) Δ9-
desaturase. Adapted from (Steenson et al. 2017). Reproduced under the Creative Commons 
Attribution License. 
 
 
1.5.1.2 Fructose and hepatic DNL 
As outlined in section 1.4, the metabolism of fructose to triose-phosphates is an unregulated 
process, which provides a pool of three-carbon intermediates within fructose-metabolising 
cells, which may be channelled towards DNL. The majority of studies to date investigating 
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whether fructose stimulates DNL have focussed on hepatic FA synthesis, which is typically 
measured as the appearance of de novo FA in lipoproteins within the Sf 20-400 range. 
However, as shown in Figure 1.5, there is a significant degree of overlap in the density ranges 
of CM and VLDL, particularly in the case of smaller CM and CMR, which may predominate in 
the fasted state, and larger post-prandial VLDL1 particles (Sf > 400). Therefore, the use of 
ultracentrifugation to separate lipoproteins of intestinal (Sf > 400) and hepatic origin (Sf 20-
400), while the most commonly used method, does not completely separate apoB48- and 
apoB100-containing lipoproteins. In humans, substantial amounts of TAG are carried by CM 
in the Sf 60-400 density range, particularly in response to meals containing saturated FA and 
in the later post-prandial phase, when a greater number of small, dense CMR are present in 
the circulation (Jackson et al. 2002, Jackson et al. 2005, Jackson et al. 2006). A methodological 
solution to this problem is discussed in section 1.5.2.2 and section 2.1.7. Caution is therefore 
required in interpreting studies reporting values for ‘hepatic DNL’ (Sf 60-400), which may also 
include some contribution from intestinal DNL. Equally, larger VLDL1 particles (Sf > 400) may 
also be incorrectly labelled as CM. Despite this caveat, the studies discussed here will be 
assumed to relate to ‘hepatic’ DNL, and in section 1.5.1.3  to relate to ‘intestinal’ DNL.    
It was recently shown, using 71 obese male subjects, that the consumption of 75 g of fructose 
per day for a 12-week period, in addition to an ad libitum diet, led to an increase in fasting 
hepatic DNL (12.3 vs. 16.5 %), as well as at 4 h and 8 h post-prandially, following an oral fat 
tolerance test (OFTT) (Taskinen et al. 2017). This was assessed using stable isotope techniques 
(see section 1.6), whereby DNL was determined from the appearance of ‘labelled’ [13C]-
palmitate in the VLDL1 lipoprotein fraction (Sf 60-400). The researchers also reported that DNL  
explained 16 % of the overall increase in post-prandial TAG that was observed following the 
fructose intervention. An acute fructose load of 1.4 g/kg of body weight (BW), given in 13 
doses over a period of 6 h, was shown to stimulate hepatic DNL in 15 lean and overweight 
subjects (9 male [M], 6 female [F]) (Hudgins et al. 2011). Mean fractional DNL peaked at 2.4 
times fasted (0 h) values by 8 h into the study (10.2 ± 7.5 fasted vs. 24.2 ± 10.3 % [mean ± SD]).  
The effect of fructose on hepatic DNL in comparison to other CHO types has been reported in 
other studies. For example, in a study of 8 healthy males (body mass index [BMI] < 30 kg/m2) 
consuming a 25% fructose diet for 9 days, their total hepatic DNL was found to be 7.6 % higher 
than when consuming a complex CHO control diet (Schwarz et al. 2015). A significant increase 
in hepatic DNL has also been reported following longer-term consumption of fructose. 
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Stanhope and colleagues reported that consuming fructose-sweetened drinks over a 10-week 
period, as part of an isoenergetic diet, led to a significantly higher hepatic fractional DNL in 
the post-prandial state (+75 %), in comparison to the same period drinking glucose-sweetened 
drinks (+27 %) (Stanhope et al. 2009). 
Given the complexity of hepatic energy metabolism, one important question is whether 
fructose may enhance DNL directly by acting as a substrate. This was reported by Chong et al, 
who traced the metabolic fate of oral loads of fructose and glucose (0.75 g/kg body weight) in 
14 healthy subjects (8 male, 6 female), by measuring the conversion of [13C]-fructose and [13C]-
glucose to [13C]-palmitate within circulating VLDL1 (Chong et al. 2007). Although this only 
accounted for ~0.4% of total VLDL-TAG, it was noted that this value may have been 
underestimated due to methodological limitations, as the authors only estimated DNL at a 
single time point and were unable to account for the 13C-enrichment of the fatty acid 
precursor pool used for hepatic TAG synthesis. In spite of this, the [13C]-palmitate 
concentration was significantly higher after fructose loading than after glucose, which yielded 
[13C]-palmitate values similar to baseline (fasted).  A larger 2.9-fold difference in [13C]-
palmitate in the total TRL fraction (Sf > 20) was reported by Egli and colleagues, during an oral 
fructose test (0.2 g/kg fat-free mass; 0.1% [U-13C]-fructose) in 8 healthy males, following a 4-
day diet either high (30% of energy) or low in fructose (Egli et al. 2013). However, this 
difference did not attain significance, due an unexpectedly high inter-individual variation. 
These studies clearly demonstrate that ingestion of a fructose load results in the conversion 
of a proportion of fructose carbons into de novo lipids via hepatic DNL. However, perhaps of 
greater relevance, is how fructose is metabolised when it is eaten as part of a mixed-nutrient 
meal. This was investigated by Theytaz et al, who reported the conversion of [13C]-fructose to 
[13C]-palmitate within VLDL, following consumption of a mixed meal containing fructose (0.5 
g/kg body weight [BW]), fat (0.3 g/kg BW) and protein (0.3 g/kg BW) (Theytaz et al. 2014). 
Unfortunately, the amount of fructose channelled towards DNL could not be calculated, due 
to the lack of measurement of the ‘labelled’ acetyl-CoA precursor pool used for FA synthesis. 
Taken together, the studies discussed above clearly demonstrate that the ingestion of fructose 
is associated with some degree of de novo lipid synthesis within hepatocytes, and that 
fructose can be used as a DNL substrate. However, as already discussed above, it is possible 
that some of the de novo FA may have been derived from enterocytes of the small intestine, 
due to the overlapping density ranges of VLDL and CM lipoproteins.  
 56 
 
1.5.1.3 Fructose and intestinal DNL 
Although few studies have been conducted to date, there is limited evidence from animals 
and humans that fructose-stimulated DNL occurs within enterocytes of the small intestine. 
Using Syrian golden hamsters, Haidari et al (2002) reported DNL within primary enterocytes, 
which had been isolated from animals fed either a high-fructose diet (60%) or a chow diet for 
3 weeks (Haidari et al. 2002). Enterocytes from fructose-fed animals incorporated three times 
the amount of radio-isotope label [3H]-acetate into FA, compared to chow-fed animals, 
indicating not only the presence of enterocyte DNL, but its upregulation in response to chronic 
fructose feeding. The authors also demonstrated the direct conversion of [14C]-fructose into 
TAG secreted by the enterocytes, confirming that fructose can act as a DNL substrate.  
The presence of de novo FA within TAG of the Sf > 400 TRL fraction, which may be assumed to 
be predominantly of intestinal origin, has also been demonstrated in humans. In the 
aforementioned work of Theytaz et al (2014), 8 healthy (mean BMI = 22 kg/m2) volunteers 
(4M, 4F) were given one of three mixed meals containing protein and lipid (both 0.3 g/kg BW; 
ProLip), ProLip plus fructose (0.5 g/kg; Fru) or ProLip plus fructose and glucose (both 0.5 g/kg; 
Fru + Glu), with the fructose component containing 1 % [U-13C]-fructose to trace its 
metabolism. Feeding of both Fru and Fru + Glu meals led to detectable [13C]-palmitate in the 
Sf > 400 TRL fraction, with a greater [13C]-palmitate incremental area under the curve (iAUC) 
response following Fru + Glu (~2 μmol/L*360 min) than after Fru alone (~1.2 μmol/L*360 min), 
although this difference did not attain significance (P < 0.08). Whether this may imply that co-
ingestion of fructose and glucose favours the disposal of fructose carbons via DNL remains to 
be seen. This difference could be explained by a difference in energy intake between the Fru 
(6 kcal/kg BW) and Fru + Glu (8 kcal/kg) test meals. Indeed, the issue of overall energy intake 
remains one of the main challenges in the interpretation of findings from many studies 
showing deleterious effects of fructose on lipid metabolism (Tappy et al. 2010).  
Another more recent study was conducted by the same group, using the protocol described 
above (ProLip and Fr + G meals) with 8 obese (mean BMI = 44 kg/m2) patients (5W, 3M) who 
had undergone Roux-en-Y gastric bypass surgery (RYGB) and 8 control subjects, who were 
matched for age, weight and gender (Surowska et al. 2016). Again, the authors demonstrated 
DNL from [U-13C]-fructose within human enterocytes. Interestingly, in control subjects, the 
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reported iAUC for CM-[13C]-palmitate (Sf > 400) was almost 2-fold greater than the iAUC for 
VLDL-[13C]-palmitate (Sf 20-400), suggesting enterocytes contributed more de novo palmitate 
to the overall circulating TRL-TG pool than hepatocytes. However, these estimates of hepatic 
and intestinal DNL reported were only qualitative, as the enrichment of isotope tracer in the 
acetyl-CoA precursor pool was not measured.  
 
 
1.5.2 Fructose and CM metabolism 
1.5.2.1 Fructose and apoB48 concentration 
The size of CM and their remnants is known to vary widely (75 – 1200 nm diameter) according 
to their TAG content (Demignot et al. 2014), which is influenced by several factors, including 
the amount and type of dietary fat consumed, as well as age and gender (Knuth et al. 2006, 
Griffo et al. 2014, Milan et al. 2016). One common feature of CM, however, is that each 
lipoprotein contains only a single structural apoB48 molecule, which is not degraded or 
exchanged during particle metabolism (see section 1.2.5). The plasma concentration of 
apoB48 may therefore be taken as a measure of the CM and CMR particle number, and may 
be more informative when considered together with the total or TRL-TAG concentration. 
Several studies have investigated the effect of fructose feeding on apoB48 levels in both 
humans and animals.  
Syrian golden hamsters have a lipoprotein metabolism more similar to humans than either 
mice or rats, with a larger proportion of circulating lipids carried in non-HDL lipoproteins. 
Although HDL is the principal lipid carrier in Syrian golden hamsters, animals quickly develop 
HyperTAG when fed a cholesterol-rich diet, as well as insulin resistance on a high-fat, high-
CHO diet (Dalbøge et al. 2015). Therefore, they may be considered a preferred animal model 
for the study of diet-induced dyslipidaemia. Chronic feeding of a high fructose (60%) diet vs. 
a chow diet for 2–3 weeks was reported to increase total plasma and TRL apoB48 levels, both 
in the fast and fed states, in Syrian golden hamsters (Haidari et al. 2002, Qin et al. 2009). This 
was shown to be due to an enhanced apoB48 stability and secretion, with a tendency towards 
the production of larger TG-rich CM-like particles in the Sf > 400 fraction (Haidari et al. 2002). 
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Studies in humans using more physiologically-relevant amounts of fructose have also 
observed effects on apoB48. In the above-mentioned study by Egli and colleagues (2013), a 
group of nine healthy (BMI 22.1 ± 1.9 kg/m2), young (21.5 ± 2.7 years) male subjects, 
consumed a 4-day high-fructose (HFru) diet (30 % energy), or a 4-day isocaloric control diet 
(30 % complex CHO). Plasma apoB48 and TRL-TAG concentrations were significantly higher in 
both the fasted state (approximately two-fold) and following an oral fructose challenge (0.2 
g/kg BW) after the HFru diet, therefore indicating an enhanced intestinal CM production.  
In an acute study of 9 young (21.2 ± 0.3 years), healthy weight (BMI 20.5 ± 0.8 kg/m2) Japanese 
women, participants were given one of four drinks, containing either glucose or fructose (0.5 
g/kg body weight), OFTT cream (0.35 g/kg as fat) or fructose and cream together. The 
researchers found that the consumption of fructose and OFTT cream led to a significantly 
greater plasma apoB48 iAUC response (p<0.05), with a delayed peak (higher at 4 and 6h), in 
comparison to fructose, fat or glucose given alone (Saito et al. 2013). A subsequent study by 
the same group, again using healthy Japanese females (n = 12), altered the relative 
proportions of glucose and fructose (w/w) in the test meal (0.5 g/kg body weight), giving either 
100% glucose or fructose, 90% fructose and 10% glucose, or 55% fructose and 45% glucose, in 
combination with the same amount of OFTT cream (Saito et al. 2015). All drinks significantly 
increased plasma apoB48 levels, compared to fasted values. However, 6h after all fructose-
containing drinks, apoB48 levels remained significantly raised above fasted values, while that 
for 100 % glucose drink returned to pre-meal levels. Taken together, these observations may 
suggest either a greater CM secretion, or a delayed plasma clearance, in response to fructose.   
A more detailed investigation of apoB48 metabolism in response to fructose feeding was 
undertaken by Xiao and colleagues (Xiao et al. 2013). Seven healthy males, aged 23 to 55 years 
old (mean BMI 23.6 kg/m2), received an intraduodenal infusion of a 20% (w/v) Intralipid (IL) 
solution (60 mL/h) over a 14 h period, either with or without a co-infusion of glucose (IL + Glu) 
or fructose (IL + Fru) solution (both 20% w/v, 60 mL/h). An infusion of [2H3]-leucine was started 
5 h into the study, in order to measure apoB48 kinetics in the post-prandial state. The TRL-
apoB48 production rate (PR) was significantly increased during both the IL + Glu (P < 0.01) and 
IL + Fru (P < 0.05) infusions, versus IL only. However, while the IL + Glu infusion also led to a 
corresponding increase in the TRL-apoB48 fractional clearance rate (FCR; P < 0.05), no such 
increase in the FCR was observed for the IL + Fru group, indicating an impaired CM clearance. 
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These effects on apoB48 lipoprotein kinetics were accompanied by an increase in total plasma 
TG and TRL-TG in IL + Glu (P < 0.05 for both) and IL + Fru groups (P < 0.01 for both).  
Both the human and animal data discussed above, although quantitatively limited at present, 
indicate that fructose does indeed increase circulating apoB48 levels, both when consumed 
alone and as part of a mixed nutrient meal. These effects also appear to be greater when 
fructose, or fructose-containing meals, are consumed, in comparison to glucose.  
 
1.5.2.2 Fructose and CM-TAG concentration 
Several of the fructose feeding studies already discussed above, have reported data for the 
effect of fructose feeding on TAG concentration within the Sf > 400 fraction, which is 
commonly assumed to represent CM. Most of these studies, however, did not detect a 
significant effect of fructose on CM-TAG levels. Chronic fructose consumption for 10 weeks, 
in the study of Taskinen et al (2017), resulted in an almost significant post-prandial AUC for 
Sf > 400 TAG (P = 0.09), although the corresponding iAUC was far from significant (P = 0.74) 
(Taskinen et al. 2017). The studies of Theytaz et al (2014) and Surowska et al (2016), also 
reported non-significant effects on Sf > 400 TAG. In the latter study, control subjects that 
consumed Fru + Glu in addition to ProLip, displayed a higher Sf > 400 TAG response, with a 
larger delayed peak and higher iAUC over the 360 min time course, compared to ProLip alone. 
These differences were not significant, perhaps owing to the low statistical power of the study 
(Surowska et al. 2016). In the earlier study, providing ProLip with either Fru, or Fru + Glu, did 
not differentially affect the Sf > 400 TAG response, giving equivocal iAUC values (Theytaz et al. 
2014). 
In the Syrian golden hamster experiments of Haidari et al (2002), the post-prandial Sf > 400 
TAG secretion rate increased after 3 weeks of a high-fructose diet, versus a chow diet, 
although again this difference did not achieve significance (P = 0.14) (Haidari et al. 2002). The 
study by Chong and colleagues (2007), however, did detect a significantly higher Sf > 400 TAG 
concentration after consuming fructose, as compared to glucose (P = 0.03), although only in 
the later post-prandial phase (240 - 360 min) (Chong et al. 2007).  
One possible explanation for a lack of significant effect in these studies, aside from either a 
low statistical power or high inter-individual variability in the post-prandial response, is due 
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to the overlapping density ranges of CM, CMR and VLDL lipoproteins (see section 1.2.4). The 
presumption that CM-TAG may be isolated sufficiently from the Sf > 400 fraction is not true, 
as significant amounts of intestinally-derived TAG is known to reside in the Sf 60–400 (VLDL1) 
fraction (Jackson et al. 2002, Jackson et al. 2005, Jackson et al. 2006).  
 
1.6 Stable isotope tracer techniques 
1.6.1  General tracer theory 
The term ‘stable isotope’ refers to atoms of an element that possess the same number of 
protons, but a different number of neutrons to the most commonly-occurring isotope of that 
element. For example, carbon-13 (13C) contains one more proton than carbon-12 (12C) and so 
has a higher atomic mass, with the two isotopes having natural abundances of 98.92 % and 
1.08 %, respectively (Chinkes et al. 1996). Biological molecules are therefore composed of a 
mixture of 12C and 13C atoms that reflects these natural abundances, as well the stable 
isotopes of other common biological elements, including nitrogen (14N and 15N), oxygen (16O, 
17O and 18O) and hydrogen (1H and 2H). Stable isotope use in metabolic research has increased 
in the last few decades, largely due to the commercial availability of highly purified (≥ 99 %) 
compounds that are universally ‘labelled’ in all positions, such as [13C6]-glucose, as well as the 
use of gas chromatography-mass spectrometry (GC-MS) or GC-isotope ratio mass 
spectrometry (GC-IRMS), which confers a high degree of precision in detecting differences in 
the abundance of isotopes within a sample (Koletzko et al. 1998). 
In human stable isotope studies, an enriched ‘tracer’ containing labelled atoms (e.g. [2H5]-
glycerol) is administered, either orally or intravenously, in order to measure the metabolism 
of a particular molecule, termed the ‘tracee’. A tracer should have the same physical, chemical 
and biological properties as the tracee, mix uniformly with the tracee and reflect the tracee’s 
metabolism in vivo (Pont et al. 1998). The incorporation of the labelled tracer into the 
metabolite of interest over time can be determined by blood sampling, allowing the rate of 
product synthesis to be calculated. For example, labelled [13C2]-acetate may be used to trace 
the synthesis of de novo palmitate from an acetate ‘precursor’ pool (see section 1.5.1.1).    
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GC-MS can be used to separate and quantify ions of different masses, corresponding to the 
labelled and unlabelled forms of the product, thus allowing the enrichment of the product to 
be calculated as the tracer-to-tracee ratio (TTR) (Patterson 1997). Stable isotope tracers offer 
several advantages over the use of radioactive isotopes, such as 14C. Firstly, the absence of 
radioactivity makes them safer for in vivo use in human experiments. Also, their stability 
allows the study of more complex metabolic pathways over longer periods of time. Tracers 
with different labels can also be administered via alternate routes (e.g. oral and intravenous) 
to label the same metabolite or metabolic pathway (Koletzko et al. 1998). However, as noted 
above, naturally-occurring stable isotopes are present within biological molecules, which must 
be corrected for to obtain the enrichment due to tracer incorporation. The most common way 
to do this is to take separate blood samples to measure the ‘background’ enrichment of the 
molecule of interest, which can then be subtracted to obtain the corrected enrichment in the 
sample.  
         
1.6.2  Measurement of VLDL-TAG and CM-TAG kinetics 
1.6.2.1 Studies of VLDL-TAG kinetics in the fasted state 
In the last few decades, stable isotope methodologies for the measurement of lipoprotein 
kinetics in vivo have been developed and refined, to allow study of the quantitative dynamics 
of lipoprotein metabolism in the fasted steady-state (Magkos et al. 2009). A labelled 
precursor, usually either glycerol or palmitate, is administered as a bolus injection or a 
constant infusion, allowing calculation of lipoprotein kinetic parameters, including the VLDL-
TAG production rate (PR) and fractional catabolic rate (FCR).  
Lemieux et al (1999) compared the use of bolus injections of radioactive [2H3]-glycerol and 
stable [2H5]-glycerol, to measure the FCR of VLDL-TAG. The [2H5]-glycerol bolus provided a 
safer and shorter duration method for repeated measurement of VLDL-TAG kinetics (Lemieux 
et al. 1999). In a later study by Patterson et al (2002), an intravenous [2H5]-glycerol bolus was 
combined with compartmental modelling of tracer data to determine VLDL-TAG FCR, and 
compared to the use of [1-13C]-palmitate (intravenous bolus) or [2,2-2H2]-palmitate (bolus and 
constant infusion) (Patterson et al. 2002). The authors concluded that this approach gave a 
faster and more accurate estimation of VLDL-TAG kinetics, which accounted for tracer 
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recycling through intrahepatic lipid pools, an issue which is problematic when using 
radiolabelled [2H3]-glycerol or a constant infusion protocol. The same protocol has since been 
used successfully for the simultaneous measurement of VLDL apoB100 and TAG kinetics, by 
injecting boluses of [2H3]-leucine and [2H5]-glycerol, respectively, as well as to demonstrate 
that diabetic dyslipidaemia is driven by an overproduction of VLDL1 particles (Adiels et al. 
2005, Adiels et al. 2005a). Our laboratory recently used a [2H5]-glycerol bolus and 
compartmental modelling to study the differential effects of high- (26 % E) and low-sugar (6 
% E) diets in men with non-alcoholic fatty liver disease (NAFLD) and low liver fat ‘control’ 
subjects (Umpleby et al. 2017). In response to a high-sugar diet, a greater amount of hepatic 
TAG was channelled towards VLDL1-TAG in control subjects (P < 0.02), but in contrast, 
individuals with NAFLD exhibited a higher production of VLDL2-TAG (P < 0.05).             
 
1.6.2.2 Studies of VLDL-TAG and CM-TAG in the post-prandial state 
Post-prandial studies of lipoprotein TAG kinetics in vivo are complicated by the dynamic 
effects of meal ingestion on VLDL-TAG kinetics, meaning that the steady-state required for 
quantitative kinetic calculations cannot be assumed (Søndergaard et al. 2012). Various 
continuous feeding protocols have been developed to try and overcome this problem. For 
example, Welty at al consistently achieved a steady post-prandial plasma and VLDL-TAG in 
several studies, when subjects were fed 20 small meals every hour (45 % energy as CHO, 15 % 
protein, 40 % fat) (Cohn et al. 1990, Lichtenstein et al. 1992, Welty et al. 2004). However, it 
was noted that a steady-state was difficult to maintain in some subjects. A similar feeding 
regimen has also been used to achieve a steady-state, where participants consumed 1700 kcal 
(55 % CHO, 38 % fat, 7 % protein) divided into equal portions consumed every two hours (Pont 
et al. 2002). 
All of the studies mentioned above measured apoB particle kinetics, but did not provide any 
estimate of the kinetics of TAG within VLDL. This is important, as changes in VLDL-TAG do not 
necessarily correlate with changes in the number of VLDL, but may be the result of an altered 
VLDL particle size and therefore TAG content (Mittendorfer et al. 2003).   
One alternative to using solid meals, is to use mixed-nutrient ‘liquid meals’ to elicit a steady-
state plasma TAG. Sun et al (2013) took this approach to develop a novel methodology for the 
measurement of both VLDL- and CM-TAG in the post-prandial state. Five healthy males, aged 
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56.6 ± 3.0 years (mean ± SEM) and with a BMI of 24.4 ± 1.1 kg/m2, were studied. The subjects 
consumed liquid meals consisting of 88 % energy as fat, 11 % CHO and 1% protein, every two 
hours for a period of 11 h (Sun et al. 2013). An intravenous bolus of [2H5]-glycerol (750 mg) 
was given 4 h after the commencement of feeding, when a steady-state was assumed to have 
been established. The study successfully achieved a steady plasma TAG concentration of 2.04 
± 0.27 mmol/L, with no significant differences during the 7 h during which CM-TAG and VLDL-
TAG kinetics were measured. There was no significant difference between the CM and VLDL1 
FCR during the study, with 47 % of the total TAG PR from CM-TAG. 
The methodology developed and validated in this study was subsequently applied to the 
investigation of CM-TAG and VLDL-TAG kinetics in eight men with metabolic syndrome (BMI 
29.7 ± 1.1 kg/m2), compared to eight healthy aged-matched controls (BMI 23.1 ± 0.4 kg/m2). 
In subjects with metabolic syndrome, the PR of CM, VLDL1 and VLDL2 TAG was higher than in 
lean controls, with no difference in FCR for any of the lipoprotein classes, indicating that the 
post-prandial hyperTAG observed was due to an increase in CM-TAG and VLDL-TAG 
production.  
To date, no kinetic studies on the effects of fructose consumption on post-prandial VLDL-TAG 
or CM-TAG kinetics have been conducted. The proposed in vivo study, described in the next 
section, will attempt to provide the first known data for these parameters using human 
subjects in the fed state.                    
 
1.6.3 Measurement of DNL in humans 
The direct measurement of DNL in humans using stable isotopes was first undertaken by 
Hellerstein et al (1991), using an intravenous infusion of [1-13C]-acetate to label the cytosolic 
acetyl-CoA pool in the liver, as the precursor for de novo FA synthesis (Hellerstein et al. 1991). 
By taking blood samples to measure the [13C]-enrichment of palmitate within circulating VLDL-
TAG, it is possible to determine the fractional contribution of DNL. However, one important 
requirement of this method is the need to calculate the [13C]-enrichment of the intrahepatic 
precursor pool used for palmitate synthesis via a technique termed mass isotopomer 
distribution analysis (MIDA), which computes the precursor enrichment based on 
mathematical combinatorial probabilities relating the relative proportions of palmitate 
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‘isotopomers’ within the sampled product pool (Hellerstein et al. 1999). Palmitate is 
synthesised from n = 8 acetate molecules and may therefore contain any number of labelled 
[13C]-acetate subunits, from a minimum of 0 (M0) to a maximum of 8 (M8), therefore giving a 
range of isotopomers (M0 to M8), each with a different number of subunits incorporated. By 
measuring the distribution of palmitate isotopomers by GC-MS and comparing this with 
expected mathematical distributions for a given n, it is possible to calculate the isotopic 
enrichment of the precursor pool. While several methods have been proposed for performing 
this calculation, a comparison of these approaches showed that they yielded similar results 
(Chinkes et al. 1996).  
An alternative method for the in vivo measurement of DNL in humans, which uses an orally 
administered deuterated water (2H2O) load to label total body water (TBW), was first 
presented by Leitch et al (1991). This method involves measuring the incorporation of 
deuterium atoms into de novo palmitate, or other fatty acids, by determining [2H]-enrichment 
via isotope ratio mass spectrometry (IRMS), which confers a greater degree of sensitivity to 
detect mass differences than is possible with GC-MS. Measurements of the precursor pool 
(TBW) enrichment can be easily made by sampling the [2H]-enrichment in plasma water. Using 
deuterated water to measure DNL confers several advantages over the use of an [13C]-acetate 
infusion, including its relatively low cost, easier mode of administration (orally) and more rapid 
equilibration with the TBW precursor pool (Murphy 2006). Deuterated water was used as the 
tracer in one of the largest dietary intervention studies conducted to date to investigate the 
effect of fructose on hepatic DNL (Taskinen et al. 2017). In 71 abdominally obese men, 
consuming 75 g of fructose per day for 12 weeks, in addition to their habitual diet, led to a 
significant increase in both fasted and post-prandial DNL (4 h and 8 h post-meal), which was 
measured as de novo palmitate in the VLDL1 fraction (Sf 60-400). The present study will also 
utilise deuterated water in order to quantify DNL, although this will be measured in TAG-
palmitate from both hepatic (VLDL) and intestinal (CM) lipoproteins, which will be separated 
more precisely on the basis of both particle density and apolipoprotein B content (see section 
2.2.2).  
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1.7 Proposed work 
There is an increasing body of evidence associating a high-sugar diet with multiple CVD risk 
factors over the life course. One of these risk factors is post-prandial hyperTAG, which is 
recognised as an independent risk factor for CVD. A raised plasma TAG concentration may 
result from either an increased production, or an impaired clearance, of TRL and their remnant 
particles. A greater production of intestinal CM and CMR are an established feature of 
hyperTAG, in both the fasted and fed states. Consumption of the monosaccharide fructose 
has been linked to hyperTAG, particularly as its metabolism is not subject to feedback 
regulation, as with glucose. An ingested fructose load may be rapidly metabolised to provide 
a large intracellular pool of three-carbon intermediates, which are channelled into several 
metabolic pathways, including DNL. Fructose has been demonstrated to increase the number 
of post-prandial CM and to stimulate intestinal DNL. However, the quantitative importance of 
fructose-induced enterocyte DNL remains unknown. Equally, while post-prandial CM particle 
numbers are known to be affected by fructose feeding, no study to date has reported the 
exact effects on CM-TAG, as well as VLDL-TAG, due to methodological limitations. These two 
areas will form the focus of this project.  
The present work provides the first accurate quantification of the effects of fructose on 
intestinal and hepatic TAG metabolism, including CM-TAG and VLDL-TAG production and 
fractional clearance rates, as well as rates of DNL. An immunoaffinity method will be employed 
to purify CM and VLDL using monoclonal antibodies, allowing the distinct effects of fructose 
on the liver and small intestine to be determined. A continuous feeding protocol will be 
utilised, in order to establish a steady post-prandial state, thus allowing calculation of the 
above mentioned parameters through the use of oral and intravenously administered stable 
isotope tracers. The human study will be centred on three research questions:  
1. Does fructose acutely increase post-prandial plasma TAG?  
2. Does fructose enhance intestinal and/or hepatic TAG production or impair its 
clearance? 
3. Does fructose increase intestinal and/or hepatic DNL? 
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A complementary set of in vitro experiments will also be performed using the Caco-2 cell line, 
which possesses a well-characterised phenotype similar to small intestinal enterocytes. The 
cell experiments will focus on two research questions:     
4. Does fructose have specific effects on enterocyte TAG metabolism, in comparison to 
glucose? 
5. Are there any concentration-dependent effects of fructose and/or glucose on 
enterocyte TAG metabolism? 
1.8 Hypotheses 
For the human study, the following hypothesis will be tested: 
 High-fructose meals exacerbate post-prandial plasma TAG levels by altering CM-TAG 
and VLDL-TAG kinetics, as well as the induction of de novo lipogenesis, relative to low-
fructose control meals. 
For the in vitro Caco-2 cell studies, the following hypothesis will be tested: 
 De novo lipogenesis in Caco-2 cells is greater in response to fructose than glucose, and 
increases in a dose-dependent manner. 
1.9 Aims 
1. To perform a human study of post-prandial CM-TAG and VLDL-TAG kinetics in the 
steady-state, to determine the effects of consuming high-fructose (30 % of energy) 
mixed-nutrient liquid meals, in comparison to isocaloric, complex CHO control liquid 
meals (30 % of energy). This will aim to address research questions 1 and 2. 
2. To investigate the effect of high-fructose meals on intestinal and hepatic DNL. This will 
aim to address research question 3. 
3. To use an in vitro Caco-2 cell model to investigate the dose-dependent effects of 
fructose and glucose on enterocyte FA metabolism, including TAG synthesis, DNL and 
de novo TAG-glycerol formation. This will aim to address research questions 4 and 5. 
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Chapter 2 Methods 
2.1 Methods used in the human study 
2.1.1 Subjects 
The study was reviewed and received a favourable opinion from the University of Surrey 
(sponsor) Research Integrity and Governance Office and the NHS  Research Ethics Committee 
(REC reference: 15/LO/0891; South East Coast – Surrey). The study was registered with the 
National Institute for Health Research Clinical Research Network and listed on the website of 
the Health Research Authority (IRAS No: 19064). Subjects were recruited from Guildford 
(Surrey, UK) and the surrounding area via ethics committee approved recruitment emails and 
posters. All participants were given a copy of the participant information sheet and sufficient 
time to consider their participation, prior to undergoing informed consent with a doctor who 
explained the purpose and potential risks of the research. The inclusion and exclusion criteria 
are shown in Table 2.1.  
 
Table 2.1. Inclusion and exclusion criteria for the human study. 
Inclusion Criteria Exclusion Criteria 
 Gender:   Male 
 Ethnicity: Caucasian 
 Age: 18 – 50 
 BMI:  25 – 32 kg/m2 
 < 3 sessions of aerobic exercise per 
week 
 Weight stable for the previous 3 
months (± 2.5 kg) 
 Normal blood haemoglobin content 
(13.5-17.5 g/dL) 
 Blood pressure below 160/100 mmHg 
(systolic/diastolic) 
 Fasting plasma glucose > 7 mmol/L 
 Fasting plasma TAG > 4 mmol/L 
 Smoker 
 Type 1 or type 2 diabetes 
 Prescribed lipid-lowering medications 
 Endocrinological, cardiovascular, 
gastrointestinal and liver diseases or 
renal impairment  
 History of eating disorders, nausea or 
vomiting 
 Alcohol intake > 32 g/day or history of 
drug abuse 
 Relevant food allergies or 
intolerances e.g. fructose 
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The subjects who were recruited were generally healthy, although with an overweight to 
slightly obese BMI (25-32 kg/m2), as it has been shown that men with a higher BMI exhibit a 
greater production of intestinal CM and VLDL particles than lean controls (Shojaee-Moradie 
et al. 2013). 
2.1.2 Study design 
This was an acute dietary intervention study with a randomised crossover design, involving 
two post-prandial metabolic study days. On each study day, participants consumed regular 
high-fat drinks every hour for 11 h, which were either high (30%) or low (0%) in fructose, in 
order to elicit a steady post-prandial TAG response. Following the first metabolic study day, 
participants underwent a 4-week washout period before completing the second study day.  
2.1.3 Study power 
The primary outcome measure for the study was the CM-TAG production rate (PR) in response 
to high- or low-fructose test drinks. In a previous study conducted by our research group, 8 
healthy lean males (BMI 23.1 ± 0.4 [mean ± SEM]) underwent the same feeding protocol as 
proposed for the current study (section 2.1.4) (Shojaee-Moradie et al. 2013). Subjects had a 
mean (± SD) CM-TAG PR of 11.82 ± 5.26 g/day. Assuming a recruitment of 10 males for the 
current study, it was determined that this would yield a smallest detectable mean difference 
of 7.44 g/day at a power of 80% and α = 0.05 (two-tailed paired-samples t-test). Due to the 
lack of existing data on within-subject variability, this value may have been an overestimate. 
The calculation was verified by a senior medical statistician (Dr Sig Johnsen, Surrey Clinical 
Trials Unit).      
2.1.4 Metabolic study day protocol 
Subjects were requested to avoid consuming alcohol and not to undertake any strenuous 
exercise for 24 h prior to each metabolic study day. Subjects attended the Centre for 
Endocrinology, Diabetes and Research (Cedar) at Royal Surrey County Hospital on the 
afternoon before each study day for a non-fasted blood sample, in order to determine their 
background level of plasma deuterated water (2H2O) (section 2.1.20) and VLDL-TAG palmitate. 
At this visit, participants were given two bottles containing loading doses of 2H2O (99.8%, 
Cambridge Isotope Laboratories Inc., USA), to be consumed at 7pm and 10pm on the evening 
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prior to the study day, providing a total of 3 g/kg of body water. Subjects also received a low-
fat standardised meal (Big Soup, 500 g, Heinz) to consume between 6 pm and 7 pm, as well as 
additional ad libitum drinking water (Buxton, Nestlé Waters UK Ltd) containing 4.5 g/L 2H2O, 
to consume following the first 2H2O loading dose. Subjects were requested to consume no 
food or drinks other than those provided until the next day. 
Prior to each metabolic study day, participants completed a standardised food diary for 4 days, 
in order to assess their energy and macronutrient intake. Participants were given detailed 
instructions on how to complete each diary. All food diaries were analysed using the Nutrition 
Analysis Software Nutritics (version 5.025; Nutritics Ltd, Dublin, Republic of Ireland). 
The clinical protocol for each metabolic study is summarised in Figure 2.1. Subjects arrived 
fasted (≥ 12 h) to the Cedar centre at approximately 7.30 am. The subjects’ height, weight, 
waist-to-hip ratio and other anthropometric measurements were taken, as well as three 
fasted blood pressure measurements to calculate the mean. A cannula was inserted into the 
antecubital vein of the forearm for blood sampling. A fasted blood sample was taken at 
approximately 8 am (-240 min). Subjects then consumed either high- or low-fructose drinks 
every hour for the following 11 h (Table 2.2). Each test drink contained commercially available 
ingredients: refined olive oil (13.4 mL; Napolina UK Ltd); whey protein powder (8.1 g; 
Myprotein.com, UK), and either fructose powder (15.0 g; Tate & Lyle, UK) for the high-fructose 
drink, or maltodextrin powder (16.0 g; Myprotein.com, UK) as a complex CHO control for the 
low-fructose drink. Drinks were also prepared using 2H2O-enriched water (5g/L) and no added 
sugar squash concentrate (Tesco Ltd, UK) as a flavouring. All test drinks were made in batches 
<12 h before each study day and stored in sealed containers at 4 °C until required. Participants 
were given < 3 minutes to consume each drink.  
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Table 2.2.Composition of metabolic study day test drinks. 
Each drink (204 kcal) provided 55% of energy as fat (refined olive oil) and 30% of energy as either 
fructose (high-fructose drink) or maltodextrin (low-fructose drink). Eleven drinks were consumed at 
hourly intervals throughout the study day. CCHO, complex carbohydrate; NMES, non-milk extrinsic 
sugars (from squash concentrate).  
 
 
 
Figure 2.1. Summary of the clinical protocol for metabolic study days.  
A baseline blood sample was taken (-240 min) before subjects consumed 11 identical high-fat (55%) 
drinks, either high- (30%) or low-fructose (0%), every hour for 11 h. Blood samples were taken at the 
times indicated with red arrows. At 0 min an intravenous (i.v.) bolus of 2H5-glycerol (75 µmol/kg) was 
administered.  
 
At 12.00 pm (0 min), an intravenous bolus (75 µmol/kg) of 2H5-glycerol (30 mg/mL, 2.5 mL per 
vial, Pharmacy of Guy’s and St Thomas’ NHS Foundation Trust, UK) was administered, once a 
post-prandial steady state had been established, as informed by a previous study conducted 
within our group (Sun et al. 2013). Blood samples were taken for isolation of TRL-TAG at -240, 
0, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 and 420 min. Samples for measurement of free 
 High fructose drink Low fructose drink 
Nutrient Energy (kcal) Composition (%) Energy (kcal) Composition (%) 
Fructose 60 29.8 0 0 
CCHO 0 0 61 29.8 
Fat 112 55.0 112 55.0 
Protein 30 14.8 30 14.8 
NMES 1 0.4 1 0.4 
Total 204 100.0 204 100.0 
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plasma glycerol enrichment were taken at -240, 0, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 
300, 360 and 420 min. Hourly samples were taken at -240, 0, 60, 120, 180, 240, 300, 360 and 
420 min for plasma 2H2O, glucose, insulin, total TAG and other clinical chemistry 
measurements (section 2.1.22).      
 
2.1.5 Summary of the analytical methods used in the human study 
The schematic shown in Figure 2.2 summarises the stages of sample preparation for isolation 
and processing of TRL-TAG samples, prior to analysis by gas chromatography-mass 
spectrometry (GC-MS) or gas chromatography-isotope ratio mass spectrometry (GC-IRMS). All 
materials for laboratory analysis of human study samples, as described in sections 2.1.6 to 
2.1.24, were obtained from Sigma-Aldrich (UK), unless otherwise stated. 
 
Figure 2.2. Summary of the sample preparation methods used in the human study.  
CM, chylomicron; FAME, fatty acid methyl ester; GC-MS, gas chromatography mass spectrometry; GC-
IRMS, gas chromatography isotope ratio mass spectrometry; TAG, triacylglycerol; TLC, thin layer 
chromatography; VLDL, very low-density lipoprotein.    
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2.1.6 Ultracentrifugation to obtain triacylglycerol-rich lipoprotein fraction 
Plasma from blood samples collected during metabolic study days (see Figure 2.1) was 
separated within one hour by centrifugation at 3,000 rpm (x 1,750 RCF) for 10 min at 4°C 
(Heraeus Labofuge 400R centrifuge, Thermo Fisher Scientific, UK).  Triacylglycerol-rich 
lipoproteins (TRL) were separated from plasma by flotation ultracentrifugation using an LE80-
K ultracentrifuge with a type 50.4 Ti fixed-angle rotor (Beckman Coulter Inc., USA), to obtain 
particles with a Svedberg flotation rate (Sf) > 20  (Havel et al. 1955). Three mL of plasma was 
transferred to a 4.7 mL pollyallomer OptiSeal™ centrifuge tube (Beckman Coulter Inc., USA) 
which had been pre-coated with polyvinyl alcohol (PVA). Samples were carefully overlaid with 
1.5 mL of saline at a density of 1.006 g/mL containing 0.1% (weight/volume, w/v) 
ethylenediaminetetraacetic acid (EDTA), to give a final volume of 4.5 mL. Samples were 
centrifuged at 37,000 rpm (147,425 x g) for 16 h at 4°C. The top of the tube was then cut and 
the 1 mL fraction transferred to a volumetric flask and made up to 2 mL by washing the cut 
tube top with an additional 1 mL of 1.006 g/mL saline. The TAG concentration of each sample 
was measured using a COBAS MIRA auto-analyser (Roche Diagnostics, USA) as detailed in 
section 2.1.22.1. The required amount of sample (µL) for immunoaffinity chromatography 
(section 2.1.7) was then calculated. Samples were stored at 4 °C for no longer than 24 h prior 
to use for immunoaffinity chromatography.      
2.1.7 Separation of apoB100 and apoB48-containing lipoproteins by 
immunoaffinity chromatography 
2.1.7.1 Preparation of Protein G Sepharose Matrix coupled apoB100 antibodies 
Three separate antibody-Protein G matrices were prepared using Protein G Sepharose™ 4 Fast 
Flow media (GE Healthcare, USA) as the solid support (2 mg Protein G/mL), to allow separation 
of apoB100- and apoB48-containing lipoproteins (see section 2.1.7.3). Three bulk quantities 
of matrix were prepared in 15 mL centrifuge tubes, containing 0.06 mL (120 µg), 0.04 mL (80 
µg) and 0.09 mL (180 µg) of Protein G Sepharose per sample, with a sufficient amount for 20 
samples. This provided sufficient matrix for the binding of the three monoclonal apoB100 
antibodies 4G3, 5E11 and BSol16 (Ottawa Heart Institute, Ontario, Canada), respectively. Prior 
to antibody binding, the solid phase was washed sequentially with a 10-times volume of 
deionised H2O (di H2O), 1 mM hydrochloric acid and 20 mM sodium phosphate coupling buffer 
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(Na2HPO4, coupling buffer, pH 7.0). Following each wash, tubes were centrifuged (1,000 rpm, 
10 min, 4 ⁰C) and the supernatant discarded. The three apoB100 antibodies (1 mg/mL; 75 µg 
per sample) were then coupled separately to the Protein G Sepharose by mixing gently on a 
rotator (SB3, Stuart, UK) overnight at 2 rpm and 4 ⁰C. The following day, the three antibody-
Protein G tubes were centrifuged (1000 rpm, 20 min, 4 °C) and the concentration of uncoupled 
antibody remaining in the supernatant was measured by a BCA protein assay, as described in 
section 2.1.7.2. Complete antibody coupling was assumed to have occurred if the protein 
concentration was less than 2.5% of the total antibody concentration. Each antibody-Protein 
G matrix tube was then washed twice with coupling buffer, centrifuged (1000 rpm, 10 min, 4 
°C) and the supernatant discarded following each wash. The final volume in each tube was 
made up to 5 mL with coupling buffer, to allow adequate matrix for 20 samples. Each of the 
three antibody matrices was then aliquoted (200 µL per sample) into individual 3.5 mL glass 
vials and stored at 4 °C, ready for immunoaffinity lipoprotein separation (section 2.1.7.3). 
2.1.7.2 Bicinchoninic acid (BCA) assay to check antibody binding   
Following antibody coupling (section 2.1.7.1), a BCA protein assay was performed as per the 
manufacturer’s instructions (Pierce™ BCA protein assay kit, Thermo Fisher Scientific, UK) to 
check for any uncoupled antibody in the supernatant of each of the three preparations. A 
series of standards were prepared by sequential dilution of a bovine serum albumin standard 
(BSA, 2 mg/mL), supplied with the kit, to give a working range of 5-250 µg/mL. Samples (25 
µL) were added in triplicate, and standards (25 µL) in duplicate, to a 96-well microplate and 
200 µL of working reagent from the kit also added. The plate was covered and incubated at 
37 °C for 30 min, before cooling to room temperature. The plate was placed into a microplate 
reader (Opsys microplate reader, DYNEX Technologies, UK) and the absorbance measured at 
540 nm (DYNEX Technologies Revelation software, version 4.25).            
 
2.1.7.3 Separation of apoB100 and apoB48-containing lipoproteins by immunoaffinity 
chromatography  
An immunoaffinity chromatography method, previously developed and validated in our 
laboratory (Sun et al. 2013), was used to separate apoB100- (Bound) and apoB48- (Unbound) 
containing lipoproteins following ultracentrifugation to obtain the Sf > 20 fraction (section 
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2.1.6). As illustrated in Figure 2.3, this separation method involves the sequential use of three 
monoclonal antibodies (4G3, 5E11 and BSol16), which recognise distinct and non-overlapping 
epitopes within the C-terminal region of the apoB100 molecule (between amino acids 2980-
4536), which are not present within apoB48. It was previously determined by Sun et al. (2013) 
that the sequential use of three antibodies gave a better separation of apoB100- and  apoB48-
containing lipoproteins, in comparison to a single step separation using  All three antibodies 
have been characterised previously to identify their epitope binding sites (Wang et al. 2000).   
   
 
Figure 2.3. A schematic showing the epitopes within apoB100 recognised by 4G3, 5E11 and BSol16 
antibodies. 
Numbers indicate the start and end residues for each binding domain, as well as the N-terminal (NH2-
) and C-terminal (-COOH) ends of the molecule. Figure based on (Wang et al. 2000).     
 
The apoB100- and apoB48- containing lipoproteins in each Sf > 20 sample were separated via 
three sequential antibody separation steps (Figure 2.4). This approach was shown by Sun et al 
(2013) to give a better separation than the use of either a single step method involving a 
mixture of the three antibodies, or two sequential antibody separation steps. The proficiency 
of separation of the two lipoprotein species was determined by the absence of apoB48 in the 
bound fraction (SDS-PAGE), as well as the absence of apoB100 in the unbound fraction 
(Western blotting) (Sun et al. 2013).    
Prior to immunoaffinity chromatography, samples were diluted to give a concentration of 1 
mmol/L of TAG, thus ensuring optimal antibody binding, before loading onto the aliquoted 
4G3 matrix (200 µL per sample) to give a final volume of 0.5 mL, which was made up with 
coupling buffer as required. The 4G3 matrix vials were incubated overnight while gently mixing 
on a rotator (2 rpm, 4 °C). The following day, after centrifugation (1000 rpm, 20 min, 4 °C), the 
supernatant (Unbound fraction) was carefully transferred to a new glass vial (one per sample) 
containing the 5E11 matrix. The bound phase in the 4G3 matrix vials was then washed twice 
with 0.5 mL of coupling buffer to collect any residual unbound lipoproteins. Following each 
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wash, vials were centrifuged (1000 rpm, 20 min, 4 °C) and the supernatant transferred to the 
5E11 matrix vials, which subsequently contained all three supernatants (Unbound fraction). 
The 5E11 vials were incubated overnight while gently mixing on a rotator (2 rpm, 4 °C). The 
remaining 4G3 bound fraction was stored in the fridge (4 °C). The next day, 5E11 matrix vials 
were washed twice, centrifuged (1000 rpm, 20 min, 4 °C) and the supernatants added to vials 
containing BSol16 matrix. The BSol16 matrix vials were incubated overnight while gently 
mixing on a rotator (2 rpm, 4 °C). Again, 0.5 mL of coupling buffer was added to the 5E11 
matrix vials (Bound fraction), which were stored in the fridge (4 °C). On the final day, BSol16 
matrix vials were washed twice and centrifuged (1000 rpm, 20 min, 4 °C) to collect the 
Unbound supernatant (apoB48-containing lipoproteins), which was transferred into a new 7 
mL glass vial labelled ‘Unbound’.  
 
 
Figure 2.4. Overview of the immunoaffinity chromatography method used to separate apoB100- and 
apoB48-containing lipoproteins.  
Three sequential incubation steps with the monoclonal antibodies 4G3, 5E11 and BSol16 gives 
Unbound (supernatant) and Bound (matrix) fractions from each incubation stage, which are pooled 
prior to lipid extraction. 
 
The Bound fractions from the 4G3, 5E11 and BSol16 matrix vials were all combined into a 
separate 7 mL glass vial (one per sample) labelled ‘Bound’. Each of the 4G3, 5E11 and BSol16 
vials was washed twice with 1 mL of coupling buffer to ensure all of the Bound phase was 
transferred into the labelled Bound vial. These vials were then centrifuged (1000 rpm, 30 min, 
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4 °C), the supernatant discarded and the samples reconstituted in 0.5 mL of coupling buffer 
and stored in the fridge (4 °C), ready for lipid extraction (section 2.1.8).  
The Unbound vials were covered with parafilm, stored in the freezer overnight at -20 °C, then 
frozen at -80 °C for 4 h. Samples were lyophilised to dryness by placing onto a freeze drier 
(ModulyoD, Thermo Fisher Scientific, UK) and then reconstituted in 0.5 mL of deionised water, 
ready for lipid extraction (section 2.1.8). 
 
2.1.7.4 Validation of the immunoaffinity chromatography separation method  
The method described in section 2.1.7.3 had previously been validated by Sun et al. (2013) 
using both Sf > 60 and Sf 20-60 TRL fractions via two separate techniques. Firstly, sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with protein silver staining 
(Bio-Rad, UK) demonstrated an absence of apoB48 in the Bound fraction and an absence of 
apoB100 in the Unbound fraction. Secondly, western blotting was used to demonstrate the 
absence of apoB100 in Unbound fractions (Sun et al. 2013). It was also determined that the 
use of three antibodies, rather than two antibodies, achieved a better separation of apoB48- 
and apoB100-containing lipoproteins, as did using a sequential separation approach rather 
than a single separation step with the same quantities of antibody matrices.           
2.1.8 Lipid extraction from lipoprotein fractions 
Lipid extraction was performed based on the procedure of Folch (Folch et al. 1957). Following 
immunoaffinity chromatography (section 2.1.7) the total lipid content of apoB100- (Bound) 
and apoB48- (Unbound) containing lipoproteins was extracted overnight (4 °C) with a 4-fold 
volume of a chloroform-methanol solution (2:1 ratio, % v/v), also containing 0.01% (% w/v) 
butylated hydroxytoluene (SAFC, Sigma-Aldrich). The next day, samples were centrifuged 
(Sorvall Legend RT Centrifuge, Thermofisher Scientific, Hamphshire, UK) at 2,500 rpm 
(corresponding to RCF 1,439 x g) for 30 min at 4 °C and the infranatant (lower phase) carefully 
transferred to a clean, labelled 7 mL glass vial. A second extraction was performed on the 
remaining supernatant (upper phase) with a further 2-fold volume of chloroform-methanol 
solution (2:1 ratio, % v/v) at 4 °C for a minimum of 1 h. Samples were again centrifuged at 
2,500 rpm (RCF 1,439 x g) for 30 min (4 °C) and the infranatant (lower phase) combined with 
that from the first extraction. To the combined samples, 0.75 mL of potassium chloride (KCl; 
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0.88% w/v) was then added to equal 25% of the total infranatant volume (3 mL). Samples were 
vortexed and centrifuged at 2,500 rpm (RCF 1,439 x g) for 30 min (4 °C) and the supernatant 
aqueous layer removed and discarded. A 100 µL volume of ethanol was added to the 
remaining lower phase, which was placed under a gentle stream of oxygen-free nitrogen (OFN; 
(NitroFlow® Lab, Parker Filtration & Separation B.V., Netherlands) and evaporated to dryness. 
Samples were reconstituted in 100 µL of chloroform ready for thin-layer chromatography 
(TLC).    
2.1.9 Separation of TAG by thin layer chromatography 
A developing chamber containing hexane-diethyl ether-acetic acid (70:30:2, % v/v) as the 
mobile phase was used to separate the different lipid classes present within the samples. Thin-
layer chromatography (TLC) plates (20×20cm aluminium sheets, Silica Gel 60, VWR 
International Ltd, UK) were prepared as shown in Figure 2.5, with extracted lipid samples (100 
µL) loaded onto plates to give a 2 cm wide band, 2 cm from the bottom and edges of the plate. 
Plates were placed into the developing chamber for 20-30 min, until the solvent front (mobile 
phase) was 3 cm from the top edge of the plate. Plates were removed and any excess mobile 
phase allowed to dry. Plates were sprayed with a 0.1 % (w/v) solution of 8-anilino-1-
naphthalenesulfonic acid in di H2O, which acts as a fluorescent molecular probe, and placed 
in a UV light box to visualise lipid bands present in the sample. A spotting standard (50 µL 
glyceryl trioleate, 1 mg/mL) prepared in chloroform was included with each batch of TLC plates 
to positively identify the position of the TAG bands in the samples from that of other 
phosphorescent lipid bands. TAG bands were lightly circled using a pencil, then TLC plates 
were cut and each sample band was carefully scraped off into a labelled 10 mL glass vial using 
a scalpel.      
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Figure 2.5. Diagram showing how silica gel plates were prepared and developed for thin-layer 
chromatography (TLC).  
Samples (1-4) were loaded to give a 2 cm wide band. Plates were developed until the solvent front was 
3 cm from the top edge. The approximate final position of the TAG in each sample is shown. 
 
2.1.10 TAG hydrolysis and derivatisation to fatty acid methyl esters (FAME) 
The scraped TAG bands from TLC plates were heated overnight (50 °C) in a solution of toluene 
(1 mL) and hydrochloric acid in methanol (1 mM, 2 mL). This step allowed simultaneous 
hydrolysis of the TAG, to yield free fatty acids (FFA) and glycerol, and derivatisation of FFA into 
fatty acid methyl esters (FAME). Immediately prior to hydrolysis and derivatisation, a 50 µL 
volume of heptadecanoate in chloroform (1 mg/mL) was also added to each sample as an 
internal standard (50 µg per sample), to allow quantification of FAMEs following GC-MS 
analysis (section 2.1.14).   
The following day, samples were cooled before adding 2 mL of 5% sodium chloride in H2O (%, 
w/v) and 3 mL of hexane. Samples were vortexed and left to stand at 4 °C for 30 min. The 
samples were then centrifuged at 2,500 rpm (RCF 1,439 x g) for 30 min (4 °C) and the 
supernatant (solvent) phase transferred to a new labelled 7 mL vial. Samples were placed 
under a gentle OFN stream, evaporated to dryness and then re-suspended in 100 µL of hexane 
and transferred to labelled GC vials (Thermo Fisher Scientific, UK; 300 µL volume) ready for 
measurement of total FAMEs concentration via GC-MS (section 2.1.14) and palmitate 
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enrichment via GC-IRMS (section 2.1.19). The remaining infranatant (aqueous phase), 
containing the TAG-glycerol moiety, was further processed to purify (section 2.1.12) and 
derivatise (section 2.1.13) the glycerol.  
2.1.11 Preparation of plasma glycerol samples 
During metabolic study visits, blood samples for plasma glycerol analysis were collected into 
4 mL vacutainers containing 68 IU of lithium heparin (BD, USA) and separated by 
centrifugation immediately following collection (section 2.1.6). Two plasma aliquots per 
sample (≥ 0.5 mL each) were then transferred to 2.0 mL microtubes and stored at -20°C until 
further analysis in the Wolfson laboratory of the Diabetes and Metabolic Medicine group. To 
prepare samples for glycerol derivatisation (section 2.1.13), 0.5 mL of plasma was transferred 
to an LP4 test tube and deproteinised by addition of 1 mL of 3.5% (w/v) 5-sulphosalicylic acid 
in di H2O for 30 minutes at 4 °C. An additional tube with 0.5 mL di H2O was included as an 
extraction/derivatisation blank. Following centrifugation at 2,000 rpm for 20 min at 4 °C, the 
supernatant was collected and purified by ion exchange chromatography (section 2.1.12), 
before derivatisation (section 2.1.13) and measurement of glycerol enrichment by GC-MS 
(section 2.1.19).           
2.1.12 Purification of TAG-glycerol and plasma glycerol by ion exchange 
chromatography  
Samples containing either plasma glycerol (section 2.1.11), or glycerol released from the 
hydrolysis of TAG (section 2.1.10), were purified by ion exchange chromatography. Columns 
(Evergreen, UK) were washed with 0.5 mL of di H2O, packed with 2 cm of AG50W-X8 cation 
resin (Bio-rad, UK) and then washed with a further 1 mL of di H2O, followed by 2 cm of AG1-
X8 anion resin (Bio-rad, UK) and finally washed with 2 mL of di H2O. Samples were then 
transferred to columns and the purified glycerol eluted with 3 mL of di H2O, which was 
collected in a new 7 mL glass vial. Samples were then dried overnight by lyophilisation on a 
freeze drier (ModulyoD, Thermo Fisher Scientific, UK).          
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2.1.13 Derivatisation of TAG-glycerol and plasma glycerol 
Glycerol samples were converted to their tert.-butyldimethylsilyl (tBDMS) derivative. This 
method yields fragments upon electron impact (EI) ionisation GC-MS that contain the entire 
glycerol molecule, therefore making it more suitable for quantifying stable isotopic 
enrichment in 2H-labelled glycerol. No enriched atoms are lost, leading to greater precision 
and lower background enrichment values than for other methods (Flakoll et al. 2000, Adiels 
et al. 2010). Derivatisation was achieved by adding 100 µL of pyridine and 100 µL of N-tert-
Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA). Samples were vortexed and 
placed on a heating block at 70 °C for 4 h, after which they were removed and allowed to sit 
at room temperature for a further 24 h, before being dried under a stream of OFN to end the 
derivatisation. Samples were re-constituted in 100 µL of decane, vortexed and transferred to 
autosampler vials ready for GC-MS analysis (section 2.1.19).         
2.1.14 Measurement of Bound and Unbound TAG fatty acid concentration by 
gas chromatography-mass spectrometry (GC-MS) 
The total fatty acid methyl ester (FAME) content of Bound (VLDL) and Unbound (CM) samples 
was analysed on an Agilent 5973 network mass selective detector (Agilent Technologies, UK). 
A 0.2 µL volume of each sample was injected into the column by a splitless injection mode 
(7683 auto-sampler, Agilent, UK) with the injector temperature set to 250 °C. The GC was 
equipped with a 30 m, 250 µm internal diameter, 0.25 µm film thickness FAMEWAX capillary 
column (Crossbond™ polyethylene glycol; Thames Restek, UK). Helium was used as the carrier 
gas at a flow rate of 1.3 mL/min. The initial GC oven temperature was 100 °C, which was held 
for 3 min, then increased to 200 °C at a rate of 25 °C/min and held for 6 min. This was then 
increased to a final temperature of 240 °C and held for 5 min. The total run time was 19.6 min. 
Individual FAME peaks were identified based on their retention time (RT) relative to the 
analytical standard RM6 (FAMEs mixture; Supelco, USA), as well as by comparing their mass 
spectra to an online standard reference database (National Institute of Standards and 
Technology [NIST], U.S. Department of Commerce, USA). An example chromatogram showing 
the FAME peaks identified in samples is shown in Figure 2.6. An example mass spectrum for 
methyl palmitate is shown in Figure 2.7, which displays both the ‘molecular ion’ (loss of a 
single electron) at m/z = 270 and characteristic ‘McLafferty ion’ at m/z = 74, indicative of a 
methyl ester molecule. The seven FA identified were myristate (14:0), palmitate (16:0), 
 81 
palmitoleate (16:1, n-7), heptadecanoate (17:0, internal standard), stearate (18:0), oleate 
(18:1, n-9) and linoleate (18:2, n-6). 
Following identification, FAME peaks for all of the seven FA present in each sample were 
integrated to obtain the area under the curve. The corrected area for each peak was calculated 
by the computer software (Chemstation, Agilent, UK), which accounts for the baseline signal 
in the chromatogram. Corrected area data was used to calculate the μg quantity of each FAME 
(FA) by reference to the internal standard (heptadecanoate, 50 µg per sample), as in Equation 
1. This was converted to a μmol amount of each FA by dividing by the molecular weight (MW). 
The amount of TAG (μmol) in each sample was then calculated as in Equation 2, by summing 
all FA amounts (μmol) and dividing by a factor of 3, to account for the number of FA per TAG 
molecule. A three-step correction process was then applied to this value, to account for 
sample recovery (%), the sample volume (μL) used for immunoaffinity chromatography (AF) 
and the plasma volume used for ultracentrifugation (3 mL), thus yielding the correct amount 
of Bound (VLDL) and Unbound (CM) TAG in the original plasma sample. 
Firstly, the recovery (%) was calculated for each sample as in Equation 3, which was applied 
to TAG values to account for losses during the processing of samples (Equation 4). The 
resulting values were then converted into a concentration by accounting for the volume of 
each TRL sample loaded onto antibody matrixes for AF (μL), as in Equation 5. Finally, these 
TAG concentration values were corrected by a factor of 2/3, to account for the original plasma 
volume (3 mL) used for ultracentrifugation, which was concentrated into a TRL sample volume 
of 2 mL after tube cutting. In order to check the calculation of Bound and Unbound TAG 
concentrations, these two values were compared with TRL-TAG values measured using the 
COBAS MIRA auto-analyser on the day of ultracentrifuge tube cutting (section 2.1.6).       
 
Equation 1:   
 
 Quantity of FA (µg)   =   Area of FAME sample peak         X     Quantity of internal standard (50 µg) 
             Area of internal standard (HA) 
Equation 2: 
TAG content of sample (µmol)        =           Sum of all FA (µmol) 
                      3 (FA per TAG)                    
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Equation 3: 
Sample recovery (%)  =                            TAG in sample (µmol)                                  X   100 
                             TAG amount used for AF separation (µmol)  
 
Equation 4: 
TAG corrected for recovery (μmol)  =                            TAG in sample (µmol)                                  X   100 
                                                                        Sample recovery (%) 
Equation 5: 
TAG concentration (mmol/L)  =                 TAG corrected for recovery (µmol)                        X   1000 
                                                               Sample volume used for AF (μl) 
 
 
Figure 2.6. An example chromatogram of a Bound sample showing the retention times (RT) of fatty 
acid methyl esters.  
The RT of peaks were compared to a standard reference material (RM6): 14:0 (methyl myristate); 16:0 
(methyl palmitate); 16:1, n-7 (methyl palmitoleate); 17:0 (methyl heptadecanoate); 18:0 (methyl 
stearate); 18:1, n-9 (methyl oleate); 18:2, n-6 (methyl linoleate).       
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Figure 2.7. An example mass spectrum for methyl palmitate.  
The molecular ion at m/z = 270 is shown and the characteristic McLafferty ion at m/z = 74 indicating a 
methyl ester. The compound structure for methyl palmitate is displayed inset.  
 
2.1.15 Standard and QC preparation for Bound and Unbound TAG fatty acid 
concentration 
Fatty acid standards were prepared as shown in Table 2.3 to give a theoretical molar ratio in 
the range 0 to 0.912, using a 125.2 µmol/L stock solution of palmitate (16:0) and a 109.8 
µmol/L stock solution of heptadecanoate (17:0), prepared in chloroform.  
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Table 2.3. Preparation of standards for measuring fatty acid concentrations. 
No. 16:0 (nmol) 17:0 (nmol) Theoretical ratio      
16:0 /17:0 
Observed ratio  
16:0 /17:0 
1 0 7.43 0 0 
2 0.80 7.43 0.114 0.103 (0.0019) 
3 1.61 7.43 0.228 0.224 (0.0025) 
4 3.21 7.43 0.456 0.460 (0.0066) 
5 9.63 7.43 0.912 0.976 (0.0113) 
Both the theoretical molar ratio and the mean observed ratio (±SEM) measured on the GC-MS are 
given (n=10 runs): 16:0, palmitate; 17:0, heptadecanoate.  
 
Standards were measured at the start and end of each sample run in order to ensure within- 
and between-run precision of the GC-MS instrument was maintained (Figure 2.8). The mean 
slope of the observed (measured) versus the theoretical (calculated) palmitate to 
heptadecanoate µmolar ratio was 1.0772 and the linearity (R2) was 0.9989 (n=10 runs).  
 
 
Figure 2.8. Standard curve for fatty acid concentration in Bound and Unbound TAG.  
Standards were measured at the start and end of each run. Results are mean ± SEM (n=10 runs). 
 
A set of three replicate QCs were also extracted (section 2.1.8), purified (section 2.1.9) and 
derivatised (section 2.1.10) with each sample batch, to determine the within- and between-
batch reproducibility of the sample preparation protocol. These contained glyceryl 
 85 
tripalmitate (5 µg) and glyceryl heptadecanoate (50 µg). The resultant ratio of methyl 
palmitate to methyl heptadecanoate (PA/HA ratio) was measured on the GC-MS as described 
(section 2.1.14). The within- and between-batch CVs for the PA/HA ratio were 4.3 % and 6.4 
%, respectively.    
 
2.1.16 Measurement of [2H5]-glycerol enrichment in plasma and Bound and 
Unbound TAG by GC-MS 
The [2H5]-enrichment of Bound and Unbound TAG-glycerol and plasma glycerol samples was 
measured on an Agilent 5973 network mass selective detector (Agilent Technologies, UK) 
(Adiels et al. 2010).  The system was equipped with a 6890N GC fitted with a 30 m, 0.25 mm 
internal diameter, 0.25 µm film thickness Rtx-5 capillary column (Crossbond® 5% diphenyl / 
95% dimethyl polysiloxane; Thames Restek Ltd, UK) and the carrier gas used was helium 
(column flow rate 1.0 mL/min). A 0.2 µL volume of each sample was injected into the column 
by a splitless injection mode (7683 auto-sampler, Agilent, UK) with the injector temperature 
set to 250 °C. The initial oven temperature was 70 °C, which was held for 1 min, then increased 
firstly at 25 °C/min to 150 °C, then ramped at 30 °C/min to 300 °C  and held for 5 min. The 
retention time for glycerol was approximately 8 min and the total run time was 14.2 min. The 
interface temperature was 280 °C and the quadrupole temperature was 150 °C. The MS was 
operated in electron impact ionisation (EI) mode, which is more desirable than chemical 
ionisation (CI) as it maintains a cleaner ion source, thus reducing GC-MS maintenance. It is also 
more widely available, even on more low-cost bench-top mass spectrometer systems (Adiels 
et al. 2010). The two ions monitored were m/z 377 and m/z 382 (Figure 2.9), corresponding 
to the ion fragments of tri-[tert-butyldimethylsilyl]-glycerol (tracee) and tri-[tert-
butyldimethylsilyl]-2H5-glycerol (tracer), respectively. The isotopic enrichment of 2H5-glycerol 
relative to unlabelled glycerol in Bound (VLDL) and Unbound TAG (CM) fractions was 
measured for each time point as the ratio (R) between the peak areas for m/z 377 and m/z 
382 ions. The TTR of samples at each time point was then determined using the following 
equation: 
TTRt = Rt – R0 
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Where Rt was the measured tracer-to-tracee ratio at a given time point and R0 was the tracer-
to-tracee ratio at baseline (0 min), prior to administration of the tracer bolus (2H5-glycerol). 
 
 
Figure 2.9. An example chromatogram showing selective ion monitoring for glycerol tracer (D5) and 
tracee (D0) ion fragments.  
The ion fragment at m/z = 377 (top) corresponds to the unlabelled tracee (tri-[tert-butyldimethylsilyl]-
glycerol) and the ion fragment at m/z = 382 corresponds to the labelled tracer (tri-[tert-
butyldimethylsilyl]-[2H5]-glycerol). 
 
2.1.17 Standard and QC preparation for [2H5]-enrichment in Bound and 
Unbound TAG  
Glycerol standards were prepared as shown in Table 2.4 to give a theoretical TTR in the range 
of 0 to 0.0331, using a 274.2 µmol/L stock solution of unlabelled glycerol (D0) and a 15.1 
µmol/L stock solution of labelled [2H5]-glycerol (D5; Cambridge isotopes, USA).  
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Table 2.4. Preparation of standards for measuring Bound and Unbound TAG-glycerol enrichment. 
No. D5 (nmol) D0 (nmol) Theoretical TTR      
D5 / D0 
Observed TTR  
D5 / D0 
1 0 82.256 0 0 
2 0.227 82.256 0.0028 0.0031 (0.00006) 
3 0.454 82.256 0.0055 0.0059 (0.00007) 
4 0.681 82.256 0.0083 0.0087 (0.00010) 
5 1.363 82.256 0.0166 0.0176 (0.00017) 
6 2.120 82.256 0.0258 0.0273 (0.00029) 
7 2.725 82.256 0.0331 0.0357 (0.00032) 
Both the calculated theoretical molar ratio and the mean observed ratio (±SEM) measured on the 
GC-MS are given (n=14 runs): D5, labelled [2H5] –glycerol (tracer); D0, unlabelled glycerol (tracee); 
TTR, tracer-to-tracee ratio. 
 
Standards were measured at the start and end of each sample run in order to ensure within- 
and between-run precision of the GC-MS instrument was maintained (Figure 2.10). The mean 
slope of the observed versus the theoretical TTR was 1.0693 and the linearity (R2) was 0.9998 
(n=12 runs). 
 
Figure 2.10. Glycerol enrichment standard curve for Bound and Unbound TAG-glycerol. 
The graph represents the ratio (TTR) of tracer (D5) to tracee (D0). Standards were measured at the start 
and end of each run. Results are mean ± SEM (n=12 runs). 
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A set of basal (no tracer), low and high enrichment QCs (n=12) were also prepared using the 
D0 and D5 stock solutions detailed above, then derivatised (section 2.1.13) with each sample 
batch, to determine the between-batch reproducibility of the derivatisation procedure. The 
TTR ratio for each QC was measured on the GC-MS as described (section 2.1.16). The between-
batch CVs were 9.3 %, 7.3 % and 6.0 % for the basal, low and high QCs, respectively.    
 
2.1.18 Standard and QC preparation for [2H5]-enrichment in plasma  
Glycerol standards in the range of 0 to 1.447 TTR were prepared, to reflect the expected 
enrichments in plasma following injection of the [2H5]-glycerol bolus. Two stock solutions were 
used; a 415.9 µmol/L stock solution of glycerol (D0) and 752.1 µmol/L stock solution of 2H5-
glycerol (D5) (Cambridge isotopes, USA), as shown in Table 2.5.  
 
Table 2.5. Preparation of standards for measuring plasma glycerol enrichment. 
No. D5 (nmol) D0 (nmol) Theoretical TTR      
D5 / D0 
Observed TTR  
D5 / D0 
1 0 103.97 0 0 
2 11.28 103.97 0.109 0.130 (0.0073) 
3 22.56 103.97 0.217 0.244 (0.0125) 
4 33.85 103.97 0.326 0.362 (0.0137) 
5 45.13 103.97 0.434 0.475 (0.0160) 
6 67.69 103.97 0.651 0.726 (0.0231) 
7 90.26 103.97 0.868 0.963 (0.0166) 
8 112.82 103.97 1.085 1.190 (0.0142) 
9 150.43 103.97 1.447 1.510 (0.0136) 
Both the calculated theoretical molar ratio and the mean observed ratio (±SEM) measured on the 
GC-MS are given (n=12 runs): D5, labelled 2H5 –glycerol (tracer); D0, unlabelled glycerol (tracee); TTR, 
tracer-to-tracee ratio. 
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Standards were measured at the start and end of each sample run in order to ensure within- 
and between-run precision of the GC-MS instrument was maintained (Figure 2.1). The mean 
slope of the observed versus the theoretical TTR was 1.0584 and the linearity (R2) was 0.9983 
(n=12). 
 
 
Figure 2.11. Glycerol enrichment standard curve for plasma glycerol. 
The graph represents the ratio of tracer (D5) to tracee (D0). Standards were measured at the start and 
end of each run. Results are mean ± SEM (n=12). 
 
A set of basal (no tracer), low and high enrichment QCs (n=6) were also prepared using the D0 
and D5 stock solutions detailed above, then derivatised (section 2.1.13) with each sample 
batch to determine the between-batch reproducibility of the derivatisation procedure. The 
TTR ratio for each QC was measured on the GC-MS as described (section 2.1.16). The between-
batch CVs were 9.0 %, 5.0 % and 1.6 % for the basal, low and high QCs, respectively.    
 
2.1.19 Measurement of Bound and Unbound TAG-palmitate enrichment by 
gas chromatography isotope ratio mass spectrometry (GC-IRMS) 
The [2H]-enrichment of the palmitate methyl ester (PAME) generated from the hydrolysis and 
derivatisation (section 2.1.10) of TAG extracted from Bound and Unbound samples was 
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measured to determine hepatic and intestinal DNL, respectively. Some of the de novo 
palmitate formed via DNL may also have been further elongated and/or desaturated, forming 
other FA such as stearic and oleic acid. Due to time and resource limitations pertaining to the 
operation of the GC-MS instrument, it was not possible to measure the enrichment in these 
other FA products. However, with respect to the utilisation of [13C]-fructose as a DNL 
substrate, it has previously been reported that palmitate is the predominant DNL product in 
VLDL-TAG in humans, with limited elongation and desaturation to stearic or oleic acid, when 
an acute fructose load is given (Chong et al. 2007). It was therefore reasonable to consider 
13C-palmitate enrichment as a measure of DNL, especially as this is the FA typically measured 
in previous human studies (Schwarz et al. 2003, Hudgins et al. 2011, Taskinen et al. 2017, 
Beysen et al. 2018). 
A Thermo Trace 1310 GC was coupled to a Delta V Advantage isotope ratio mass spectrometer, 
with a GC Isolink II interface. The carrier gas was helium with a flow rate of 1.2 mL/min. The 
injection port temperature was set at 240 °C, with an initial oven temperature of 120 °C (held 
for 1 min), which was then ramped to 170 °C at a rate of 20 °C/min and held for 5 min, then 
increased again to 195 °C at a rate of 1 °C/min (no hold), and finally raised to 240 °C at a rate 
of 45 °C/min and held for 5 min. A 1 μL sample volume was injected by split-less injection 
mode using a FAMEWAX capillary column (see section 2.1.14). Following GC separation, the 
PAME was subjected to high temperature conversion (HTC) in an oven at 1400 °C. The 
resulting H2 was ionised and analysed by an MS monitoring ions m/z 2 and 3, corresponding 
to H2 (non-enriched) and HD (enriched) molecules, respectively. An external reference gas was 
used, which was calibrated by Biogeochemical Laboratories (Indiana University, USA).                  
 
2.1.20 Measurement of plasma water enrichment by GC-IRMS 
Plasma samples were analysed in duplicate for 2H2O enrichment with a Gasbench II inlet 
system and Delta V Advantage isotope ratio mass spectrometer (Thermo Scientific, Hemel 
Hempstead, UK). The [2H2]-enrichment was measured using a platinum catalyst rod. Sample 
tubes were capped and flushed (100 mL/min) with the equilibration gas, 2 % H2 in helium, and 
equilibrated for 6 h at 22.5 °C. Isotopic enrichment was measured relative to laboratory 
standards previously calibrated against the international standards Vienna Standard Mean 
Ocean Water 2 (VSMO2), Standard Light Arctic Precipitation (SLAP2) and Greenland Ice Sheet 
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Precipitation (GISP) (International Atomic Energy Agency, Vienna, Austria). A series of four QCs 
of different enrichments were run with each set of samples, all of which had a mean CV < 2 %. 
 
2.1.21 Standard preparation for Bound and Unbound TAG-palmitate 
enrichment 
Palmitate enrichment standards were prepared as shown in Table 2.6 to give a theoretical TTR 
in the range of 0 to 0.0164, using a 96.97 µmol/L stock solution of unlabelled palmitate (D0) 
and a 0.498 µmol/L stock solution of labelled [12-d1]-palmitate (D1).  
 
 
Table 2.6. Preparation of standards for measuring Bound and Unbound TAG-palmitate enrichment. 
No. D1 (nmol) D0 (nmol) Theoretical TTR      
D1/ D0 
Observed TTR  
D1/ D0 
1 0 24.24 0 0 
2 0.025 24.24 0.0010 0.0013 
3 0.050 24.24 0.0020 0.0022 
4 0.100 24.24 0.0041 0.0033 
5 0.199 24.24 0.0082 0.0077 
6 0.299 24.24 0.0123 0.0124 
7 0.399 24.24 0.0164 0.0158 
Both the calculated theoretical molar ratio and the mean observed ratio measured on the GC-MS are 
given (n=6 runs): D1, labelled [12-d1]-palmitate (tracer); D0, unlabelled palmitate (tracee); TTR, tracer-
to-tracee ratio. 
 
Standards were measured at the start of each sample run in order to ensure between-run 
precision of the GC-MS instrument was maintained (Figure 2.12). The mean slope of the 
observed versus the theoretical TTR was 0.9696 and the linearity (R2) was 0.9957 (n=6 runs). 
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Figure 2.12 Palmitate enrichment standard curve for Bound and Unbound TAG-palmitate.  
The graph represents the ratio of tracer (D1) to tracee (D0). Standards were measured at the start and 
end of each run. Results are mean ± SEM (n=6). 
 
 
2.1.22 Measurement of metabolite concentrations in plasma, serum and TRL 
fraction by auto-analyser 
Assays for plasma TAG, TRL-TAG, glucose, NEFA, total cholesterol, TRL-cholesterol, HDL-
cholesterol and apoB were all performed on a COBAS MIRA auto-analyser (Roche Diagnostics, 
USA). Measurement of TRL-TAG was performed immediately following ultracentrifugation and 
tube cutting (section 2.1.6) on study samples collected at 15 time points (-240, 0, 30, 45 60, 
90, 120, 150, 180, 240, 300, 360 and 420 min). All other measurements were performed on 
thawed samples that had been stored at -80 °C. Plasma TAG, glucose and NEFA were measured 
at 9 time points (-240, 0, 60, 120, 180, 240, 300, 360 and 420 min). Plasma cholesterol, HDL-
cholesterol and apoB were measured at 6 time points (-240, 0, 120, 240, 360 and 420 min) 
and TRL-cholesterol only on fasted samples (-240 min). Prior to each assay, appropriate pre-
calibrations were performed using standards supplied by the manufacturer and quality 
controls (QCs) were included in each batch to determine the inter-assay precision. 
Measurements were only performed if QC values were within acceptable confidence limits, as 
indicated by the manufacturer. 
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2.1.22.1 Plasma and TRL-TAG 
Plasma and TRL-TAG were determined using a colorimetric assay (ABX Pentra Triglycerides CP 
kit, ref: A11A01640; Horiba ABX, France). The absorbance of a quinoneimine pigment was 
measured bichromatically at a wavelength of 500 nm. For ‘N’ (low) and ‘P’ (high) QCs, the 
between-assay coefficients of variation (CVs) were 1.6 % and 4.8 % for plasma TAG and 2.9 % 
and 7.2 % for TRL-TAG, respectively.   
  
2.1.22.2 Total and TRL-cholesterol 
Total and TRL-cholesterol were measured using an enzymatic photometric assay based on 
Trinder’s reaction, whereby development of the indicator quinoneimine, catalysed by the 
enzyme peroxidase, is quantified by measuring absorbance bichromatically at 500 nm 
wavelength (ABX Pentra Cholesterol CP kit, ref: A11A01634; Horiba ABX, France). The 
between-assay CVs for N (low) and P (high) QCs were 0.8 % and 0.4 % for total cholesterol, 
and 2.3 % and 2.0 % for TRL-cholesterol, respectively. 
  
2.1.22.3 HDL cholesterol 
A two stage method was used to measure HDL cholesterol (ABX Pentra HDL Direct CP kit, ref: 
A11A01636; Horiba ABX, France). The first reagent accelerates the conversion of non-HDL 
unesterified cholesterol to a colourless product. A second reagent consisting of an HDL-
specific detergent, which dissolves and disrupts HDL, then acts to allow cholesterol esterase 
and a chromagenic coupler to develop a quantifiable colour, which is measured at a 
wavelength of 600 nm. The between-assay CVs were 0.3 % and 1.6 % for low (N) and high (P) 
controls, respectively.    
 
2.1.22.4 LDL cholesterol 
Plasma LDL cholesterol was not measured directly, but instead a value was calculated for each 
time point using the Friedewald Equation (Friedewald et al. 1972): 
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LDL cholesterol (mmol/L) = [total cholesterol] – [HDL cholesterol] – ([TAG]/2.19) 
 
2.1.22.5 Total apoB 
Total apoB was measured via an immunoturbidimetry method (ABX Pentra Apo B kit, ref: 
A11A01688; Horiba ABX, France). The principle of this technique is based on the direct 
correlation between the turbidity generated by apoB-immune complexes and the 
concentration of apoB in the sample. The between-assay CVs were 1.4 % and 2.5 % for the 
low and high QCs, respectively.   
 
2.1.22.6 Plasma glucose 
Plasma glucose was determined enzymatically via the Trinder method, which utilises glucose 
oxidase and peroxidase sequentially to generate quinoneimine dye. The absorbance of the 
dye was then measured bichromatically at a wavelength of 500 nm. The between-assay CVs 
were 2.0 % and 2.8 % for N and P, respectively. Two additional QCs of known glucose 
concentration (5.56 and 10.0 mmol/L) were also included, which had respective CVs of 1.0 % 
and 2.3 %.  
    
2.1.22.7 Plasma NEFA 
Plasma NEFA concentration was measured by a colorimetric/enzymatic assay (kit ref: 434-
91795, Alpha Laboratories Ltd, Eastleigh, UK). This method firstly converts NEFA to Acyl-CoA, 
which is then oxidised to yield 2,3-trans-Enoyl-CoA and hydrogen peroxide. The hydrogen 
peroxide then undergoes a quantitative oxidation condensation reaction, which develops a 
blue-purple pigment. The absorbance of the blue-purple colour, which is directly proportional 
to the concentration of NEFA in the sample, is measured at 550 nm. The between-assay 
precision was determined using Control Serum 1 (ref: 410-00104, Alpha Laboratories Ltd, 
Eastleigh, UK), which produced a CV of 3.0 %. 
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2.1.23 Measurement of serum insulin concentration 
Serum insulin on each metabolic study day was measured at 9 time points (-240, 0, 60, 120, 
180, 240, 300, 360 and 420 min) via radioimmunoassay (RIA). This technique has four basic 
requirements; a specific antiserum to the antigen of interest (insulin), the availability of a 
radioactive-labelled form of the antigen, a method whereby antibody-bound tracer can be 
separated from the unbound tracer and, finally, an instrument to count radioactivity. The EMD 
Millipore Human Insulin assay (kit ref: HI-14K; EMD Millipore Corporation, MA, USA) was used 
to analyse samples, which utilises 125I-labelled human insulin and human insulin antiserum to 
determine insulin concentration, via the double antibody/PEG technique (Desbuquois et al. 
1971). A standard curve was setup for each assay. All samples were analysed within a single 
batch. The within-assay precision was determined using low and high QCs, with respective 
reference ranges of 76.4 – 159.7 pmol/L and 229.2 – 472.3 pmol/L, and corresponding CVs of 
3.2 % for the low QC and 2.3 % for the high QC.      
 
2.1.24 Measurement of TRL apoB100 and apoB48 concentrations by enzyme-
linked immunosorbent assay (ELISA) 
2.1.24.1  Principle of the apoB100 ELISA 
The concentration of apoB100 in TRL fraction samples was measured using a previously 
developed in-house “sandwich” ELISA. This method used a quantitative sandwich enzyme 
immunoassay technique, which captured apoB100 antigen within TRL samples by creating a 
sandwich between the primary antibody, a polyclonal anti-apoB, and the secondary antibody, 
a biotinylated monoclonal 4G3 antibody, which was specific to apB100. A streptavidin-alkaline 
phosphatase enzyme complex was then added to plates, before finally incubating with a 
substrate in order to generate a colour response, the absorbance of which was measured at 
540 nm.   
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2.1.24.2 Method for the apoB100 ELISA 
The TRL samples from 6 time points were measured for each metabolic study day. Microplates 
used for each assay were coated with 15 µg per well of the primary antibody; sheep anti-
human apolipoprotein B (IgG fraction) (ref: PC086; The Binding Site Group Ltd, UK) in 100 µL 
of phosphate buffer (0.041 mmol/L K2HPO4 and 0.009 mmol/L KH2PO4 in di H2O, pH 7.4), 
covered and stored at 4 °C for 2-3 days, prior to performing the assay. On the day of the assay, 
microplates were allowed to warm to room temperature (r.t.) and washed three times with 
300 µL of washing buffer per well (phosphate buffer with 0.02 % (w/v) thiomersal [VWR 
International Ltd., UK] and 0.1 % (v/v) Triton X-100 [Merck Millipore, Germany]). Plates were 
inverted and struck firmly on absorbent paper to remove any excess buffer from wells. In 
order to prevent non-specific binding, the plates were then blocked with 200 µL/well of buffer 
A (phosphate buffer with 0.02 % (w/v) thiomersal  and 1 % (w/v) BSA) and placed on an orbital 
shaker to mix gently at 150 rpm for 1 h at r.t. Plates were then washed again three times with 
washing buffer (300 µL/well) as already described.  
TRL samples were diluted either 1:200, 1:300 or 1:500 with buffer A, depending on the 
previously measured TRL-TAG concentration value (section 2.1.22.1), thus ensuring the 
apoB100 concentration was within range of the assay. An in-house isolated LDL fraction was 
included as a positive QC for the assay, which was diluted 1:30000 with buffer A. A series of 8 
turbidimetry standards was used for the assay (Table 2.7), which were made using a stock 
solution of apoB standard (1 mg/L; ADVIA Chemistry Systems, Siemens Healthcare Ltd, UK). 
Aliquots of standards were prepared in advance and stored at -80 °C until required.  
Following blocking of microplates, standards, QCs and diluted samples (100 µL/well) were 
loaded as quickly as possible, then the plate was covered and incubated on the orbital shaker 
(150 rpm) for 2 h at r.t. Plates were again washed three times with washing buffer, before 
adding the secondary antibody (100 µL/well); biotinylated monoclonal 4G3 antibody (Ottawa 
Heart Institute, Ontario, Canada), which was diluted 1:40000 with buffer B (phosphate buffer 
with 0.02 % (w/v) thiomersal and 0.5 % (w/v) BSA). Plates were covered and incubated on the 
orbital shaker again at r.t. for 2 h. The wash cycle was repeated before adding 100 µL/well of 
streptavidin-alkaline phosphatase (Thermo Fisher Scientific, UK), which had been diluted 
1:3000 (v/v) with buffer B. Plates were incubated at r.t. on the orbital shaker for 45-60 min 
and then washed three times, as before. The enzyme substrate (phenolphthalein 
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monophosphate dicyclohexylammonium salt), which was prepared at 8 mg/mL (w/v) in a 
substrate buffer (per litre: 97 mL diethanolamine, 0.2 g NaN3, 0.095 g MgCl2.anhydrous, 15.2 
mL concentrated HCl [BDH, UK] and 887.8 mL di H2O, pH 9.8) was then added at 100 µL/well 
and plates covered and incubated at r.t. for approximately 35 min, until a sufficient colour 
response had developed. Finally, the enzymatic reaction was stopped by adding 200 µL/well 
of stop solution (15 g glycine, 0.372 g EDTA disodium salt, 6.4 g NaOH in 1 litre di H2O). Plates 
were placed on a microplate reader (Opsys microplate reader, DYNEX Technologies, UK) and 
the absorbance measured at 540 nm (DYNEX Technologies Revelation software, version 4.25), 
with a reference wavelength of 630 nm. The software was used to determine the best fitting 
curve for the standards (Figure 2.13) based on the inputted concentrations (Table 2.7) and 
their respective optical density (OD) values. The resulting best fit was a cubic regression with 
linear axes scaling, with the equation y = 2.264x3 - 5.7683x2 + 5.3268x - 0.0124 (R2 = 0.9986).                        
 
Table 2.7. Preparation of standards used for the apoB100 ELISA assay.  
No. Dilution factor of 
standard 
ApoB concentration (mg/L) Mean Abs (540 nm) 
1 (blank) 0 0.014 
2 1:50000 0.02 0.094 
3 1:25000 0.05 0.185 
4 1:10000 0.10 0.478 
5 1:7500 0.13 0.613 
6 1:5000 0.20 0.846 
7 1:2500 0.40 1.337 
8 1:1000 1.00 1.810 
Turbidimetry standards were prepared from a 1 mg/L stock solution of apoB by serial dilution with 
buffer A as indicated. Standard 1 (blank) contained only buffer. The mean ± SEM (n=4) measured 
optical density (OD) value is shown for each standard. 
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Figure 2.13. Standard curve for apoB100 ELISA assay. 
Results for each standard are mean ± SEM (n=4). OD, optical density.   
 
2.1.24.3 Principle of the apoB48 ELISA 
The concentration of apoB48 in TRL fraction samples was measured using a commercially 
available ELISA kit (ref: AKHB48, Shibayagi Co., Ltd, Japan), which utilised a “sandwich” 
immunoassay method, as described in section 2.1.24.1. The primary antibody for the assay 
was a monoclonal anti-apoB48, which was pre-coated onto wells. The secondary antibody was 
a biotin-conjugated anti-apoB48 antibody, which was subsequently bound by a horseradish 
peroxidase (HRP)–conjugated streptavidin enzyme complex. In order to develop a colour 
response, a chromogenic HRP substrate was added, which generates a yellow product, and 
the reaction was stopped using 1 M H2SO4. The absorbance was measured at 450 nm. The 
performance characteristics of the assay, as advised by the manufacturer, are shown Table 
2.8. 
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Table 2.8. Performance characteristics of the apoB48 ELISA. 
Performance characteristic Value(s) and additional information 
Assay range 2.5 ng/mL to 160 ng/mL 
Specificity All antibodies in the kit were tested and had no 
cross-reactivity with human apoB100 
Assay precision Within assay variation (n=3 samples, 5 replicates 
per assay) gave a mean CV of < 10 %.  
Reproducibility Between assay variation (n=3 samples, 3 days, 3 
replicates per assay) gave a mean CV of < 10 %   
Information was obtained from the kit instruction manual (version C1, issued 21 August 2017). 
 
 
2.1.24.4 Method for the apoB48 ELISA 
All of the necessary antibodies, apoB48 stock for making standards, substrate and stop 
solutions, as well as buffer and wash solutions, were supplied with the kit (ref: AKHB48, 
Shibayagi Co., Ltd, Japan). These were re-constituted and/or diluted as directed in the 
instruction manual prior to use. On the day of the assay, all plates and reagents were removed 
from storage at 4 °C and allowed to equilibrate to r.t. The pre-coated 96-well plates supplied 
with the assay kit were firstly washed four times with 300 µL/well of washing buffer, before 
striking upside-down on absorbent paper to remove residual buffer from wells.  Standards 
were prepared by serial dilution of a human apoB48 standard (320 ng/mL) supplied with the 
kit. The TRL samples were diluted either 1:200, 1:300 or 1:500 with buffer in order to bring 
apoB48 concentrations with the measurement range of the assay and according to previously 
measured TRL-TAG values (section 2.1.22.1). Both a positive QC (in-house CM-rich lymph 
fraction) and a negative QC (in-house LDL fraction used for apoB100 ELISA assay) were also 
included, which were diluted 1:300 with buffer. Standards, QCs and TRL samples were added 
to wells (50 µL) in duplicate, the plate was shaken (600-1,2000 rpm for 10 seconds) and then 
incubated at r.t. for 1 h. Plates were then washed four times as already described, followed 
by addition of 50 µL of diluted (1:100) biotinylated anti-apoB48 antibody solution, before 
shaking and incubating at r.t. for 1 h. The plates were washed again four times, 50 µl per well 
of diluted (1:100) HRP-conjugated streptavidin solution was added, and plates were shaken 
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and incubated for 30 min at r.t. The wash cycle was repeated and 50 µl per well of 
chromogenic HRP substrate (3, 3’, 5, 5’-tetramthylbenzidine, TMB) was added and plates 
shaken and incubated for 20 min at r.t. to develop a colour response. Finally, 50 µl per well of 
stop solution (1 M H2SO4) was added and plates were shaken and the absorbance of the 
chromogenic pigment read at 450 nm on a microplate reader (Opsys microplate reader, 
DYNEX Technologies, UK). The standard curve was used to calculate the unknown 
concentration of TRL samples, which utilised a logarithmic/logarithmic axes scaling by cubic 
regression for the standard curve best fit.    
 
 
2.2 Data analysis for the human study 
2.2.1 Multi-compartmental model to determine VLDL-TAG and CM-TAG 
kinetics 
The [2H5]-enrichment of plasma glycerol and the glycerol extracted from Bound and Unbound 
TAG were measured to provide estimates of the precursor and product pools, respectively, 
used for de novo TAG synthesis. Although in vivo, enterocytes are considered to 
predominantly use the 2-MAG pathway for the synthesis of de novo TAG (prior to 
incorporation into CM), glycerol may also be utilised for TAG synthesis via the glycerol-3-
phosphate (G-3-P) pathway. In contrast, hepatic TAG synthesis occurs mainly via the G-3-P 
route. Therefore, the utilisation of isotopically labelled [2H5]-glycerol as a precursor allows the 
simultaneous measurement of TAG synthesis rates in both the liver and intestine. While it may 
be considered more accurate to utilise [2H5]-labelled MAG in order to measure exogenous TAG 
kinetics in the intestine, using a glycerol tracer allows for the rapid uptake and equilibration 
of the tracer with the precursor pool used for TAG synthesis (endogenous glycerol), as glycerol 
is readily taken up by cells of the liver and intestine. Therefore, it is possible to calculate the 
kinetic parameters described below.          
Lipoprotein kinetic parameters were calculated using the modelling software SAAM II (SAAM 
Institute, Seattle, USA). A compartmental model developed by Dr Roman Hovorka (University 
of Cambridge, UK) was used to obtain the best fit curves of CM-TAG and VLDL-TAG data to all 
kinetic parameters. The model is shown in Figure 2.14 and Figure 2.15.   
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The model uses the enrichment of [2H5]-glycerol in plasma and TAG, which changes as labelled 
glycerol is removed from plasma and incorporated into TAG, to calculate CM-TAG and VLDL-
TAG kinetics. It is assumed that unlabelled glycerol (tracee) remains in a steady-state 
throughout the experimental period, such that the rates of appearance, disappearance and 
incorporation of glycerol into TAG are constant. The incorporation of glycerol into CM-TAG by 
the intestine and VLDL-TAG by the liver are subject to a delay, which represents the time 
required for intestinal and hepatic TAG synthesis. 
The fractional catabolic rate (FCR) of CM-TAG and VLDL-TAG was the main output from the 
model, which is equal to the fractional secretion rate (FSR) under steady-state conditions. The 
CM-TAG and VLDL-TAG production rates (PR) were calculated as the product of the FCR and 
the corresponding pool size (PS), as follows: 
 
CM-TAG PR (mg/kg/d)  =  [CM-TAG FCR (pools/d)  x  CM-TAG PS (mg)] / Body weight (kg) 
and 
VLDL-TAG PR (mg/kg/d)  =  [VLDL-TAG FCR (pools/d)  x  VLDL-TAG PS (mg)] / Body weight (kg) 
 
For both CM-TAG and VLDL-TAG, PS was determined as the product of the mean steady-state 
CM-TAG or VLDL-TAG concentration (mg/dL) times plasma volume, where the plasma volume 
was determined according to the method of Pearson et al (Pearson et al. 1995).        
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Figure 2.14. Compartmental model for determining kinetics of CM-TAG using [2H5]-glycerol.  
The glycerol tracer was injected into plasma, taken up by the intestine and incorporated into TAG used 
for CM lipoprotein synthesis and secretion into plasma. The model included a compartment for CM-
TAG (CM1 and CM2) and a compartment to represent the delay in the appearance of CM-TAG following 
administration of the glycerol bolus. 
 
 
Figure 2.15. Compartmental model for determining kinetics of VLDL-TAG using [2H5]-glycerol.  
The glycerol tracer was injected into plasma, taken up by the liver and incorporated into TAG used for 
VLDL lipoprotein synthesis and secretion into plasma. The model included a compartment for VLDL-
TAG (VLDL1 and VLDL2) and a compartment to represent the delay in the appearance of VLDL-TAG 
following administration of the glycerol bolus. 
   
2.2.2 Calculation of percentage DNL and de novo palmitate concentration 
2.2.2.1 Percentage intestinal and hepatic DNL 
The enrichment of 2H2O in plasma was determined as described in 2.1.20, which represented 
the precursor pool for de novo palmitate synthesis. This was then used to calculate the 
deuterium enrichment in palmitate that would have been expected if DNL were the only 
source of FA used for CM-TAG and VLDL-TAG synthesis. In other words, the maximum 
theoretical enrichment of palmitate. By comparing the observed deuterium enrichment of 
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palmitate (2.1.19) with the theoretical maximum value, it is possible to calculate the 
percentage contribution of de novo palmitate, derived from DNL, to the CM-TAG and VLDL-
TAG palmitate concentrations. 
If all FA within CM-TAG or VLDL-TAG are derived from DNL, the maximum theoretical 
palmitate enrichment would be as follows: 
Maximum palmitate enrichment (TTR) = 2H2O TTR x N 
Where 2H2O TTR is the enrichment of plasma water and N is the maximum number of 
deuterium atoms that can be incorporated into a molecule of palmitate during synthesis. For 
the present study N was 22 for palmitate, based on previous experimental observations 
(Diraison et al. 1997). Although palmitate contains 31 hydrogen atoms that could potentially 
be labelled, these hydrogen atoms are not equivalent, as they are derived from different 
sources (7 from H2O, 14 from NADPH and 10 from acetyl-CoA) (Murphy 2006). Due to an 
incomplete equilibration of [2H]-enrichment between total body water and that in NADPH and 
acetyl-CoA pools, the N number must be experimentally determined in order to allow an 
accurate quantification of DNL.      
The percentage contribution of DNL to circulating CM-TAG and VLDL-TAG palmitate can 
therefore be calculated as follows: 
% DNL CM-TAG palmitate = (CM-TAG palmitate TTR / maximum palmitate TTR) x 100 
And 
% DNL VLDL-TAG palmitate = (VLDL-TAG palmitate TTR / maximum palmitate TTR) x 100 
 
2.2.2.2 Intestinal and hepatic de novo palmitate concentration 
Once the percentage DNL is known, it is possible to calculate the concentration of CM-TAG 
and VLDL-TAG palmitate derived from DNL (μmol/L), as described previously (Parks et al. 
2008). These can be calculated as follows: 
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Intestinal de novo palmitate (μmol/L) = (% DNL CM-TAG palmitate x CM-TAG palmitate 
concentration [μmol/L]) / 100 
And 
Hepatic de novo palmitate (μmol/L) = (% DNL VLDL-TAG palmitate x VLDL-TAG palmitate 
concentration [μmol/L]) / 100 
 
2.3 Methods used in the cell culture experiments 
2.3.1 Culturing of Caco-2 cells 
Caco-2 cells (passage 47) were obtained from Public Health England (European Collection of 
Cell Cultures [Ref: 09042001], Salisbury, UK), which had been tested to confirm dome, 
microvilli and TJ formation in culture, as well as intestinal permeability and transport 
functionality. All materials required for cell culture experiments were obtained from Sigma-
Aldrich (UK), unless otherwise stated. Cells were cultured in 75 cm2 plastic flasks at 37 °C in an 
incubator with 5 % carbon dioxide (CO2) and 95 % air atmosphere with a constant 95 % relative 
humidity. The standard medium used to culture cells consisted of Dulbecco’s Modified Eagle’s 
Medium (DMEM: 25 mmol/L glucose) supplemented with 1 % (v/v) L-glutamine, 1 % non-
essential amino acids (NEAA) and 1 % penicillin-streptomycin, as well as 20 % (v/v) heat-
inactivated foetal bovine serum (FBS; Antibody Production Services Ltd, Bedford, UK), 
hereafter referred to as ‘DMEM complete’. Cells were passaged once they reached 80-90 % 
confluence, as estimated using a light microscope. The culture medium was aspirated and 
flasks were washed with 10 mL of DMEM without additional components, before 3 mL of pre-
warmed trypsin-EDTA was added and cells were returned to the incubator for 5 min. A light 
microscope was used to ensure a sufficient proportion of cells had detached (cells became 
small and round), after which 3 mL of DMEM complete was added to the flask to ‘quench’ the 
action of the trypsin. The total flask volume was transferred to a 15 mL centrifuge tube and 
centrifuged at 1,000 rpm (RCF = 232 x g) for 5 min, after which the medium was aspirated and 
the remaining cell pellet re-suspended in 1 mL of DMEM complete. A 10 µL sample was diluted 
in 10 mL (v/v) of Isoton solution (Beckman Coulter, USA) and the cell count (0.5 mL) measured 
twice using a Z1 Coulter Particle Counter (Beckman Coulter). The values were added together 
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and corrected for the dilution (1:1000) to calculate the total number of cells in the 1 mL 
suspension. The required amount of cell suspension for cell seeding was calculated in two 
steps as follows: 
 
Dilution factor = [seeding area (of flask/well) x seeding density required (cells/cm2)]  
                                                                   Media volume per flask/well (e.g. 10 mL) 
 
Volume of cell suspension required (µL)   =  Total media volume (µL) 
                                                                                    Dilution factor 
 
2.3.2 Preparation of frozen cell stocks   
For the cryopreservation of cell stocks, cells were maintained as described in section 2.3.1, 
although following centrifugation, cells were re-suspended in FBS-dimethyl sulphoxide 
(DMSO; 9:1 v/v: Sigma-Aldrich, UK) to give a concentration of 1 x 106 cells/mL and 1 mL 
aliquots were immediately transferred to cryovials clearly labelled with the cell type, passage 
number and date. Vials were cooled gradually in a ‘Mr Frosty’ freezing container (Thermo 
Fisher Scientific, UK), then placed in a freezer at -80 °C for 16-24 hours, before transferring to 
a liquid nitrogen dewar for long-term storage.  
An aliquot of cell supernatant was sent to a specialist sequencing company (GATC Biotech, 
Germany) to test for the presence of mycoplasma species. The test indicated an absence of 
mycoplasma DNA in the sample relative the World Health Organization’s international 
standard.    
2.3.3 Plating of frozen cell stocks 
Cryopreserved cell stocks were revived as necessary. An ampoule containing 1 x 106 cells/mL 
was removed from the liquid nitrogen dewar, thawed for 1 min at room temperature and then 
2 min in a water bath at 37 °C. The cell suspension was quickly added to 20 mL of pre-warmed 
 106 
DMEM complete medium and transferred to two 75 cm2 culture flasks (10 mL per flask). The 
medium was changed the day after seeding and cells were then cultured as described in 
section 2.3.1. 
2.3.4 Experiments to determine cell viability 
Prior to conducting the experiments described in section 2.3.5, preliminary cell viability 
experiments were performed to ensure that the range of fructose and glucose concentrations 
used would not adversely affect normal Caco-2 cell growth and metabolic activity. All 
materials were from Sigma-Aldrich (UK), unless otherwise stated. 
  
2.3.4.1 Treatment conditions 
Cells were seeded at 5 x 103 cells/cm2 into 12 well plates (3.9 cm2 well area) and grown to 
approximately 90 % confluence for 7-8 days in DMEM complete medium, which was changed 
24 hours after seeding and every 2-3 days thereafter. Cell confluence was estimated using a 
light microscope. For preparation of treatment media, 250  mmol/L stock solutions of glucose 
and fructose were made by dissolving each monosaccharide in carbohydrate- (CHO) free 
complete DMEM (Gibco™, Thermo Fischer Scientific, UK), which contained NEAA, antibiotics, 
L-glutamine (all 1 % v/v)  and FBS (20 % v/v), but no glucose or other source of hexose sugar.  
Stock solutions were filter-sterilised using a 10 mL syringe fitted with a Minisart® 0.2 µm filter 
attachment (Sartorius, Germany). Treatment media were then prepared by diluting these 
stock solutions with CHO-free complete DMEM to achieve the desired molarity. Three 
different concentrations (5 mM, 25 mM and 50 mM) of fructose and glucose were tested for 
their effects on cell viability over a period of 96 h, giving a total of 6 treatment conditions. The 
25 mM glucose condition was used as a control in each experiment, in order to allow the 
relative percent viability to be calculated (section 2.3.4.2). Each treatment was tested in 
triplicate with n=3 independent experiments (9 wells per treatment type). Treatment media 
were changed daily as required at 24 h, 48 h and 72 h. Prior to treatment, all wells were 
washed with 1 mL of CHO-free DMEM containing 1 % L-glutamine, but no other additional 
components (‘CHO free DMEM’), before adding 1 mL of each treatment medium.  
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2.3.4.2 MTT cell viability assay 
The potential cytotoxicity of each treatment condition was assessed using a common 
colorimetric cell viability assay, whereby cell metabolic activity is taken as an index of the 
number of viable cells present (van Meerloo et al. 2011). The yellow tetrazolium dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used, which is reduced by 
mitochondrial reductase to form a lipid-soluble formazan, which has a purple colour (Stockert 
et al. 2012). The absorbance of the purple dye can be measured spectrophotometrically. The 
MTT solution was prepared at a concentration of 5 mg/mL in 10 mL of CHO free DMEM 
immediately prior to use, filter-sterilised and wrapped in foil to protect the photo-labile dye 
from degradation. For the final two hours of each treatment period, 100 µl of medium was 
removed from each well and replaced with 100 µl of MTT solution, to give a final concentration 
of 0.5 mg/mL. At the end of the treatment period, cell media were aspirated and 500 µL of 
DMSO was added to each well to lyse the cells. The 12 well plates were placed on a plate 
shaker for 20 minutes to extract the dye from the cells and then 50 µL of each sample was 
transferred to a 96 well plate and diluted as required with DMSO, which was also used as the 
blank reference. The absorbance was measured at 540 nm on a GENios microplate reader 
(Tecan Group, Switzerland). Relative percent viability was calculated by subtracting blank 
(DMSO) absorbance values to determine the mean absorbance for each treatment, expressed 
as a percentage of the control condition (25 mM glucose). 
 
2.3.5 Experiments to determine the effect of different fructose and glucose 
concentrations on Caco-2 TAG metabolism 
2.3.5.1 Description of the Transwell® enterocyte model 
The cell culture experiments described in this section employed a widely-utilised in vitro 
model of intestinal absorption, involving Caco-2 cells cultured on Transwell® plates (Figure 
2.16). These 6 well plates feature a removable plastic insert with a permeable membrane (0.4 
µm pore size, 4.67 cm2 area, 24 mm insert diameter; Corning Inc., USA), on which cells grow 
to form a confluent and highly-differentiated monolayer. This creates separate ‘apical’ and 
‘basolateral’ compartments, intended to represent the intestinal lumen and the circulation, 
respectively. Also, this model permits access to each separate compartment, allowing 
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treatment with, and collection of, different media types. The suitability of Caco-2 cells grown 
in this manner to function as an intestinal epithelial transport model has been well 
characterised (Hidalgo et al. 1989). Caco-2 cells differentiate to form a polarised monolayer 
with TJ, and are capable of forming intracellular lipid droplets as well as synthesising and 
secreting both CM- and VLDL-like particles (Bateman et al. 2007).  
 
 
 
Figure 2.16. A diagram of the Transwell® model used for Caco-2 cell culture experiments.  
Cells are grown on a removable insert with a permeable membrane, allowing separate access to the 
apical and basolateral compartments for treatment with, and collection of, different media types. 
 
2.3.5.2 Transepithelial electrical resistance measurements (TEER) 
The most common method for assessing the integrity of cell monolayers grown on membrane 
supports is to perform transepithelial electrical resistance measurements (TEER), which 
provide an indication of cell differentiation and TJ formation (Grasset et al. 1984). For the 
experiments described in section 2.3.5.3, a Millicell-ERS2 Volt-Ohm Meter (Millipore Corp., 
USA) was used to record TEER values according to the manufacturer’s instructions. The system 
is comprised of a meter and a ‘chopstick’ like electrode, with a silver/silver chloride pellet on 
each tip, and is used to take measurements as shown in Figure 2.17. The ‘chopstick’ meter 
was positioned with the shorter electrode in the upper compartment (apical) and the longer 
electrode in the lower compartment (basolateral), therefore allowing the resistance across 
the monolayer to be measured. The TEER value of each monolayer (Ω) was corrected by 
subtracting the measured resistance for a blank insert with no cells, although containing CHO-
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free medium. Values were not corrected for the membrane area, in accordance with the 
manufacturer’s instructions, which recommends no unit area correction for Transwell® inserts 
of 24 mm and above. The system described provides a reliable and convenient method for 
assessing cell confluence (quantitative) and monolayer health (qualitative) and has been 
effectively used before in previous experiments investigating Caco-2 cell function in response 
to different FA (Bateman et al. 2007). Any wells with a TEER value of less than 300 Ω were not 
used, as a low TEER indicates poor TJ integrity of the monolayer (Ohashi et al. 2009). 
Transwell® plates were removed from the incubator and allowed to equilibrate to r.t. for 20 
min before taking measurements, to avoid variation in resistance values due to temperature 
changes. 
 
 
Figure 2.17. Method for taking transepithelial electrical resistance (TEER) measurements.  
A Millicell ERS-2® Volt-Ohm Meter was used. The ‘chopstick’ meter is positioned with the shorter 
electrode in the upper (apical) compartment and the longer electrode in the lower compartment 
(basolateral). Image from the Millipore Millicell ERS-2® User Guide. 
 
2.3.5.3 Treatment conditions 
Caco-2 cells (passage 49 to 55) were seeded at 5 x 105 cells/mL (1.5 mL; 1.61 x 105 cells/cm2) 
onto the apical membrane insert of 6 well Transwell® plates and grown to confluence in 
DMEM complete medium (1.5 mL apical compartment; 2.6 mL basolateral compartment). One 
well on each plate was not seeded with cells and only maintained with CHO-free medium in 
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order to act as a blank reference for TEER measurements. The media was changed and TEER 
measurements were taken every 3-4 days post-seeding. Cells reached confluence 
approximately 14 days after seeding. However, experiments were only initiated 21 days post-
seeding, as this extended culturing period has been shown to maximise the ability of Caco-2 
cells to synthesise and secrete TAG, with an enhanced secretion efficiency compared to 14 
days post-seeding (Chateau et al. 2005).  
Only cell monolayers with a TEER > 250 Ω were used for experiments. Cell monolayers were 
washed with 1 mL of CHO-free DMEM (no additions) prior to treatment for 96 h. Seven 
different fructose and glucose treatments were prepared, as follows: 
5 mM glucose (5G), 25 mM glucose (25G), 50 mM glucose (50G), 5 mM fructose (5F), 25 mM 
fructose (25F), 50 mM fructose (50F), or 12.5 mM glucose and 12.5 mM fructose (G/F Mix) 
These concentrations were chosen based on the results of the MTT cell viability assay (see 
section 4.4.1), which indicated no deleterious effects of any of the concentrations. Treatment 
media were added to the apical compartment (1.5 mL/well) and changed every 24 h, with 
TEER measurements taken prior to media change. The basolateral medium (CHO free DLS 
medium) was collected and replaced every 24 h. Treatment media were prepared as described 
in section 2.3.4.1. However, three alterations to the media composition were made.  
Firstly, FBS was replaced with a lipid-depleted foetal bovine serum (LDS; 20% v/v; First Link 
(UK) Ltd, Birmingham), in order to remove any potential sources of NEFA. Secondly, a fatty 
acid (FA) taurocholic acid (TC) micelle mixture (0.5 mmol/L), prepared as described in section 
2.3.5.4, was added to media in order to stimulate TAG synthesis and the secretion of TAG-
enriched apoB48-containing lipoproteins by cells (Chateau et al. 2005). This mixture had a FA 
composition similar to the typical UK diet (Pot et al. 2011). Finally, stable isotope tracers were 
added to media in order calculate DNL in response to each fructose/glucose condition. Both 
FA-TC micelles and stable isotope tracers were prepared as stock solutions in CHO free 
complete medium containing DLS, and diluted into treatment media to give the desired final 
concentrations. 
Two sets of experiments were performed to test the concentration-dependent effects of 
fructose and glucose on Caco-2 TAG metabolism. In a first set of experiments, the tracer [13C2]-
sodium acetate was added to all treatment media (5 mmol/L) in order to measure the total 
amount of DNL, by labelling the intracellular acetyl-CoA precursor pool used for palmitate 
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synthesis (Kamphorst et al. 2014). In a second set of experiments, this was replaced with either 
[13C6]-fructose or [13C6]-glucose in treatment media (20 % of total fructose/glucose 
concentration) to trace the utilisation of fructose and glucose as substrates for DNL. In a third 
set of experiments, the same seven fructose and glucose treatments were administered 
without any stable isotope tracers added to media, therefore allowing calculation of the 
naturally-occurring [13C]-enrichment within TAG-palmitate. Three independent replicates 
were performed for each experiment.  
 
2.3.5.4 Preparation of fatty acid micelle solutions for cell experiments 
Lipid micelles were prepared using quantities of 5 different FA (Sigma-Aldrich, UK) and 
taurocholic acid (TC; Sigma-Aldrich, UK). Such FA-TC micelles have been shown to favour the 
secretion of apoB48-containing TRL by Caco-2 cells, by providing FA in a form similar to that 
of post-digestion duodenal micelles in vivo (Chateau et al. 2005). Fatty acids were weighed 
out into separate glass durans (Table 2.9). Five TC solutions were prepared by weighing out 
separate 0.269 g quantities of taurocholic acid sodium hydrate (Sigma-Aldrich, UK) into 50 mL 
tubes, and dissolving each in 25 mL of pre-warmed CHO free complete medium containing 
LDS to give a concentration of 10 mmol/L. Sodium palmitate and sodium stearate were each 
added to 1 mL of TC solution and left on a heating block for 5 min at 70 °C to dissolve, before 
adding to the remaining 24 mL of TC solution to give a target concentration of 5 mmol/L. Other 
FAs (sodium oleate, linoleic acid sodium salt, α-linolenic acid) were added directly into the 
pre-warmed TC solutions (25 mL; 5 mmol/L). All FA-TC solutions were placed on ice and 
sonicated for 20-30 min (15 sec pulses with a 30 sec break) using a Soniprep 150 (MSE Ltd, UK) 
until opalescent, before shaking gently for 2 h at 37 °C to allow micelles to anneal. FA-micelle 
solutions were then filter-sterilised. To determine the final FA-micelle concentration, each 
solution was diluted 1:10 with no additions DMEM and assayed for NEFA concentration by an 
enzymatic method (Wako NEFA-HR assay. Alpha Laboratories, UK) using the ILAB600 clinical 
chemistry analyser. Solutions were then aliquoted and stored at -20 °C until needed. Fatty acid 
micelle solutions were added to treatment media to yield a total concentration of 0.5 mmol/L. 
The final composition of saturated, unsaturated and polyunsaturated FA-TC in media was 
designed to reflect the typical dietary fat intake of the UK adult population (Pot et al. 2011, 
Weech et al. 2014). 
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Table 2.9. Preparation and composition of fatty acid micelles added to treatment media. 
Fatty acid (FA) Amount 
weighed (g) 
FA-micelle 
conc. 
(mmol/L) 
Final FA-TC conc. in 
treatment media 
(mmol/L) 
Composition in 
treatment media 
(%) 
Sodium palmitate 0.070  3.56 0.138 27.6 
Sodium stearate 0.077 3.29 0.065 12.9 
Sodium oleate 0.071 5.86 0.198 39.5 
Linoleic acid 
sodium salt 
0.076 7.65 0.083 16.6 
α-Linolenic acid 0.070 8.25 0.017 3.4 
Total 0.501 100 
Five fatty acid (FA) micelle solutions were prepared by mixing with taurocholic acid and sonicating, 
followed by 2 h at 37 °C to anneal. The final FA-micelle concentration was measured enzymatically 
using an iLAB 600 auto-analyser. The composition in treatment media was designed to reflect the 
typical UK dietary fat intake. 
 
2.3.5.5 Sample collection 
During the 96 h treatment period, basolateral media from each well were collected at 24 h, 
48 h, 72 h and 96 h (total volume = 10.8 mL) and replaced with CHO-free DLS medium. 
Basolateral media from each treatment were pooled and frozen at -20 °C, before being 
lyophilised to dryness using a freeze drier (ModulyoD, Thermo Fisher Scientific, UK). Samples 
were then re-constituted in 0.5 mL of di H2O prior to lipid extraction (section 2.3.5.6). Cell 
monolayers were harvested from each insert at the end of the treatment period. Monolayers 
were washed twice with ice-cold phosphate-buffered saline (PBS) and Transwell® plates 
placed on ice, after which 200 µL of ice-cold lysis buffer (Cell Signaling Technology Inc., USA) 
was added directly to the monolayers, before scraping with a cell scraper and transferring to 
an Eppendorf tube. Samples were centrifuged at 4 °C for 5 min at 4000 rpm to remove the 
DNA pellet. A 20 µL volume of supernatant was removed to determine the total cellular 
protein concentration (mg/mL) via BCA assay, as described in section 2.1.7.2. Cell lysates were 
then frozen at -20 °C until lipid extraction. 
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2.3.5.6 Summary of the analytical methods used in cell culture experiments 
The flowchart in Figure 2.18 summarises the main stages of preparation and analysis for 
samples from the cell culture experiments. 
 
 
Figure 2.18. Flowchart summarising the main stages in the preparation of cell culture samples for 
GC-MS analysis. 
FAME, fatty acid methyl ester; GC-MS, gas chromatography-mass spectrometry; TAG, triacylglycerol; 
TLC, thin layer chromatography. 
    
 
 
2.3.5.7 Extraction, purification and derivatisation of intracellular and secreted TAG 
The TAG content of both intracellular (cell lysate) and basolateral (cell media) samples was 
analysed by firstly extracting the total lipid content as described in section 2.1.8, after which 
TLC was used to separate TAG from other lipid classes present in the samples, such as 
phospholipids (section 2.1.9). Purified TAG bands from TLC separation were cut and scraped 
into 7 mL glass vials, then simultaneously hydrolysed, and the fatty acid component 
derivatised to FAME (section 2.1.10). The FAME component of TAG was then analysed by GC-
MS (section 2.3.5.8).   
The remaining TAG-glycerol from samples was then purified by ion exchange chromatography 
(section 2.1.12), before derivatisation to yield the tBDMS derivative of glycerol (section 
2.1.13). 
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2.3.5.8 Measurement of TAG fatty acid concentration by GC-MS 
Following derivatisation to FAME, the concentration of fatty acids from intracellular (cell 
lysate) and secreted (basolateral) TAG was determined by GC-MS, as described in section 
2.1.14. The reference material RM6, as well as mass spectra from an online library, were again 
used to positively identify FAMEs present in the samples (Figure 2.19), which included methyl 
palmitate (16:0), methyl palmitoleate (16:1, n-7), methyl stearate (18:0), methyl oleate (18:1, 
n-9), methyl linoleate (18:2, n-3) and methyl linolenate (18:3, n-3) as well as the internal 
standard methyl heptadecanoate (17:0).     
 
Figure 2.19. An example chromatogram showing the retention times (RT) of fatty acid methyl esters 
identified in samples from cell experiments.  
The retention time of peaks were compared to a standard reference material (RM6): 16:0 (methyl 
palmitate); 16:1, n-7 (methyl palmitoleate); 17:0 (methyl heptadecanoate); 18:0 (methyl stearate); 
18:1, n-9 (methyl oleate); 18:2, n-6 (methyl linoleate); 18:3, n-3 (methyl linolenate).       
 
A set of standards was prepared as detailed in section 2.1.15 and run at the start and end of 
each GC-MS run, in order to ensure within- and between-run precision of the instrument was 
maintained. The mean slope of the observed (measured) versus the theoretical (calculated) 
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palmitate to heptadecanoate µmolar ratio was 1.0860 and the linearity (R2) was 0.9984 (n=6 
runs), as shown in Figure 2.20. 
 
 
Figure 2.20. Standard curve for fatty acid concentration of intracellular and secreted TAG samples.  
Standards were measured at the start and end of each run. Results are mean ± SEM (n=6 runs). 
  
 
2.3.5.9  Measurement of TAG-palmitate enrichment by GC-MS 
The palmitate methyl ester (PAME) generated from the hydrolysis and derivatisation of TAG 
extracted from intracellular and secreted samples was analysed via GC-MS, in order to 
determine the [13C]-enrichment and thus the amount of de novo TAG-palmitate formed in 
response to each treatment. As mentioned for the human study (section 2.1.19), some of the 
de novo palmitate formed via DNL may have been further elongated and/or desaturated by 
Caco-2 cells to form other FA. Again, due to time and resource limitations pertaining to the 
operation of the GC-MS instrument, it was not possible to measure the enrichment in these 
other FA products.  
The isotopic enrichment of PAME was measured by selective monitoring of 9 ions: m/z = 270 
(unlabelled palmitate; M+0), m/z = 272 (M+2), m/z = 274 (M+4), m/z = 276 (M+6), m/z = 278 
(M+8), m/z = 280 (M+10), m/z = 282 (M+12), m/z = 284 (M+14) and m/z = 286 (M+16). This 
represented the full range of palmitate mass isotopomers, from unlabelled palmitate (M+0) 
synthesised with no enriched subunits, to fully-enriched M+16 palmitate synthesised from a 
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maximum of eight [13C2]-acetate subunits. An example chromatogram showing ions m/z = 270, 
m/z = 272 (M+2) and m/z = 274 (M+4) is presented in Figure 2.21. 
The GC-MS system and capillary column used to measure PAME enrichment was the same as 
described in section 2.1.16. A 0.2 µL volume of each sample was injected into the column by 
a splitless injection mode with the injector temperature set to 250 °C. The initial oven 
temperature was 100 °C, which was held for 3 min, then increased at 25 °C/min to 200 °C and 
held for 12.5 min, then ramped at 25 °C/min to 240 °C and held for 5 min. The retention time 
for methyl palmitate was approximately 10 min and the total run time was 26.1 min. The 
interface temperature was 280 °C and the quadrupole temperature was 150 °C.     
   
 
Figure 2.21. An example chromatogram showing three isotopomer ions of methyl palmitate. 
The ion fragment at m/z = 270 (top) corresponds to the unlabelled tracee (M, methyl palmitate), 
while the ion fragments at m/z = 272 (middle) and m/z = 274 (bottom) correspond to methyl 
palmitate synthesised from one (M+2) or two [13C2]-acetate molecules.  
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2.3.5.10 Standard and QC preparation for de novo TAG-palmitate 
Palmitate enrichment standards were prepared as shown in Table 2.10 to give a theoretical 
TTR in the range of 0 to 0.0303, using a 33.5 µmol/L stock solution of unlabelled glyceryl 
tripalmitate (Tripalm) and a 0.317 µmol/L stock solution of labelled glyceryl tri([13C2]-
palmitate) (13C2-Tripalm).  
 
Table 2.10. Preparation of standards for measuring de novo TAG-palmitate in cell samples. 
No. Tripalm 
(nmol) 
13C2-Tripalm 
(nmol) 
Theoretical TTR      
13C2-Tripalm/Tripalm 
Observed TTR  
13C2-Tripalm/Tripalm 
1 0 8.38 0 0 
2 0.016 8.38 0.0018 0.0015 
3 0.032 8.38 0.0038 0.0032 
4 0.063 8.38 0.0076 0.0059 
5 0.095 8.38 0.0113 0.0094 
6 0.127 8.38 0.0151 0.0137 
7 0.190 8.38 0.0227 0.0201 
8 0.253 8.38 0.0303 0.0273 
Both the calculated theoretical molar ratio and the mean observed ratio measured on the GC-MS are 
given (n=5 runs): 13C2-Tripalm, labelled glyceryl tri([13C2]-palmitate) (tracer); Tripalm, unlabelled 
glyceryl tripalmitate (tracee); TTR, tracer-to-tracee ratio. 
 
Standards were measured at the start of each sample run in order to ensure between-run 
precision of the GC-MS instrument was maintained (Figure 2.22). The mean slope of the 
observed versus the theoretical TTR was 0.9082 and the linearity (R2) was 0.9984 (n=5 runs). 
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Figure 2.22. Palmitate enrichment standard curve for measuring DNL in cell samples. 
The graph represents the ratio (TTR) of tracer ([13C2]-Tripalm) to tracee (Tripalm). Standards were 
measured at the start of each run. Results are mean ± SEM (n=5 runs). 
 
A set of basal (no tracer), low and high enrichment QCs (n=6) were also prepared using the 
PA0 and PA2 stock solutions detailed above, then derivatised (section 2.1.10) with each sample 
batch, to determine the between-batch reproducibility of the derivatisation procedure. The 
TTR ratio for each QC was measured on the GC-MS as described (section 2.3.5.9). The 
between-batch CVs were 0.84 %, 0.75 % and 0.74 % for the basal, low and high QCs, 
respectively. 
 
2.3.5.11 Calculation for determining de novo TAG-palmitate 
The [13C]-enrichment of TAG-palmitate was measured via GC-MS as described in section 
2.3.5.9. These data were used to calculate the TTR of all enriched palmitate isotopomers (M+2 
to M+16) relative to the abundance of unenriched palmitate (M+0), giving eight different TTR 
values (M+2/M+0, M+4/M+0…M+16/M+0). These TTR values represented the relative [13C]-
enrichment in palmitate molecules that had incorporated a minimum of one (M+2/M+0) to a 
maximum of eight (M+16/M+0) [13C2]-acetate subunits during palmitate synthesis. These TTR 
values were corrected for natural ‘background’ enrichment by subtracting TTR values from 
experiments conducted without any isotopic tracer added to the media. Corrected TTR values 
were summed to give the total [13C]-enrichment in TAG-palmitate, as described previously 
(Ahmed et al. 2013). The total [13C]-enrichment was then multiplied by the TAG-palmitate 
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concentration of each sample (section 2.3.5.8) to obtain the amount of de novo palmitate 
(pmol/mg cell protein) derived from each tracer type ([13C2]-acetate, [13C6]-fructose or [13C6]-
glucose). 
 
2.3.5.12 Measurement of TAG-glycerol enrichment by GC-MS 
The [13C3]-glycerol content of TAG-glycerol extracted from intracellular and basolateral 
samples was measured, to determine the utilisation of fructose and glucose as substrates for 
TAG-glycerol synthesis. Samples from experiments including [13C2]-acetate were not analysed. 
The GC-MS system, capillary column and acquisition method used were as described in section 
2.1.16. However, the acquisition method was modified to monitor for ions m/z = 377 
(unlabelled glycerol tBDMS derivative) and m/z = 380 ([13C3]-glycerol tBDMS derivative), as 
shown in Figure 2.23. 
 
 
Figure 2.23. An example chromatogram showing selective ion monitoring for glycerol tracer ([13C3]-
glycerol) and tracee (glycerol) ion fragments. 
The ion fragment at m/z = 377 (top) corresponds to the unlabelled tracee (tri-[tert-butyldimethylsilyl]-
glycerol) and the ion fragment at m/z = 380 corresponds to the labelled tracer (tri-[tert-
butyldimethylsilyl]-[13C3]-glycerol). 
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2.3.5.13 Standard and QC preparation for TAG-glycerol enrichment 
Glycerol standards were prepared as shown in Table 2.11 to give a theoretical TTR in the range 
of 0 to 0.422, using a 161.7 µmol/L stock solution of unlabelled glycerol and a 71.0 µmol/L 
stock solution of labelled [13C3]-glycerol.  
 
Table 2.11. Preparation of standards for measuring TAG-glycerol enrichment in cell samples. 
No. [13C3]-glycerol 
(nmol) 
Glycerol 
(nmol) 
Theoretical TTR      
[13C3]-glycerol/glycerol 
Observed TTR  
[13C3]-glycerol/glycerol 
1 0 40.43 0 0 
2 1.42 40.43 0.035 0.034 
3 2.84 40.43 0.070 0.069 
4 5.68 40.43 0.141 0.136 
5 8.52 40.43 0.211 0.206 
6 12.79 40.43 0.316 0.310 
7 17.05 40.43 0.422 0.413 
Both the calculated theoretical molar ratio and the mean observed ratio measured on the GC-MS are 
given (n=6 runs) for labelled [13C3]-glycerol (tracer) and unlabelled glycerol (tracee). TTR, tracer-to-
tracee ratio. 
 
The mean slope of the observed versus the theoretical TTR was 0.9803 and the linearity (R2) 
was 1.0000 (n=6), as shown in Figure 2.24. 
 
 121 
 
Figure 2.24. Glycerol enrichment standard curve for TAG-glycerol enrichment in cell samples. 
The graph represents the ratio (TTR) of tracer ([13C3]-glycerol) to tracee (glycerol). Standards were 
measured at the start and end of each run. Results are mean ± SEM (n=6 runs). 
 
A set of basal (no tracer), low and high enrichment QCs were also prepared using the stock 
solutions detailed above, then derivatised (section 2.1.13) with each sample batch, to 
determine the between-batch reproducibility of the derivatisation procedure. The TTR ratio 
for each QC was measured on the GC-MS as described (section 2.3.5.12). The between-batch 
CVs were 1.00 %, 0.92 % and 1.03 % for the basal, low and high QCs, respectively. 
 
2.3.5.14 Calculation for determining percent de novo TAG-glycerol 
The enrichment of TAG-glycerol extracted from cells and basolateral media was measured as 
described in section 2.3.5.12. The TTR of glycerol was calculated as the ratio of the m/z 380 
(labelled) ion to the m/z 377 (non-labelled) ion, representing the ratio of [13C3]-glycerol 
(tracer) to glycerol (tracee). TTR values for samples were corrected for the natural abundance 
of [13C3]-glycerol in TAG by subtracting a ‘background’ TTR value obtained from a set of 
experiments conducted without [13C6]-glucose or [13C6]-fructose added to treatment media. 
The percentage of de novo TAG-glycerol derived from either glucose or fructose was 
determined based on the method of (Chong et al. 2007) according to Equation 6:  
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Equation 6: 
 
De novo TAG-glycerol (%)   =   (TTR of TAG-glycerol/TTR treatment media)   x   100 
 
Where the TTR of TAG-glycerol in a sample represents the ratio of m/z 380/377 (corrected for 
natural abundance) and the TTR of [13C6]-glucose or [13C6]-fructose in treatment media was 
0.2, or 20 %.        
 
2.4 Statistical methods 
2.4.1 Statistical methods used for the human study 
All time course variables were analysed using a linear mixed model to compare mean steady-
state values (0 – 420 min) from high- and low-fructose visits. The model included estimation 
of the main effects for visit (visit 1 or visit 2), treatment (high- or low-fructose drink), time (0 
to 420 min), with baseline (-240 min, fasted value) added as a covariate. An interaction effect 
for visit by treatment was added, to test for the presence of any period effects. A time by 
treatment interaction was also included. All variables were checked visually for normality of 
distribution using Q-Q plots, to confirm whether each variable approximated a normal 
distribution. Any non-normally distributed variables were log-transformed prior to analysis. 
One-way repeated measures ANOVA analysis was also performed on plasma TAG, CM-TAG 
and VLDL-TAG values for steady-state time points (0 – 420 min), with time as a factor, to 
ensure there was no significant variation during this period, as a constant post-prandial TAG 
concentration was necessary for kinetic calculations. Differences between mean fasted values 
for high- and low-fructose visits were tested by paired-samples t-test (two-tailed).  
For measurements which increased in the post-prandial state, iAUC values for high- and low-
fructose visits were also calculated, as described previously (Brouns et al. 2005). Differences 
between iAUC values were analysed by paired-samples t-test (two-tailed). For fasted and post-
prandial DNL data, intestinal and hepatic DNL values were compared Spearman’s correlation 
analysis. All statistical analyses were performed using SPSS version 24 (IBM Corp, USA). For all 
tests, P < 0.05 was considered statistically significant.    
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2.4.2 Statistical methods used for cell culture experiments 
All data are presented as mean ± SD, unless otherwise stated. All statistical analyses were 
performed using SPSS version 24 (IBM Corp, USA). Data for cell viability, pre-treatment TEER 
values (days 4-21), TAG content, de novo palmitate and de novo glycerol in TAG, were all 
analysed via one-way ANOVA. Separate tests were conducted to compare differences 
between the three glucose and the three fructose conditions, both for intracellular (cell) and 
secreted (media) samples (four tests). Levene’s test for equality of variances was performed, 
to determine whether homogeneity of variances between groups could be assumed. If 
variances were homogenous (P > 0.05), the ANOVA result was interpreted and, where 
appropriate, Tukey’s HSD post hoc tests used to determine significant pairwise comparisons. 
If variances were heterogeneous (P < 0 .05), a modified Welch ANOVA was conducted and, 
where appropriate, followed with Games-Howell post hoc tests. For analysis of TEER data 
during the treatment period (days 21-25), a two-way repeated measures ANOVA 
(Greenhouse-Geisser correction) was conducted with time, treatment (condition) and time by 
treatment interaction as factors. Subsequent one-way repeated measures ANOVA tests 
(Greenhouse-Geisser correction) were conducted to determine the main effects of time and 
treatment, with Bonferroni post hoc tests used to determine pairwise differences.  
Independent-samples t-tests were run to compare secreted and intracellular data for each 
treatment condition (e.g. 5 mM glucose), as well as for comparison of equivalent glucose and 
fructose concentrations (e.g. 5 mM glucose vs. 5 mM fructose). For all statistical tests, P < 0.05 
was considered statistically significant.  
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Chapter 3 An in vivo investigation of the effect of high- and 
low-fructose meals on intestinal TAG metabolism and DNL 
in humans 
3.1 Background 
An increased plasma concentration of TRL and their remnants (CMR and LDL) is an established 
risk factor for CVD risk (Eberly et al. 2003). This may arise from either an increased secretion 
of TRL into the circulation, or an impaired clearance of TRL and their remnant particles. 
Consumption of the monosaccharide fructose has been shown to significantly increase both 
plasma TAG and TRL-TAG, in comparison to equivalent amounts of either glucose or sucrose 
(Bantle et al. 2000, Eberly et al. 2003, Teff et al. 2004, Teff et al. 2009, Stanhope et al. 2011). 
The lack of feedback regulation in fructose metabolism may favour its conversion into FA via 
the process of DNL. Stimulation of hepatic DNL in response to fructose has been widely 
reported (Faeh et al. 2005, Schwarz et al. 2015, Taskinen et al. 2017), although more recent 
evidence has also revealed that fructose carbons are utilised for intestinal DNL in humans 
(Theytaz et al. 2014). However, to date, there have been no attempts to quantify this effect 
of fructose on intestinal DNL. 
Fructose feeding also significantly increases the number of CM produced in both the fasting 
and post-prandial states, as indicated by a raised apoB48 concentration (Saito et al. 2013, Xiao 
et al. 2013, Saito et al. 2015). However, data concerning CM-TAG levels are limited, with the 
few existing studies reporting increases that were non-significant (Theytaz et al. 2014, 
Surowska et al. 2016, Taskinen et al. 2017). This may be due to methodological limitations in 
the separation of CM, which are often assumed to reside in the Sf > 400 TRL fraction, which is 
typically obtained through ultracentrifugation. In reality, a significant proportion of CM, and 
particularly CMR, are found in the Sf 60-400 fraction, and thus overlap the density range 
habitually ascribed to VLDL particles (Jackson et al. 2002). Existing data in the literature are 
therefore confounded by this lack of purified CM and VLDL lipoprotein fractions.  
One method for overcoming this problem, is to combine ultracentrifugation with an 
immunoaffinity chromatography technique (see section 2.1.7), thus separating lipoproteins 
based on both density and their unique apolipoprotein B content. Monoclonal antibodies with 
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specificity for apoB100 are used, which do not cross-react with apoB48, yielding purified 
unbound (apoB48) CM and bound (apoB100) VLDL fractions (Heath et al. 2003). Our 
laboratory used this approach to develop and validate a novel stable isotope protocol, 
involving continuous feeding, to create a steady post-prandial TAG concentration. Thus it was 
possible to measure the production rate for purified human CM-TAG in vivo (Sun et al. 2013). 
Using this protocol, Shojaee-Moradie et al (2013) demonstrated an increased CM-TAG 
concentration (Sf > 60 fraction) in men with MetSyn, compared to lean individuals, which was 
shown to be due to an enhanced PR, with no difference in the fractional catabolic rate (FCR) 
(Shojaee-Moradie et al. 2013).  
In the present study, the same protocol was used to investigate the impact of fructose 
consumption on post-prandial TAG metabolism, allowing precise determination of the 
differential effects on CM-TAG and VLDL-TAG, and thus intestinal and hepatic lipid 
metabolism, respectively. Therefore, the first definitive measure of CM- and VLDL-TAG 
concentrations in response to fructose was undertaken, as well as the first known quantitative 
estimate of intestinal DNL, as well as its relative contribution to overall TAG metabolism in 
response to high-fructose meals. 
 The aims of the research were therefore: 
1. To perform a human study of post-prandial CM-TAG and VLDL-TAG kinetics in the 
steady-state, to determine the effects of consuming high-fructose (30 % of energy) 
mixed-nutrient liquid meals, in comparison to isocaloric, complex CHO control liquid 
meals (30 % of energy). 
2. To investigate the effect of high-fructose meals on intestinal and hepatic DNL. 
The following hypothesis was tested: 
 High-fructose meals exacerbate post-prandial plasma TAG levels by altering CM-TAG 
and VLDL-TAG kinetics, as well as the induction of de novo lipogenesis, relative to low-
fructose control meals. 
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3.2 Methods 
This was an acute randomised crossover study, with all subjects attending two metabolic study 
days, where they consumed liquid mixed-nutrient meals every hour, which were either high 
or low in fructose. The inclusion and exclusion criteria are given in Table 2.1, and the protocol 
for metabolic study visits is detailed in section 2.1.4. Briefly, adult male subjects (n=6), aged 
18 to 50 and with a BMI of 25 – 32 kg/m2, were recruited from the Guildford area, with all 
subjects screened to check they had a fasted glucose < 7 mmol/L and a fasted plasma TAG < 4 
mmol/L.  On the evening prior to each metabolic study visit, subjects consumed a standardised 
meal, as well as two loading doses of 2H2O deuterated water (3 g/kg) to measure DNL, which 
was followed by an overnight fast (≥ 12 h). The next morning, subjects attended the Cedar 
centre at Royal Surrey County Hospital. Anthropometric and blood pressure measurements 
were taken, prior to cannulation. A fasted blood sample was taken, before subjects consumed 
11 high-fat liquid meals, either high (30 %) or low (0 %) in fructose, at hourly intervals (Table 
2.2), for the next 11 hours. After four hours, when a steady post-prandial state was 
established, an intravenous bolus of 2H5-glycerol (75 µmol/kg) was administered to trace the 
synthesis of de novo TAG in the small intestine and liver, therefore allowing the calculation of 
CM-TAG and VLDL-TAG kinetics, respectively.  
 
3.3 Results 
3.3.1 Subject characteristics 
A total of seven potential subjects were screened, of which six subjects were recruited into 
the study, in accordance with the inclusion and exclusion criteria given in section 2.1.1. One 
male had a BMI below the acceptable range and so was not recruited (< 25 kg/m2). All subjects 
were considered to be generally healthy, with a normal blood pressure (160/100, 
systolic/diastolic mmHg), no self-reported history of diabetes, food allergies, endocrine or 
cardiovascular disease, or hepatic, gastrointestinal or renal disorders. Subjects were non-
smokers, who had been weight stable in the 3 months prior to recruitment and with a normal 
blood haemoglobin content (13.5 – 17.5 g/dL). At the screening visit, the mean (± SEM) age of 
subjects was 32.2 ± 3.1 years, with a mean BMI of 27.3 ± 0.9 mg/m2 (Table 3.1). The subjects’ 
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mean fasted plasma TAG was 1.28 ± 0.40 mmol/L and their mean fasted glucose was 4.84 ± 
0.25 mmol/L.  
 
Table 3.1. Baseline characteristics of subjects at fasted screening visit. 
Subject code Age              
(y) 
Weight        
(kg) 
BMI       
(kg/m2) 
Glucose 
(mmol/L) 
Plasma TAG 
(mmol/L) 
FRU06 26 88.8 25.4 3.77 1.02 
FRU07 43 91.7 26.5 5.52 0.70 
FRU09 22 101.2 26.9 4.52 1.95 
FRU10 36 103.7 31.0 5.13 2.93 
FRU11 31 90.2 28.5 4.93 0.56 
FRU12 35 82.9 25.6 5.16 0.49 
Mean (± SEM) 32.2 ± 3.1  93.1 ± 3.2 27.3 ± 0.9 4.84 ± 0.25 1.28 ± 0.40 
Abbreviations: BMI, body mass index; TAG, triacylglycerol. 
 
3.3.2 Exclusion of subject FRU10 from data analysis 
Following analysis of samples from all study visits, it was revealed that subject FRU10 met the 
minimum 3 out of 5 criteria for metabolic syndrome (Table 3.2), as outlined in the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) definition 
(Rezaianzadeh et al. 2012). The research doctor for the study informed the subject of his 
results and recommended that he seek the advice of his GP. This subject was therefore 
excluded from the data analysis presented in sections 3.3.3 to 3.3.11, due to the suspected 
presence of metabolic syndrome. Individual data for subject FRU10 is provided in appendix A 
(Figure 5.2 and Figure 5.3).           
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Table 3.2. Subject FRU10 suspected presence of metabolic syndrome. 
Parameter NCEP ATP III definition 
reference range 
FRU10  mean value 
 (visits 1 and 2) 
Waist circumference (cm) ≥ 102 110 
Blood pressure (mmHg) SBP ≥ 130 and/or DBP ≥ 85 129 / 80 
Fasted TAG (mmol/L) ≥ 1.70 3.77 
Fasted glucose (mmol/L) ≥ 6.10 5.10 
Fasted HDL-C (mmol/L) ≤ 1.04 0.98 
Subject FRU10 matched the necessary minimum of 3 out 5 criteria (bold text) for metabolic 
syndrome, as defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATP III). SBP, systolic blood pressure; DBP, diastolic blood pressure. 
 
3.3.3 Diet of the subjects 
Subjects completed a standardised food diary on the four days immediately prior to each 
metabolic study visit, according to instructions given at the screening visit. There were no 
significant differences (all P > 0.05) between high- and low-fructose visits for any of the 
macronutrients analysed, including total dietary sugars, sucrose, glucose and fructose (Table 
3.3). The diet of subjects was therefore not considered to be a determinant of differences 
between high- and low-fructose study visits. 
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Table 3.3. Diet of the subjects prior to high- and low-fructose visits. 
 High-fructose visit Low-fructose visit P value (two-tailed) 
Total energy (MJ/d) 2.44 ± 0.18 2.39 ± 0.11 0.58 
Carbohydrate (%E) 41.5 ± 5.9 39.2 ± 7.2 0.45 
Fat (%E) 37.1 ± 3.6 39.5 ± 3.9 0.53 
Protein (%E) 19.7 ± 2.1 18.5 ± 3.3 0.60 
Carbohydrate (g/d) 253 ± 30 222 ± 46 0.29 
Total sugars (g/d) 111 ± 11 107 ± 20 0.83 
          Sucrose (g/d) 32 ± 6 36 ± 13 0.56 
         Glucose (g/d) 21 ± 4 14 ± 2 0.15 
         Fructose (g/d) 21 ± 4 15 ± 2 0.23 
Fibre (g/d) 24 ± 3 27 ± 5 0.43 
Protein (g/d) 126 ± 19 100 ± 12 0.10 
Fat (g/d) 95 ± 11 88 ± 17 0.33 
        SFA (g/d) 34 ± 4 38 ± 6 0.56 
       MUFA (g/d) 34 ± 6 39 ± 6 0.26 
       PUFA (g/d) 13 ± 2 14 ± 3 0.67 
Subjects completed a food diary on the four days prior to each study visit. The macronutrient 
composition was analysed using Nutritics software version 5.0.25 (Dublin, Rep. Ireland). Data are 
mean ± SEM (n = 5). Differences between high- and low-fructose visits were analysed by paired-
samples t-test (two-tailed). Abbreviations: d, day; g, grams; MJ, megajoules; %E, percentage of total 
energy.  
 
 
3.3.4 Plasma TAG and TRL-TAG 
Subjects attended two metabolic study days, separated by a four-week washout period, 
where they received drinks that were either high (30 %) or low (0 %) in fructose, representing 
two acute treatment phases with a crossover design. Mean (± SEM) fasted plasma TAG 
concentrations (-240 min) were 0.95 ± 0.28 mmol/L for the high-fructose visit and 0.87 ± 0.20 
mmol/L for the low-fructose visit, with no significant difference between visits (P = 0.056). 
Four hours after beginning the study (0 min), mean plasma TAG had increased significantly 
(Figure 3.1, panel A) to 2.10 ± 0.68 mmol/L in response to high-fructose drinks (P = 0.048), 
with an almost significant increase to 1.58 ± 0.44 mmol/L for low-fructose drinks (P = 0.052). 
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During the steady-state period (0 – 420 min), mean Plasma TAG concentrations were 2.00 ± 
0.64 mmol/L (high-fructose) and 1.48 ± 0.35 mmol/L (low-fructose), which remained constant 
during this period for both visits, as determined by one-way repeated measures ANOVA (P = 
0.57 and P = 0.48, respectively). A steady post-prandial state for kinetic calculations could 
therefore be assumed. Mean post-prandial TAG concentrations were consistently higher 
throughout the study period when feeding high-fructose drinks, in comparison to low-fructose 
drinks.  
Linear mixed model analysis of steady-state TAG concentrations revealed a significant 
treatment effect (P < 0.005), with no other significant effects for visit (P = 0.87), time (P = 
0.12), visit by treatment interaction (P = 0.052), or time by treatment interaction (P = 0.44). 
There was no significant difference (P = 0.171) between iAUC values for high- and low-fructose 
visits (Figure 3.1, panel B).  
Mean TRL-TAG concentrations during the steady-state period (0 – 420 min) were 1.68 ± 0.64 
mmol/L and 1.24 ± 0.34 mmol/L, in response to high- and low-fructose drinks, respectively. 
Linear mixed model analysis did not detect a statistically significant effect for treatment (P = 
0.145), although there were significant effects for visit (P = 0.038) and visit by treatment 
interaction (P = 0.026), indicating the presence of a ‘period effect’ (see section 3.4.5). The iAUC 
values were not significantly different (P = 0.211) between high- and low-fructose visits. 
Individual plasma TAG (Figure 5.4) and TRL-TAG responses (Figure 5.5) for each subject are 
presented in appendix A. 
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Figure 3.1. Mean plasma TAG and TRL-TAG responses to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). Time course responses for 
plasma TAG (A) and TRL-TAG (C) are presented on the left, with corresponding iAUC values (B and D) 
on the right. Data are mean ± SEM (n = 5). Time course responses were analysed by a linear mixed 
model: for plasma TAG; P < 0.005 (treatment); for TRL-TAG; P < 0.05 (visit), P < 0.05 (visit by 
treatment interaction). Mean iAUC data were analysed by paired T-test (two-tailed) (NS).        
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3.3.5 CM-TAG and VLDL-TAG 
3.3.5.1 CM-TAG and VLDL-TAG concentration 
Mean fasted CM-TAG concentrations (mean ± SEM) were not significantly different when 
either high-fructose (0.28 ± 0.14 mmol/L) or low-fructose drinks (0.24 ± 0.09 mmol/L) were 
consumed (Figure 3.2, panel A), representing the two  During the steady-state period (0 – 420 
min), mean CM-TAG concentrations were 1.25 ± 0.46 mmol/L and 0.98 ± 0.29 mmol/L, in 
response to high- and low-fructose drinks, respectively. One-way repeated measures ANOVA 
did not detect a statistically significant variation in the CM-TAG concentration during this 
period, for either high-fructose (P = 0.23) or low-fructose (P = 0.063) drinks, indicating a 
steady-state for kinetic modelling was achieved. Linear mixed model analysis did not reveal a 
significant effect of treatment (P = 0.292), although significant effects of visit (P = 0.011) and 
visit by treatment interaction (P = 0.001) were detected, indicating the presence of a 
significant period effect. There was no significant difference between mean iAUC values for 
high- and low-fructose visits (P = 0.31) (Figure 3.2, panel C).     
For VLDL-TAG, mean fasted concentrations on high- (0.27 ± 0.14 mmol/L) and low-fructose 
visits (0.21 ± 0.09 mmol/L) were not significantly different (P = 0.47). Mean steady-state values 
increased to 0.43 ± 0.19 mmol/L (high-fructose) and 0.27 ± 0.09 mmol/L (low-fructose), with 
no significant variation for either high-fructose (P = 0.90) or low-fructose visits (P = 0.40), again 
indicating that steady post-prandial concentrations for kinetic modelling were achieved. The 
linear mixed model revealed a statistically significant treatment effect (P = 0.003) of high-
fructose drinks, in comparison to low-fructose drinks, with no other significant main effects or 
interaction effects. The difference in VLDL-TAG iAUC values was almost significant between 
groups (P = 0.08). Individual CM-TAG (Figure 5.6) and VLDL-TAG (Figure 5.7) responses are 
presented in appendix A.  
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Figure 3.2. CM-TAG and VLDL-TAG responses to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). Time course responses for 
CM-TAG (A) and VLDL-TAG (C) are presented on the left, with corresponding iAUC values (B and D) on 
the right. Data are mean ± SEM (n = 5). Time course responses were analysed by a linear mixed 
model: for CM-TAG; P < 0.05 (visit), P < 0.005 (visit by treatment interaction); for VLDL-TAG; P < 0.005 
(treatment). Mean iAUC data were analysed by paired-samples t-test (two-tailed) (NS).        
 
 
3.3.5.2 Plasma [2H5]-glycerol enrichment 
In order to determine rates of CM-TAG and VLDL-TAG synthesis, an intravenous bolus of [2H5]-
glycerol was administered during metabolic study visits, at time 0 min, to label the systemic 
plasma glycerol pool used for both intestinal and hepatic TAG synthesis. The TTR enrichment 
of [2H5]-glycerol (m/z 380/377 ratio) in plasma is shown in Figure 3.3. As was expected based 
on previous studies conducted in our group (Lou 2013, Shojaee-Moradie et al. 2013), plasma 
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glycerol enrichment peaked at 5 min. Values then decreased rapidly, with the plasma TTR 
returning to levels similar to baseline by 240 min.       
 
 
Figure 3.3. Plasma [2H5]-glycerol enrichment during high- and low-fructose visits. 
Subjects received an intravenous bolus of [2H5]-glycerol (75 μmol/kg body weight) at time 0 min to 
measure CM-TAG and VLDL-TAG synthesis rates. The tracer-to-tracee ratio (TTR) of m/z 382 ([2H5]-
glycerol) and m/z 377 (unlabelled glycerol) ions, derived from plasma glycerol, was measured by GC-
MS. Data are mean ± SEM (n = 5).   
 
3.3.5.3 CM-TAG and VLDL-TAG [2H5]-glycerol enrichment 
TTR values for the [2H5]-glycerol enrichment of CM-TAG and VLDL-TAG are shown in Figure 
3.4. The mean (± SEM) glycerol enrichment in CM-TAG peaked at 90 min (0.00167 ± 0.00028) 
during the high-fructose visit and at 60 min (0.00217 ± 0.00033) during the low-fructose visit. 
For VLDL-TAG, glycerol enrichment peaked sooner for the high-fructose visit, at 60 min 
(0.00255 ± 0.00022), than during the low-fructose visit, which peaked at 90 min (0.00335 ± 
0.00042). A measurable enrichment was detected in all samples.   
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Figure 3.4. [2H5]-glycerol enrichment of CM-TAG and VLDL-TAG in response to high- and low-fructose 
drinks.  
Data are mean ± SEM (n = 5) and represent the tracer-to-tracee ratio (TTR) of m/z 382 ([2H5]-glycerol) 
and m/z 377 (unlabelled glycerol) ions, derived from the glycerol moiety of CM-TAG (A) and VLDL-TAG 
(B) and measured by GC-MS. 
 
3.3.5.4 CM-TAG and VLDL-TAG post-prandial kinetics 
As shown in Table 3.4, the mean CM-TAG PR was significantly higher in response to low-
fructose drinks than high-fructose drinks (P = 0.046), which was also accompanied by a 
correspondingly higher CM-TAG FCR, although this difference did not quite reach statistical 
significance (P = 0.073). There was no significant difference in the overall CM-TAG pool size 
(PS) between high- and low-fructose visits. For VLDL-TAG, there was no significant difference 
in the mean PR or FCR. The VLDL-TAG PS was higher during the high-fructose visit, although 
the difference did not quite attain statistical significance (P = 0.072).    
Table 3.4. Post-prandial CM-TAG and VLDL-TAG kinetics in response to high- and low-fructose drinks.  
 High-fructose Low-fructose P value 
CM-TAG PR (mg/kg/d) 152.89 ± 76.59  375.93 ± 68.80 0.046 
CM-TAG FCR (pools/d) 7.44 ± 4.01 21.69 ± 7.60 0.073 
CM-TAG PS (mg) 2976 ± 1060 2247 ± 653 0.367 
VLDL-TAG PR (mg/kg/d) 81.03 ± 19.57 68.43 ± 12.18 0.641 
VLDL-TAG FCR (pools/d) 10.35 ± 3.50 12.21 ± 2.78 0.254 
VLDL-TAG PS (mg) 1042 ± 460 634 ± 217 0.072 
Data are mean ± SEM (n = 5). Differences between high- and low-fructose visits were analysed by 
paired-samples t-test (two-tailed). P values < 0.05 are in bold text. FCR, fractional catabolic rate; PR, 
production rate; PS, pool size.  
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3.3.6 TRL apoB48 and apoB100 
Mean (± SEM) fasted TRL apoB48 concentrations were not significantly different between 
high-fructose (1.2 ± 0.5 mg/L) and low-fructose visits (1.1 ± 0.5 mg/L) (P = 0.86). During the 
steady-state period (Figure 3.5, panel A), mean TRL apoB48 concentrations were 5.48 ± 2.11 
mg/L (high-fructose) and 3.35 ± 0.79 mg/L (low-fructose). Linear mixed model analysis 
detected a significant treatment effect (P = 0.039), although there was also a significant visit 
by treatment interaction (P = 0.003), implying a substantial period effect.  
Fasted TRL apoB100 concentrations were not significantly different (P = 0.81) between high-
fructose (18.1 ± 5.4 mg/L) and low-fructose visits (19.7 ± 7.5 mg/L). During the steady-state 
period (Figure 3.5, panel C), mean TRL apoB100 concentrations were 23.89 ± 4.66 mg/L (high-
fructose) and 19.19 ± 6.26 mg/L (low-fructose). A significant treatment effect was detected by 
linear mixed model analysis (P = 0.013), with no other significant main effects or interaction 
effects (all P > 0.05). Mean iAUC values for apoB48 (P = 0.32) and apoB100 (P = 0.19) were not 
significantly different in response to high- and low-fructose drinks (Figure 3.5, panels B and 
D). The individual apoB48 (Figure 5.8) and apoB100 (Figure 5.9) responses for each subject are 
presented in appendix A.                
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Figure 3.5. TRL apoB48 and apoB100 responses to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). Time course responses for 
apoB48 (A) and apoB100 concentration (C) are presented on the left, with corresponding iAUC values 
(B and D) on the right. Data are mean ± SEM (n = 5). Time course responses were analysed by a linear 
mixed model: for apoB48; P < 0.05 (treatment), P < 0.005 (visit by treatment interaction); for 
apoB100; P < 0.05 (treatment). Mean iAUC data were analysed by paired-samples t-test (two-tailed) 
(NS).        
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3.3.7 Plasma total apoB 
Mean plasma total apoB values in the fasted state were not significantly different between 
high-fructose (0.84 ± 0.05 g/L) and low-fructose visits (0.80 ± 0.06 g/L) (P = 0.33). Mean plasma 
concentrations were lower during the steady-state period (Figure 3.6) in response to both 
high-fructose (0.74 ± 0.03 g/L) and low-fructose drinks (0.73 ± 0.06 g/L). A significant 
treatment effect was detected (P = 0.029), although there was also a significant effect of visit 
(P = 0.017) and visit by treatment interaction (P < 0.005), again indicating the presence of a 
period effect.  
 
 
 
Figure 3.6. Plasma total apoB response to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). The time course response 
for plasma total apoB is shown. Data are mean ± SEM (n = 5). Linear mixed model analysis: P < 0.05 
(treatment), P < 0.05 (visit), P < 0.005 (visit by treatment interaction). 
 
3.3.8 Intestinal and Hepatic DNL 
The percentage contribution of intestinal DNL to the total CM-TAG palmitate concentration 
was calculated (‘DNL (%)’) as described in section 2.2.2.1. Fasted intestinal DNL values ranged 
from 0.75 to 7.89 % at the high-fructose visit, and from 0.40 to 1.82 % at the low-fructose visit 
(Figure 3.7, panel A). Post-prandial (0 – 420 min) intestinal DNL (%) ranges were 0.61 to 6.46 
% at the high-fructose visit and 0.21 to 1.56 % at the low-fructose visit (Figure 3.7, panel B). 
Hepatic DNL % values (contribution of DNL to the total VLDL-TAG palmitate concentration), 
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were similar to those for intestinal DNL (Figure 3.7, panels C and D). Fasted hepatic DNL ranged 
from 0.30 to 8.13 % and from 0.19 to 2.81 %, at the high- and low-fructose study visits, 
respectively. In the fed state, hepatic DNL ranges were 1.41 to 11.50 % (high-fructose) and 
0.35 to 3.22 % (low-fructose). The greater range of fasted and post-prandial values at the high-
fructose visit were mainly attributable to subject FRU09, as indicated in Figure 3.7. The mean 
(± SEM) contribution of fasted intestinal DNL to circulating CM-TAG palmitate (%) was not 
significantly different between the high- (2.79 ± 1.34 %) and low-fructose (1.27 ± 0.42 %) visits 
(P > 0.05), nor was there a significant difference in the mean post-prandial intestinal DNL (%) 
during consumption of high- (2.33 ± 1.06 %) or low-fructose (1.08 ± 0.26 %) test drinks (P = 
0.17). For hepatic DNL (% of VLDL-TAG palmitate), there was an almost significant difference 
between mean fasted values at the high- (3.30 ± 1.36 %) and low-fructose (1.30 ± 0.51 %) visits 
(P = 0.065). Mean post-prandial (0-420 min) hepatic DNL (% of VLDL-TAG palmitate), however, 
was not significantly different in response to high- (4.36 ± 1.86 %) or low fructose drinks (2.21 
± 0.62 %) (P = 0.26). 
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Figure 3.7 Individual fasted and post-prandial percentage contribution of DNL to CM-TAG and VLDL-
TAG palmitate for subjects during high- and low-fructose visits. 
Individual values for each subject (n = 5) are shown for fasted percentage DNL (A and C), prior to 
commencing feeding, and for post-prandial (0-420 min) percentage DNL (B and D) in the steady-
state. Bars indicate mean ± SEM. Outlying data points for subject FRU09 are marked. 
 
The time course response for intestinal and hepatic DNL (% of CM-TAG or VLDL-TAG palmitate) 
of subjects during metabolic visits is shown in Figure 3.8 (panels A and C). Linear mixed model 
analysis did not reveal any significant effect of treatment for either intestinal (P = 0.10) or 
hepatic DNL (P = 0.52), or any interaction effects (all P > 0.05).  
The concentration of de novo palmitate derived from intestinal and hepatic DNL (μmol/L) was 
calculated as described in section 2.2.2.2. As with the percentage DNL, there was a large range 
of fasted values for intestinal (0.08 – 21.85 μmol/L) and hepatic (0.04 – 21.62 μmol/L) de novo 
palmitate, which was also seen for post-prandial (0-420 min) intestinal (0.21 – 33.28 μmol/L) 
and hepatic (0.15 – 34.08 μmol/L) de novo palmitate. However, as already discussed above 
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for percentage DNL, this variation was principally due to the much higher fasted and post-
prandial values of subject FRU09 at the high-fructose visit.  
 
Figure 3.8. Intestinal and hepatic DNL in response to high- or low-fructose drinks. 
Time course responses for percentage intestinal (A) and hepatic (C) DNL (% contribution of DNL to 
CM-TAG and VLDL-TAG palmitate concentrations), as well as intestinal (B) and hepatic de novo 
palmitate (μmol/L, panel D) are presented. Data are mean ± SEM (n = 5). Time course responses were 
analysed by a linear mixed model (NS).     
 
There were no significant differences in the fasted intestinal (5.09 ± 4.20 μmol/L vs. 1.45 ± 
0.92 μmol/L; P = 0.33) or hepatic concentrations of de novo palmitate (5.22 ± 4.12 μmol/L vs. 
1.48 ± 1.02 μmol/L; P = 0.30) between high- and low-fructose visits, respectively. There were 
also no significant differences in the post-prandial intestinal (8.33 ± 6.26 μmol/L vs. 1.77 ± 0.61 
μmol/L; P = 0.32) or hepatic de novo palmitate concentrations (8.42 ± 6.47 μmol/L vs. 1.69 ± 
1.08 μmol/L; P = 0.28) during high- or low-fructose feeding, respectively.  
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For mixed model analysis of intestinal de novo palmitate (μmol/L), there was an almost 
significant treatment effect (P = 0.057), although this was accompanied by a significant visit 
by treatment interaction (P = 0.002). There was no significant treatment effect for hepatic de 
novo palmitate (P = 0.89).  
Subjects’ individual percentage intestinal (Figure 3.9) and hepatic DNL (Figure 3.10) responses 
(contribution to CM-TAG or VLDL-TAG palmitate), as well as intestinal (Figure 3.11) and 
hepatic de novo palmitate (Figure 3.12) responses, are presented on the following pages. 
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Figure 3.9. Individual intestinal DNL (percentage of CM-TAG palmitate) responses to high- and low-
fructose drinks.  
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Figure 3.10. Individual hepatic DNL (percentage of VLDL-TAG palmitate) responses to high- and low-
fructose drinks.  
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Figure 3.11. Individual intestinal de novo palmitate (μmol/L) responses to high- and low-fructose 
drinks. 
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Figure 3.12. Individual hepatic de novo palmitate (μmol/L) responses to high- and low-fructose 
drinks. 
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It was noted that the within subject values for intestinal and hepatic DNL were similar for both 
high- and low-fructose visits. Due to the lack of any significant treatment effects, these data 
were pooled (n = 10) and analysed by Spearman’s correlation analysis. This showed a highly 
significant correlation between percentage intestinal and hepatic DNL values in both the 
fasted (ρ = 0.939, P < 0.0001) and post-prandial states (ρ = 0.818, P = 0.004), as shown in Figure 
3.13 (panels A and B). The same was also observed for the de novo palmitate concentrations, 
with highly significant correlations for both fasted (ρ = 0.915, P = 0.0002) and post-prandial de 
novo palmitate (ρ = 0.842, P = 0.002) (Figure 3.13, panels C and D). These analyses indicated 
a strong relationship between subjects’ intestinal and hepatic DNL, both in the fasted and fed 
states.   
 
 
Figure 3.13. Correlation between intestinal and hepatic DNL in the fasted and post-prandial states. 
Percentage DNL values in the fasted (A) and post-prandial (B) states are presented above (% 
contribution of DNL to CM-TAG and VLDL-TAG palmitate concentrations), with corresponding de 
novo palmitate (μmol/L) concentrations in the fasted (C) and post-prandial states (D) below. Data are 
mean ± SEM (n = 10) and were analysed by Spearman’s rank-order correlation. Spearman’s 
coefficients (ρ) and corresponding two-tailed P values are shown inset.   
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3.3.9 Glucose and Insulin  
Mean (±SEM) fasted glucose concentrations were 4.63 ± 0.26 mmol/L and 4.76 ± 0.12 mmol/L 
on high-fructose and low-fructose visits, respectively, which increased to steady-state mean 
values of 5.21 ± 0.09 mmol/L (high-fructose) and 5.67 ± 0.23 mmol/L (low-fructose), during 
consumption of test drinks (Figure 3.14). Mean fasted insulin concentrations were 65.6 ± 12.4 
pmol/L and 85.4 ± 20.0 pmol/L on high- and low-fructose visits, respectively, which were 
almost significantly different (P = 0.063). Post-prandial mean insulin values were 113.0 ± 16.5 
pmol/L and 171.5 ± 31.5 pmol/L, in response to high- and low-fructose drinks, respectively, 
which were significantly different (P = 0.025).  
Linear mixed model analysis revealed a significant treatment effect for both glucose (P < 
0.005) and insulin (P = 0.005), although there was also a significant effect of visit (P = 0.024) 
and visit by treatment interaction (P < 0.005) for glucose, as well as a significant visit by 
treatment interaction for insulin (P < 0.005), demonstrating the presence of a period effect. 
Mean iAUC values for glucose were not significantly different (P = 0.115), although the higher 
iAUC insulin during the low-fructose visit was almost statistically significant (P = 0.058). 
Individual glucose (Figure 5.11) and insulin (Figure 5.12) responses of subjects are presented 
in appendix A.     
The fasted glucose and insulin values of subjects were used to calculate their homeostasis 
model assessment 2 of insulin resistance (HOMA2-IR) using the HOMA2 Calculator (The 
Oxford Centre for Diabetes, Endocrinology and Metabolism [OCDEM], University of Oxford, 
UK). Mean values were 1.2 ± 0.2 at the high-fructose visit and 1.6 ± 0.4 at the low-fructose 
visit, indicating that subjects could be considered insulin sensitive (Gayoso-Diz et al. 2013).    
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Figure 3.14. Plasma glucose and serum insulin responses to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). Time course responses for 
plasma glucose (A) and serum insulin (C) are presented on the left, with corresponding iAUC values (B 
and D) on the right. Data are mean ± SEM (n = 5). Time course responses were analysed by a linear 
mixed model: for glucose; P < 0.005 (treatment), P < 0.05 (visit) P < 0.005 (visit by treatment 
interaction); for insulin; P = 0.005 (treatment), P < 0.005 (visit by treatment interaction). Mean iAUC 
and values were analysed by paired-samples t-test (two-tailed) (NS).        
 
 
3.3.10 NEFA 
Mean (±SEM) fasted NEFA concentrations were not significantly different (P = 0.49) between 
high-fructose (0.69 ± 0.17 mmol/L) and low-fructose visits (0.81 ± 0.13 mmol/L). Steady-state 
mean values were 0.38 ± 0.06 mmol/L (high-fructose) and 0.35 ± 0.05 mmol/L (low-fructose). 
Linear mixed model analysis revealed a significant treatment effect (P = 0.013), but also a 
significant visit by treatment interaction (P < 0.005).  
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Figure 3.15. Plasma NEFA response to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). The time course response 
for NEFA is shown. Data are mean ± SEM (n = 5). Analysis by linear mixed model: P < 0.05 
(treatment), P < 0.005 (visit by treatment interaction).  
  
 
3.3.11 Total, LDL and HDL Cholesterol 
Fasted total cholesterol, LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) concentrations 
were not significantly different between high- and low-fructose visits (all P = 0.93). During the 
steady-state period for the high-fructose visit, mean (± SEM) total cholesterol, LDL-C and HDL-
C concentrations decreased to 4.35 ± 0.15 mmol/L, 2.23 ± 0.15 mmol/L and 1.12 ± 0.11 
mmol/L, respectively. Steady-state means for total cholesterol (4.15 ± 0.26 mmol/L), LDL-C 
(2.30 ± 0.19 mmol/L) and HDL-C (1.18 ± 0.11 mmol/L) were also lower during the low-fructose 
visit. For HDL-C, there was a significant treatment effect (P < 0.005), as well as a significant 
visit by treatment interaction (P < 0.005). No effect of treatment was detected for total 
cholesterol  (P = 0.10) or LDL-C (P = 0.48).    
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Figure 3.16. Total, LDL and HDL cholesterol responses to high- or low-fructose drinks. 
Subjects consumed drinks every hour (red arrows) from fasted (-240 min). Time course responses for 
total cholesterol (panel A), LDL cholesterol (LDL-C, panel B) and HDL cholesterol (HDL-C, panel C) are 
shown. Data are mean ± SEM (n = 5). Time course responses were analysed by a linear mixed model: 
for total cholesterol; P < 0.01 (visit), P < 0.005 (visit by treatment interaction); for HDL-C; P < 0.005 
(treatment), P < 0.005 (visit by treatment interaction).  
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3.4 Discussion 
3.4.1 Effect of fructose on post-prandial plasma TAG 
In the current study, ingestion of hourly mixed-nutrient meals containing 30 % energy (E) as 
fructose led to a significantly greater post-prandial plasma TAG concentration over a 11 h 
period (P < 0.005), in comparison to consumption of drinks with an equivalent amount of 
CCHO (Figure 3.1), although no significant effect on TRL-TAG levels was observed. This acute 
effect of fructose consumption on plasma TAG levels is in agreement with three other 
previously published post-prandial studies. Abraha et al (1998) recruited six healthy non-
diabetic subjects (3M, 3F) with a median BMI of 23.6 (range 17.6 -  kg/m2, who were given 
solid test meals consisting of 1g fat/kg BW and 0.75 g/kg of either fructose or starch (Abraha 
et al. 1998). The mean iAUC TAG response was significantly higher (P = 0.027) during the 6 h 
after the fructose meal (609 ± 83 mmol/L*360 min) than the starch meal (379 ± 78 
mmol/L*360 min), with a pronounced difference evident in the later post-prandial phase (180 
– 360 min). In another acute study performed by the same group, feeding subjects (8M, 6F; 
BMI range 22-31 kg/m2) 0.75 g/kg BW of either fructose or glucose, in addition to 0.5 g/kg oil 
(85 % palm oil, 15 % safflower oil), led to a greater plasma TAG excursion after the fructose 
test meal (P = 0.001) (Chong et al. 2007). In a third study, an acutely raised plasma TAG was 
also reported in seventeen obese subjects (8F, mean BMI 34.7 ± 1.0 kg/m2; 9M, mean BMI 
34.5 ± 1.0 kg/m2) consuming three mixed-nutrient solid meals (15 % E from fat; 15 % from 
protein; 55 % from CHO), with 30 % of total calories contributed by fructose-sweetened 
beverages, in comparison to glucose beverages (Teff et al. 2009). These findings support the 
acute effect of fructose on plasma TAG seen in the current study, albeit in obese individuals, 
as opposed to subjects who were overweight to slightly obese (BMI range 24.8 – 30.0 kg/m2). 
Nonetheless, this study had perhaps the most similar design to the current study, as 
participants were given the same percentage of calories as fructose (30 %), as well as protein, 
and also consumed multiple meals throughout the study period. However, our study 
employed a much greater fat percentage (55 %) and overall load (135 g/d) in the test meals 
than in any of the above-mentioned studies, which was necessary to ensure a raised post-
prandial TAG concentration was maintained for stable isotope kinetic calculations. Also, the 
total CHO amount administered on high- (165 g fructose) and low-fructose (176 g 
maltodextrin) study visits was higher than the above-mentioned studies. Although such a dose 
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of fructose may seem extreme, it is only approximately 20 g higher than the estimated mean 
(± SEM) daily consumption for males in the USA aged 19 – 22 years old (134 ± 12 g/d), and 
approximately 40 – 50 g higher than for adult males aged 23 – 50 years (118 ± 4 g/d) (Marriott 
et al. 2009). Therefore, it is possible that among these high-fructose consumers (95th 
percentile), some individuals may be consuming daily fructose loads equivalent to that given 
in the present study. In addition, the 30 % percent of calories subjects consumed as fructose 
was the same as for a previous four-day dietary intervention (Egli et al. 2013), and similar to 
two other interventions of 12 d (Stanhope et al. 2011) and 10 weeks (Stanhope et al. 2009), 
where 25 % E was given as fructose, with all three reporting a significant effect of fructose on 
post-prandial plasma TAG concentration. A lower fructose dose of 17 % E, consumed by 
healthy adults (mean BMI ~25 kg/m2) over a six week period, was also shown to significantly 
increase subsequent post-prandial TAG levels over a 24 h period, compared to the same daily 
dose of glucose, although this effect was only seen in men (+32 %, P < 0.001) and not in women 
(+3 %, NS) (Bantle et al. 2000). A significant acute effect of fructose has, however, been 
reported in normal weight (BMI ~ 20-21 kg/m2) Japanese females after consumption of 
fructose in combination with an oral fat tolerance test (OFTT) consisting of cream (0.35 g 
fat/kg BW) (Saito et al. 2013, Saito et al. 2015), in comparison to the same OFTT with glucose. 
An acute fructose-induced elevation of plasma TAG levels in females (P < 0.005) was also 
reported following a single day consuming three test meals (55 % CCHO, 30 % fat, 15 % 
protein), providing 30 % E as fructose or glucose (Teff et al. 2004). Therefore, even an acute 
dose of fructose, in combination with an oral fat load, can exacerbate post-prandial plasma 
TAG in both males, as seen in the current study, as well as in females.  
    
3.4.2 Effect of fructose on hepatic and intestinal TAG metabolism 
Mean post-prandial CM-TAG and VLDL-TAG concentrations in this study were greater 
following consumption of fructose, as compared to CCHO, although this effect was only 
significant for VLDL-TAG. Data from previous studies investigating the effect of fructose 
consumption on post-prandial VLDL-TAG are inconsistent. One acute study showed a 
significantly higher VLDL-TAG after a high-fat meal with fructose (Chong et al. 2007), whereas 
in two other studies a greater, yet non-significant, VLDL-TAG iAUC was reported following 
acute fructose consumption (Theytaz et al. 2014, Surowska et al. 2016). As with the current 
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study, the low number of subjects, as well as differences in the pattern of iAUC response 
between subjects (appendix A, figure A-IV and figure A-V), may account for this inconsistency. 
In a recent large scale (n = 71) dietary intervention study, where subjects were studied before 
and after consuming 75 g fructose/d as beverages for a 12 week period, in addition to their 
normal diet (Taskinen et al. 2017), post-prandial VLDL1-TAG AUC response was significantly 
higher post-intervention (P = 0.02). However, the corresponding mean (± SD) incremental AUC 
responses for VLDL1-TAG pre-intervention (138 ± 143 mmol/L*480min) and post-intervention 
(142 ± 135 mmol/L*480min) were not significantly different. The high error in these values 
would appear to indicate a large inter-individual variation in the VLDL-TAG response, which 
may have been due to the range of ages (21 – 65), BMI (25.6 – 38.3 kg/m2) and fasted plasma 
TAG values (0.6 – 4.7 mmol/L) of the men studied.        
The current study provides the first evidence to date on the acute effects of fructose on post-
prandial VLDL-TAG and CM-TAG kinetics, including rates of secretion and clearance. The 
significantly greater VLDL-TAG concentration exhibited by subjects during high-fructose 
feeding was not associated with any significant differences in VLDL-TAG PR or FCR, although 
there was an overall difference in the pool size, which approached statistical significance (P = 
0.072). In addition to the higher VLDL-TAG concentration, a significantly higher TRL apoB100 
concentration was observed. These results appear to suggest that fructose consumption 
stimulated production of a greater number of VLDL particles, without increasing the particle 
size, relative to the CCHO treatment. These effects on hepatic TAG metabolism are likely to 
have been mediated by the significant difference in post-prandial insulin concentrations. 
Acute hyperinsulinaemia suppresses VLDL apoB100 and TAG secretion in healthy individuals 
(Lewis et al. 1993, Lewis et al. 1995, Adiels et al. 2007). Therefore, the lower insulin secretion 
during the high-fructose visit would be expected to elicit less suppression of VLDL particle 
production in insulin sensitive individuals, resulting in a raised VLDL-TAG concentration. This 
is supported by a study comparing VLDL-TAG kinetics in healthy males (n = 8) and males with 
type 2 diabetes mellitus (T2DM, n = 8). While in healthy individuals there was a significant 
suppression of the mean (± SEM) VLDL-TAG secretion rate (52 ± 21 %) between the fasted and 
post-prandial states (P < 0.001), no such suppression was observed in insulin-resistant subjects 
with T2DM (Søndergaard et al. 2012). Plasma NEFA concentrations in the current study were 
also suppressed less efficiently during high-fructose feeding (P < 0.05). As approximately 43 % 
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of VLDL-TAG is obtained from circulating NEFA in the fed state, a greater NEFA flux to the liver 
may have occurred, to act as a source of FA for VLDL-TAG synthesis (Barrows et al. 2006).  
In the present study, there was no difference in VLDL-TAG FCR between high- (10.35 ± 3.50 
pools/d) and low-fructose (12.21 ± 2.78 pools/d) treatments, and no significant difference in 
the VLDL-TAG PR between high- (81.03 ± 19.57 mg/kg/d) and low-fructose (68.43 ± 12.18 
mg/kg/d) visits. Considering the significantly greater TRL apoB100 and VLDL-TAG 
concentration during consumption of high-fructose drinks, one might have expected to 
observe either a higher PR, lower FCR, or perhaps both, as determinants of the difference in 
VLDL-TAG and apoB100 concentrations. Although the VLDL-TAG pool size was almost 
significantly greater during the high-fructose visit (P = 0.072), no significant differences in PR 
or FCR were observed. It may be that the small number of subjects in this study (n = 5) 
provided an insufficient power to detect a difference in VLDL-TAG PR or FCR (type II error), 
especially considering this trial investigated the acute effect of fructose in subjects that could 
generally be considered insulin sensitive, based on their fasted HOMA2-IR values. In the afore-
mentioned study of Shojaee-Moradie et al (2013), which utilised the same continuous-feeding 
protocol as in the present study, it was shown that eight males with metabolic syndrome (BMI 
29.7 ± 1.1 kg/m2) had a significantly higher VLDL1-TAG (P < 0.05) and VLDL2-TAG (P = 0.06) PR, 
in comparison to eight lean, age-matched controls (BMI 23.1 ± 0.4 kg/m2) (Shojaee-Moradie 
et al. 2013). However, in the same study, there were no differences in the VLDL1-TAG or VLDL2-
TAG FCR values between study groups. Therefore, it is possible that if the present study had 
included a greater number of subjects, or individuals with insulin resistance, that a difference 
in the VLDL-TAG PR may have been evident as an explanatory factor for the higher VLDL-TAG 
concentration. 
This supposition regarding the present study is supported by previous work demonstrating an 
imbalance between VLDL PR and FCR in response to fructose feeding. In seven healthy males, 
an intraduodenal co-infusion of fructose and lipid increased TRL apoB100 PR (P < 0.05), 
without altering FCR, in comparison to an infusion of lipid and saline (Xiao et al. 2013). In 
contrast, co-infusion of glucose and lipid did not significantly increase apoB100 PR or FCR. 
Therefore, the significantly higher TRL apoB100 concentration was the result of an enhanced 
particle secretion, rather than a reduction in clearance. However, the researchers did not 
measure the metabolism of TAG carried within VLDL, as was measured in the current study. 
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Another possible explanation for the lack of difference in VLDL-TAG FCR values between 
treatments may be competition between VLDL and CM for catabolism via LPL hydrolysis, 
which has been demonstrated in several detailed human metabolic studies (Potts et al. 1991, 
Bickerton et al. 2007, Adiels et al. 2012). As CM are the preferred substrate for endothelial LPL 
hydrolysis in the post-prandial state, the predominance of CM-TAG during both high- and low-
fructose feeding, as indicated by apoB48 and CM-TAG concentrations, likely saturated this 
common clearance pathway, leading to the accumulation of VLDL-TAG (Brunzell et al. 1973, 
Cohn et al. 1993, Schneeman et al. 1993).      
In the present study, the mean CM-TAG PR was significantly higher (2.5-fold) when subjects 
consumed low-fructose drinks, as compared to high-fructose drinks. This was accompanied by 
a correspondingly higher (2.9-fold) CM-TAG FCR, which was close to statistical significance (P 
= 0.073). The higher FCR is likely due to a greater post-prandial induction of LPL in adipose 
tissue, and possibly also in muscle (Potts et al. 1991, Bickerton et al. 2007), resulting from the 
significantly higher insulin levels observed during this visit. Adipose tissue LPL activity is 
acutely increased by insulin, although this effect is more pronounced after 3-6 h of insulin 
infusion, which may explain the more notable difference in the CM-TAG concentrations in the 
latter part (between 120 – 480 min) of the current study (Sadur et al. 1982).  
While an insulin-mediated increase in LPL activity may explain the higher CM-TAG FCR 
observed during low-fructose feeding, it cannot adequately explain the higher PR. Evidence 
from both human and animal studies has demonstrated that insulin suppresses intestinal 
apoB48 TRL secretion (Federico et al. 2006, Pavlic et al. 2010). Therefore, in insulin sensitive 
individuals, one might expect a reduced CM-TAG PR during acute hyperinsulinaemia. 
However, the increased PR may be due to the direct effect of glucose on enterocyte 
lipoprotein secretion, acting independently of insulin. For example, in ten healthy subjects 
administered a 38 g oral load of glucose 5h after the ingestion of 50 g of fat emulsion, there 
was complete mobilisation of enterocyte lipid droplets stored within jejunal tissue, as 
determined visually via lipid staining and microscopy (Robertson et al. 2003). An almost 
complete disappearance of stored lipid droplets was shown within 1 h of glucose ingestion, 
and coincided with a rise in apoB48 and TAG in the Sf > 400 range, indicating the secretion of 
large-sized CM particles. A concurrent rise in both plasma glucose (P = 0.015) and insulin (P < 
0.001) was reported, in comparison to when subjects consumed only water at 5 h, although 
intestinal TAG secretion was not suppressed. 
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In the aforementioned work of Xiao et al (2013), infusion of Intralipid with glucose led to a 
higher TRL apoB48 PR (P < 0.01) and FCR (P < 0.05), in comparison to Intralipid and saline. In 
addition, the PR and FCR were approximately 2.3-fold and 1.8-fold higher, respectively, than 
when fructose and Intralipid were administered. Although CM-TAG kinetics were not 
measured, the differences in the apoB48 kinetics between fructose and glucose infusion are 
in agreement with the 2.5-fold and 2.9-fold higher CM-TAG PR and FCR, respectively, seen in 
the current work, when glucose-containing drinks were fed rather than fructose. In a more 
recent study by Xiao and colleagues (2016), an intravenous infusion of glucose for 10 h 
increased apoB48 PR without affecting FCR, in comparison to when saline was infused (Xiao 
et al. 2016). This difference occurred under conditions of a pancreatic clamp to limit the 
effects of insulin, glucagon and growth hormone. Therefore, the authors concluded that the 
increased apoB48 production by the intestine was directly stimulated by glucose 
independently of insulin, which may have been due to an induction of LXR, known to be 
upregulated in Caco-2 cells in response to a high glucose concentration (Grenier et al. 2013). 
In mice fed LXR agonists, VLDL-TAG secretion has been shown to increase 2.5-fold after 4 days, 
due to the secretion of larger TAG-rich VLDL particles (Grefhorst et al. 2002). In addition, an 
induction of SREBP-1c transcription occurred, which upregulates the expression of many 
lipogenic genes, including the enzyme GPAT (Horton et al. 2002), which catalyses the first 
committed step in the glycerol-3-phosphate pathway of TAG synthesis. It is therefore possible 
that a similar enhancement of TAG synthesis and secretion may occur in the intestine in 
response to enteral glucose.           
Based on the findings discussed above, one may postulate that oral glucose favours the 
mobilisation of TAG stored within enterocyte LD in the post-prandial state, leading to the 
production of fewer CM particles, which are larger and more TAG-rich. In contrast, fructose 
may not stimulate the re-esterification and utilisation of TAG stores for CM synthesis to the 
same extent, leading to a greater number of smaller CM, each carrying less TAG. While 
perhaps speculative, this theory would explain the significantly higher apoB48 concentration, 
yet lower CM-TAG PR, in response to high-fructose drinks, seen in the current study. 
Enterocyte TAG stores may be mobilised at a later point in the post-prandial phase in response 
to the co-ingestion of fructose with fat, compared to when glucose is consumed. 
Subsequently, an impaired clearance of CM-TAG by LPL may then occur, as observed in this 
study. Together, these effects offer a potential explanation for the delayed increase in post-
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prandial plasma TAG levels reported by several studies where fructose and fat were 
consumed, relative to glucose (Stanhope et al. 2009, Teff et al. 2009, Theytaz et al. 2014). 
However, further post-prandial kinetic studies to compare the effects of fructose and glucose 
on CM particle (apoB48) and CM-TAG kinetics are clearly required. 
 
3.4.3 Effect of fructose on hepatic and intestinal DNL 
The present study is the first to achieve an accurate quantification of intestinal and hepatic 
DNL by separating CM and VLDL lipoproteins based on their unique apoB content, rather than 
the simple use of ultracentrifugation to give a density based separation. It was therefore 
possible to precisely measure changes in intestinal and hepatic DNL between the fasted and 
fed states, as well as in response to high- or low-fructose drinks, for the first time. For hepatic 
DNL, there was no significant effect of consuming high-fructose drinks, in comparison to low-
fructose drinks, on either the percentage DNL or de novo palmitate concentration. This is in 
contrast to several previous studies demonstrating an enhancement of hepatic DNL in 
response to fructose, where the enrichment of palmitate in the Sf 60-400 fraction was 
assumed to represent VLDL.  
In a recent study, acute fructose administration was reported to enhance post-prandial 
hepatic DNL in a dose-dependent manner. In a group of 17 healthy (27.0 ± 2.8 kg/m2) male 
subjects, post-prandial peak DNL (35 % vs. 20 %) and fasting-adjusted DNL (29 % vs. 15 %) 
were significantly greater when consuming a high-fructose dose (10 mg∙kg FFM-1∙min-1) versus 
a low-fructose dose (5 mg∙kg FFM-1∙min-1), respectively (both P < 0.001) (Beysen et al. 2018). 
As in the current study, the authors also reported a substantial degree of inter-subject 
variation in post-prandial DNL values (3 to 51 % for peak DNL; 1 to 42 % for fasting-adjusted 
DNL). Percentage DNL values in the study of Beysen et al (2018) were considerably higher than 
in the present study. There are two possible explanations for this. Firstly, during the high-
fructose dosing, subjects consumed a very high amount of fructose (approximately 355 g 
total), which was administered in the absence of other nutrients, specifically to stimulate 
maximal hepatic DNL. It has been demonstrated previously that both eucaloric and 
hypercaloric diets high in CHO elicit a greater induction of hepatic DNL than diets high in fat 
(Schwarz et al. 1995, Schwarz et al. 2003). Secondly, as no dietary fat was consumed with the 
fructose doses, de novo palmitate would be expected to make a greater fractional 
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contribution to the circulating VLDL-TAG concentration, as only endogenous FA sources would 
have been available for VLDL synthesis (intrahepatic TAG stores and plasma NEFA). In the 
current study, however, the large dietary fat load consumed by subjects (135 g) may have 
resulted in considerable dilution of de novo palmitate with unlabelled palmitate derived from 
olive oil in the test drinks (‘product pool dilution’), as palmitate accounts for approximately 
16.5 % of FA within olive oil (Orsavova et al. 2015).  
One further study, which is perhaps most relevant to the current work, investigated the acute 
effects of fructose on hepatic percentage DNL and de novo palmitate concentration. Six 
healthy subjects (4M, 2F; mean BMI 24.3 ± 2.8 kg/m2) consumed a morning bolus (85 g) of 
glucose (100:0), as well as 50:50 and 25:75 mixtures (w/w) of fructose:glucose, on separate 
visits, followed by a standardised lunch 4h later (Parks et al. 2008). In the post-lunch period 
(5.5 h), despite a significantly higher mean (± SEM) peak percentage DNL in the total TRL 
fraction (Sf > 60) when 50:50 (15.9 ± 5.4 %) and 25:75 (16.9 ± 5.2 %) mixtures had been 
consumed, relative to 100:0 glucose (7.8 ± 5.7 %; P < 0.02), there were no significant 
differences in percentage DNL in either the Sf 60-400 or Sf > 400 fractions. Concordantly, post-
lunch de novo palmitate concentrations (μmol/L) in the Sf 60-400 and Sf > 400 fractions were 
also unaffected by the type of sugar consumed. These findings are consistent with the lack of 
treatment effect observed in the present study, where de novo palmitate also made only a 
small contribution to overall CM-TAG and VLDL-TAG concentrations. Also, percentage DNL in 
the Sf > 400 fraction tended to decline in response to all treatments, a trend also noted in the 
current work, which may also have been due to dilution of de novo palmitate within post-
prandial TG-rich TRL (VLDL1 and CM) following the lunch, which supplied 31.5 g of fat.  
The work of Parks et al (2008) is the only study to date where an attempt to quantify fructose-
induced intestinal DNL, measured in the Sf > 400 TRL fraction, was undertaken. As already 
noted, ultracentrifugation to obtain the Sf > 400 fraction does not provide an adequate 
method for the separation of CM from VLDL. In all of the studies described above, it is 
therefore likely that a proportion of the DNL attributed to hepatic lipogenesis, as measured in 
the Sf 60-400 fraction, may in fact have been derived from intestinal DNL, due to overlap of 
the density ranges of these two lipoprotein species in the post-prandial state (Jackson et al. 
2002, Jackson et al. 2006).             
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While no effect of fructose on DNL was detected in the current study, there were significant 
within-subject correlations found between intestinal and hepatic DNL, in both the fasted and 
post-prandial states. Given the precision with which hepatic and intestinal lipoprotein species 
were isolated, these findings provide evidence that the intestine may be as important a source 
of newly synthesised FA as the liver, especially as post-prandial concentrations of de novo 
palmitate within CM-TAG and VLDL-TAG were found to be similar (Figure 3.8).  
DNL made only a minor contribution to overall CM-TAG and VLDL-TAG concentrations in the 
healthy subjects studied here. However, in individuals with non-alcoholic fatty liver disease 
(NAFLD), which is characterised by an accumulation of intrahepatic fat, DNL may account for 
as much as 26 % of hepatic TAG and 23 % of plasma TAG levels in the fasted state (Donnelly 
et al. 2005) and is considered to be a central factor in the progression of NAFLD (Lambert et 
al. 2014). If the strong association between rates of intestinal and hepatic DNL observed in the 
current study persists in those with NAFLD, and other states of pronounced insulin resistance 
and/or dyslipidaemia, the contribution of intestinal DNL to circulating TAG concentrations 
may be substantial.  
While anecdotal, the data gathered for subject FRU10 in the current study, who met the 
required 3 out of 5 criteria for metabolic syndrome, provides some support for this. Among 
the six subjects studied, FRU10 exhibited the highest rates of fasted (13.84 % and 17.12 %) 
and post-prandial (12.46 % and 13.98 %) percentage DNL, as well as fasted (84.67 μmol/L and 
70.35 μmol/L) and fed (157.11 μmol/L and 74.3 μmol/L) de novo palmitate, during high- and 
low-fructose visits, respectively (Figure 5.2, panel G and H; Figure 5.3 panels A and B). When 
FRU10 was included in correlation analyses to extend the range of DNL values (Figure 5.10), 
the association between intestinal and hepatic DNL remained strong, both for percentage 
fasted (ρ = 0.965, P < 0.0001) and post-prandial DNL (ρ = 0.862, P = 0.0006), as well as for 
fasted (ρ = 0.951, P < 0.0001) and post-prandial de novo palmitate (ρ = 0.910, P = 0.0001). 
Although only pertaining to a single subject, these data appear to support the hypothesis that 
intestinal DNL may also be quantitatively upregulated in insulin resistant states. Whether 
intestinal DNL can partly explain the increases in fasted and post-prandial CM-TAG noted in 
subjects with metabolic syndrome (Shojaee-Moradie et al. 2013), as established for hepatic 
TAG metabolism, remains to be seen.        
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3.4.4 Effect of fructose on plasma cholesterol concentrations 
During continuous steady-state feeding, HDL cholesterol (HDL-C) concentrations tended to 
decrease at both metabolic visits, although HDL-C was significantly lower when subjects 
consumed high-fructose drinks (Figure 3.16). The general decrease seen on both visits may be 
attributed to the effect of feeding a high fat load on post-prandial HDL-C concentrations. In a 
large cohort of normolipidaemic men (n = 317), an oral fat challenge (2.93 MJ/m2 body surface 
area) was shown to increase plasma TAG levels while decreasing HDL-C concentrations, 3.5 h 
post-prandially. Particle size analysis revealed an increase in the concentration of medium-
sized HDL particles (8.2 – 8.8 nm), a decrease in small HDL (7.3 – 8.2 nm) and no change in 
large HDL (8.8 – 13.0 nm) (Wojczynski et al. 2011). These results are consistent with the 
observation that ingestion of a large oral fat load (98 g) decreased HDL-C by 35 % in healthy, 
normolipidaemic men, which was associated with an increased CMR concentration and the 
transient appearance of TAG-enriched HDL particles, suggesting a transfer of TAG to HDL (De 
Bruin et al. 1991). In the current study, the lower HDL-C concentration may have been due to 
a greater exchange of TAG between apoB-containing lipoproteins and HDL, therefore lowering 
the HDL-C concentration due to the generation of more TAG-enriched HDL particles. Such an 
observation is supported by the significantly higher plasma and VLDL-TAG concentrations 
elicited by high-fructose drinks. However, given the small number of subjects in this study, the 
significant visit by treatment interaction detected (see section 3.4.5), as well as the lack of HDL 
sub-class analysis, it is not possible to conclude whether fructose had such an effect on HDL. 
Several chronic dietary intervention studies conducted to date have failed to detect a 
significant effect of fructose on total, HDL-C or LDL cholesterol (LDL-C), when fructose was 
consumed for periods of 4 days to 12 weeks, and in various doses (17 - 30 % E; 50 – 75 g/d) 
(Bantle et al. 2000, Egli et al. 2013, Heden et al. 2014, Schwarz et al. 2015, Taskinen et al. 
2017). The consumption of 25 % E as fructose for a period of either 2 or 10 weeks has been 
shown to increase fasted concentrations of LDL-C, small dense LDL-C and oxidised LDL-C 
(Stanhope et al. 2009, Stanhope et al. 2011), although in these studies fructose provided 
excess dietary calories. In a meta-analysis of twenty-four trials (474 participants) involving an 
isocaloric exchange of fructose for other CHO, no effect of fructose on HDL-C was reported, 
with a significant increase of total and HDL-C only when fructose intake was greater than 100 
g/d (Zhang et al. 2013). Considering this apparently inconsistent effect of fructose on 
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cholesterol levels, the modestly lower HDL-C seen in the current study should be interpreted 
with caution.       
 
3.4.5 Period effect on metabolic parameters 
A significant visit by treatment interaction, often simply referred to as a ‘period effect’, was 
detected for several of the parameters measured in the current study. This may be a common 
problem in the use of a two-treatment, two-period crossover design (‘AB/BA crossover’). It is 
not usually possible to discern whether this effect occurs due to ‘carryover’, whereby the 
treatment applied in one period persists in the subsequent period, or due to a more ‘secular’ 
change in the status of the subjects studied (period by treatment interaction), which is due to 
a factor other than the treatment given (Senn 2002). Considering the four-week washout 
included in the current study design, and the acute nature of the treatment period, it seems 
unlikely that carryover is the likely explanation for differences in the response of subjects 
according to their assignment to either ‘AB’ or ‘BA’ sequences. Moderate changes in the health 
status of the subjects seems more plausible. Mean fasted values at each metabolic visit, 
representing the ‘baseline’ for each treatment period, were not found to be significantly 
different for any of the parameters of interest. However, within-subject variability in baseline 
measurements was noted for some subjects. Given the limited number of individuals included 
in the study, it is possible that even minor changes in parameters such as body weight and 
diet, may have confounded the treatment effect observed for glucose, insulin and apoB48 
concentrations. While subjects were instructed not to alter their dietary habits or level of 
physical activity, no formal compliance checks were included to ensure that these guidelines 
were adhered to. In hindsight, a shorter washout period of perhaps one or two weeks may 
have allowed less time for changes in the health status of subjects and therefore prevented 
some of the significant period effects detected by linear mixed model analysis. Also, a greater 
number of subjects may have lessened the impact of within-subject changes on the mean 
response of the group to high- and low-fructose treatments.    
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3.4.6 Conclusion 
The current study undertook the first known measurement of intestinal DNL within human 
subjects. Intestinal DNL was found to be quantitatively similar to hepatic DNL, both in terms 
of the absolute amount of de novo palmitate within CM-TAG (μmol/L), as well as its 
percentage contribution to the circulating CM-TAG concentration.     
Another aim of the current study was to determine whether acute feeding of high-fat drinks 
containing 30 % E as fructose would elicit a greater post-prandial plasma TAG concentration 
than the consumption of low-fructose control drinks (maltodextrin glucose polymer), and 
whether alterations in lipoprotein kinetic parameters and/or DNL may explain any effect. 
Consistent with previous studies (Abraha et al. 1998, Chong et al. 2007), acute fructose feeding 
did stimulate a significantly greater post-prandial plasma TAG level (P < 0.005), which was 
associated with a significant elevation of VLDL-TAG (P = 0.003) and apoB100 (P = 0.013) 
concentrations, but no significant effect on TRL-TAG or CM-TAG. The significantly higher VLDL-
TAG concentration could not be explained by changes in either VLDL-TAG PR or FCR, possibly 
due to a lack of statistical power to detect a difference, or to the partial ‘blocking’ of VLDL-
TAG clearance by LPL in the presence of CM. Unexpectedly, lipoprotein TAG kinetic analysis 
revealed a significantly higher CM-TAG PR (P = 0.046) and almost significantly greater FCR (P 
= 0.073) in response to low-fructose drinks, indicating an enhanced production, as well as 
clearance, of exogenous TAG within CM. The difference in FCR could be best explained by the 
significantly raised post-prandial insulin level of subjects (P = 0.005) inducing a greater 
activation of endothelial LPL. This theory which was consistent with an insulin-mediated 
suppression of VLDL particle secretion, as evidenced by the lower apoB100 and higher VLDL-
TAG concentration observed during the low-fructose visit. There was no obvious explanation 
to account for the greater CM-TAG PR, although this may have been due to an induction of 
LXR and/or ChREBP in the intestine, leading a greater TAG and incorporation into CM for 
secretion.  
The immunoaffinity separation technique employed in the current study allowed the first truly 
accurate quantification of intestinal and hepatic DNL conducted to date. While no significant 
effect of fructose on DNL was detected, highly significant within-subject correlations were 
found for fasted DNL (P < 0.0001 for percentage; P < 0.0005 for absolute) and post-prandial 
DNL (P = 0.004 for percentage; P = 0.002 for absolute). Intestinal DNL may therefore make an 
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equally important contribution to fasted and post-prandial TAG levels as for hepatic 
lipogenesis; a theory supported by the similar mean concentrations of de novo palmitate in 
CM-TAG and VLDL-TAG fractions at each study visit. Whether a similar relationship exists in 
subjects with insulin resistance, where hepatic DNL is an important determinant of 
intrahepatic and VLDL-TAG levels, clearly warrants further study.          
With reference to the hypotheses outlined for the current study (section 1.8), fructose did 
stimulate a significantly higher plasma TAG concentration, which was due to a difference in 
VLDL-TAG, but not TRL-TAG or CM-TAG (hypothesis 1). The CM-TAG FCR was lower in response 
to fructose than to control drinks; a difference which almost attained statistical significance (P 
= 0.073) (hypothesis 2). High-fructose drinks did not significantly enhance post-prandial 
intestinal DNL in comparison to low-fructose control drinks, although the higher absolute 
intestinal DNL was close to statistical significance (P = 0.057).      
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Chapter 4 An in vitro investigation of the dose-dependent 
effects of fructose and glucose on TAG synthesis and DNL 
in Caco-2 cells 
4.1 Background 
The potential deleterious health effects of fructose consumption have attracted much 
attention in recent years. This includes the impact of fructose on TAG metabolism, with several 
studies reporting an increased post-prandial plasma TAG concentration in response to 
fructose feeding (Teff et al. 2004, Egli et al. 2013, Taskinen et al. 2017). Fructose may elicit this 
effect, in part, by increasing the synthesis and secretion of TAG from the small intestine 
following a high-fat meal, or through stimulating intestinal de novo lipogenesis (DNL).   
Stimulation of DNL within enterocytes in response to fructose feeding has been reported in 
both Syrian golden hamsters and, more recently in humans, including evidence that fructose 
can act as a substrate for the synthesis of new fatty acids (Haidari et al. 2002, Surowska et al. 
2016). To date, three human studies have reported a higher CM-TAG response following either 
acute or chronic consumption of fructose, in response to an oral fat load, although these 
differences did not achieve statistical significance in two studies (Surowska et al. 2016, 
Taskinen et al. 2017). In one study, CM-TAG was significantly increased, although this was only 
evident during the latter part of the post-prandial phase, 4-6 h after consuming the test meal 
(Chong et al. 2007). One of the difficulties in measuring CM-TAG response is an inability to 
accurately separate intestinal CM-TAG from hepatic VLDL-TAG via ultracentrifugation, the 
most commonly used method, as the density ranges of two lipoproteins are known to overlap 
considerably (Jackson et al. 2002).  
To complement the investigation of CM-TAG kinetics in human subjects described in Chapter 
3, the current study utilised an in vitro approach to investigate the concentration dependent 
effects of fructose and glucose, as well as a mixture of the two sugars, on enterocyte TAG 
metabolism and DNL. The total DNL capacity of cells was measured using the stable isotope 
tracer [13C2]-acetate. The utilisation of fructose ([13C6]-fructose) and glucose ([13C6]-fructose) 
for DNL was also investigated. For this purpose, the human adenocarcinoma cell line Caco-2 
was used. Caco-2 cells are a robust and well-characterised cell line, which differentiate in 
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culture to possess many properties of human enterocytes in vivo. Importantly, Caco-2 cells 
express the sugar transporters GLUT2, GLUT5 and SGLT1 (Le Gall et al. 2007). They are also 
capable of synthesising and secreting TAG within both apoB100- and apoB48-containing 
lipoproteins, when incubated with a supply of FFA (Luchoomun et al. 1999, Nauli et al. 2014). 
Cells were grown on specialised Transwell® plates, which create separate apical and 
basolateral compartments, thus providing an in vitro model of the environment of the small 
intestine.      
For the Caco-2 cell experiments described in this chapter the aim was: 
 To use an in vitro Caco-2 cell model to investigate the dose-dependent effects of 
fructose and glucose on enterocyte FA metabolism, including TAG synthesis, DNL and 
de novo TAG-glycerol formation. This will aim to address research questions 4 and 5. 
The following hypothesis was tested: 
 De novo lipogenesis in Caco-2 cells is greater in response to fructose than glucose, and 
increases in a dose-dependent manner. 
 
4.2 Caco-2 cell line characteristics 
4.2.1 Caco-2 cells as an in vitro enterocyte model 
The Caco-2 cell line was originally derived from human adenocarcinoma by Fogh et al. (1977) 
and has become a well-accepted and widely used in vitro model for intestinal transport studies 
(Fogh et al. 1977). Caco-2 cells are morphologically and physiologically similar to human 
enterocytes, and undergo spontaneous differentiation under normal culturing conditions (see 
Figure 4.1), forming a polarised monolayer with tight junctions (TJ) between cells, as well as 
distinct apical and basolateral membranes. Cells also exhibit microvilli and express several 
brush border enzymes, including sucrase and alkaline phosphatase (Trotter et al. 1991). Caco-
2 cells are capable of performing the necessary apoB mRNA editing required to synthesise and 
secrete both apoB100- (VLDL) and apoB48-containing (CM) TRL, in response to an apical 
supply of FFA (Traber et al. 1987, Luchoomun et al. 1999, Nauli et al. 2014). Furthermore, cells 
are known to express the sugar transporters GLUT2, GLUT5 and SGLT1 (Le Gall et al. 2007).  
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Figure 4.1.Transmission electron micrograph of Caco-2 cells grown in culture.  
Cells grown in culture for 28 days fully differentiate and the presence of microvilli (MV) and tight 
junctions (TJ) can be noted. LM, lateral membrane. Magnification x 34,000. Image taken from Caco-2 
product documentation (available at https://www.phe-culturecollections.org.uk, last accessed 
16/05/2018).    
 
There are several differences between differentiated Caco-2 cells and mature human 
enterocytes that should be noted. Firstly, while Caco-2 cells synthesise both apoB48 and 
apoB100, human enterocytes only produce apoB48 (Glickman et al. 1986). Secondly, Caco-2 
cells are devoid of a mucus layer and feature ‘tighter’ TJ than either porcine jejunum or rat 
ileo-jejunum (Hidalgo et al. 1989, Legen et al. 2005). Thirdly, TAG synthesis in Caco-2 cells 
occurs predominantly via the G-3-P pathway, rather than the 2-MAG pathway responsible for 
~80 % of TAG synthesis in enterocyte in vivo (Trotter et al. 1993).  One further potential 
drawback is the reported inter-laboratory variation in the functional phenotype of Cac-2 cells 
(Briske-Anderson et al. 1997). 
Despite these limitations, Caco-2 cells remain a well-characterised, robust and easily-
maintainable cell line for the investigation of enterocyte absorption and metabolism 
(Awortwe et al. 2014).  
 
 
 168 
4.2.2 Factors affecting Caco-2 TAG secretion 
Caco-2 cells possess a limited capacity for TAG secretion within lipoproteins, which may be an 
issue when translating findings to an in vivo context (Levy et al. 1995). However, several 
studies have reported how feeding of specific FA, or FA mixtures, may maximise the secretion 
of larger, more TAG-rich lipoproteins by cells. The monounsaturated FA (MUFA) oleic acid (OA) 
has been shown to increase TAG secretion, and in particular to favour the secretion of apoB48- 
and TAG-rich CM lipoproteins, in comparison to no lipid controls or saturated FA (SFA) 
treatment (van Greevenbroek et al. 1996, Luchoomun et al. 1999, van Greevenbroek et al. 
2000, Bateman et al. 2007). These effects were proportionate to the ratio of OA to SFA (van 
Greevenbroek et al. 2000). In addition, chronic OA treatment for 9 days noticeably increased 
secreted TAG and apoB48 during the final 3 day period (Bateman et al. 2007).  
The polyunsaturated FA (PUFA) linoleic acid (LA) has been observed to have similar effects to 
OA, stimulating TAG secretion by being preferentially translocated to the ER by MTP for 
lipoprotein synthesis (Levy et al. 1995, van Greevenbroek et al. 1995, van Greevenbroek et al. 
1996). SFA, on the contrary, appear to be preferentially channelled toward phospholipid 
rather than lipoprotein synthesis, are not efficacious in stimulating TAG secretion and appear 
to have detrimental morphological effects on cells, reducing the integrity of cellular TJ and 
leading to poorly-formed, stunted microvilli (van Greevenbroek et al. 1995, van Greevenbroek 
et al. 1996, van Greevenbroek et al. 2000, Bateman et al. 2007, Jackson et al. 2009). These 
negative effects on cellular structure may be reversed by treatment with OA (Bateman et al. 
2007). 
Four-day treatment of Caco-2 cells with both MUFA- and PUFA-rich mixtures has been 
demonstrated to increase intracellular TAG accumulation, with the MUFA-rich mixture 
specifically associated with higher TAG and apoB100 secretion (Jackson et al. 2009). A lipid 
mixture mimicking the composition of olive oil (high OA) was also shown to stimulate 1.5-fold 
greater lipoprotein secretion in comparison to a ‘corn oil’ mixture (high LA), with a greater 
TAG/apoB ratio indicating the formation of larger, more lipid-rich CM (van Greevenbroek et 
al. 1996). In summary, treating Caco-2 cells with unsaturated FA, favours a greater re-synthesis 
of the lipid supply into TAG and secretion in apoB-containing lipoproteins, with MUFA having 
the most pronounced effect. 
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Only one study to date has assessed the level of TAG synthesis and secretion in response to 
different glucose concentrations (Pauquai et al. 2006). Caco-2 cells were cultured for 2 weeks 
post-confluence on microporous membrane inserts, creating separate apical (Ap) and 
basolateral (BL) compartments, which contained 0/5 mM glucose (Ap/BL; low glucose) or 
25/25 mM glucose (high glucose). Interestingly, the low glucose condition resulted in twice 
the TAG secretion compared to high glucose, with an enlarged TRL size, but similar level of 
TAG synthesis. The level of MTP in cells was not responsible for this effect, but rather an 
increase in the TAG content available for TRL assembly within the ER lumen. Thus, Caco-2 cells 
appear to respond to a low glucose supply by channelling intracellular TAG towards TRL as 
opposed to cytosolic storage. 
 
4.3 Methods 
Caco-2 cells were cultured for experiments as described in section 2.3. Initial cell viability 
experiments were conducted (section 2.3.4), in order to check the suitability of the glucose 
and fructose concentrations used for subsequent Transwell® experiments (section 2.3.5). Cells 
were treated for 96 h with media containing a range of fructose and glucose concentrations, 
as well as stable isotope tracers, as detailed in Table 4.1. 
A mixture of FFA (0.5 mM) was also added to media to stimulate TAG synthesis and secretion. 
In order to measure the total amount of de novo palmitate synthesised in response to each 
treatment, 5 mM [13C2]-acetate was added to the treatment media. In a separate set of 
experiments, [13C2]-acetate was replaced by 20 % (v/v) [13C6]-glucose or [13C6]-fructose, to 
trace the synthesis of each sugar into de novo palmitate, as well as incorporation into the 
glycerol moiety of TAG. Both intracellular and secreted TAG were collected during the 
treatment period, and analysed by GC-MS to determine the [13C]-palmitate (section 2.3.5.9) 
and [13C3]-glycerol content (section 2.3.5.12).  
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Table 4.1. Composition of fructose and glucose treatment media used for Caco-2 experiments. 
No. Sugar type and 
concentration 
LDS (% v/v) FA-TC micelle 
mixture 
(mmol/L) 
Stable isotope tracer (mmol/L) 
1 Glucose 5 mM 20 0.5 [13C6]-glucose or [13C2]-acetate 
2 Glucose 25 mM 20 0.5 [13C6]-glucose or [13C2]-acetate 
3 Glucose 50 mM 20 0.5 [13C6]-glucose or [13C2]-acetate 
4 Fructose 5 mM 20 0.5 [13C6]-glucose or [13C2]-acetate 
5 Fructose 25 mM 20 0.5 [13C6]-glucose or [13C2]-acetate 
6 Fructose 50 mM 20 0.5 [13C6]-glucose or [13C2]-acetate 
7 Glucose 12.5 mM + 
Fructose 12.5 mM 
20 0.5 [13C6]-fructose or [13C6]-glucose 
or [13C2]-acetate 
Treatment media were prepared using carbohydrate-free medium and lipid-depleted foetal bovine 
serum (LDS). A mixture of 5 different fatty acid-taurocholic acid (FA-TC) micelles were added to 
media to give a final concentration of 0.5 mmol/L. Either [13C2]-acetate (5 mmol/L), [13C6]-fructose or 
[13C6]-glucose (20% of final sugar concentration) were added to trace the total or fructose/glucose 
derived de novo lipogenesis. The same treatments were also tested with no stable isotope added to 
media.    
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4.4 Results 
4.4.1 MTT cell viability assay to test glucose and fructose conditions used 
for Transwell® experiments 
As described in section 2.3.4, MTT cell viability assays were performed in order to assess the 
suitability of the glucose and fructose conditions used in subsequent Transwell® experiments 
(section 2.3.5), prior to these experiments being undertaken. Confluent cell monolayers were 
treated for 96 h with either 5G, 50G, 5F, 25F or 50F. The percent viability of Caco-2 cells 
following treatment is shown in Figure 4.2. Cell viability was greater than 85 % for all the 
conditions tested, relative to the 25G control condition, which was arbitrarily set to 100 %. 
One-way ANOVA detected a significant difference between conditions (P = 0.041). Post hoc 
analysis (Games-Howell) revealed that the 50F condition yielded significantly lower viability 
(86 ± 4 %, mean ±SD) than for the 50G (104 ± 5 %) and 5F (103 ± 3 %) conditions (P < 0.05). 
However, cell viability for all conditions was markedly higher than the 70 % threshold value 
recommended by ISO standard 10993-5 for in vitro cytotoxicity testing of medical devices, 
below which there may be considered cytotoxic potential (Srivastava et al. 2018). Therefore, 
in spite of some variation, all treatment conditions were determined to be suitable for use in 
the Transwell® experiments. The 12.5 mM glucose + 12.5 mM fructose mixture (G/F Mix) was 
not tested for viability, as it was assumed that this condition would be suitable, given the 
satisfactory results for the 5 mM and 25 mM glucose and fructose conditions.         
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Figure 4.2. Caco-2 cell percent viability following 96 h of treatment with different fructose and 
glucose conditions. 
The percent (%) viability for glucose (G) and fructose (F) conditions was calculated relative to 25 mM 
glucose (25G) as the control condition (100 %). Data are mean ± SD for n = 3 independent 
experiments. Differences between treatments were analysed by one-way ANOVA (Games-Howell 
post hoc); *P < 0.05 vs 50F condition. The red line indicates the threshold viability for a lack of 
cytotoxic effects (ISO standard 10993-5). 
 
 
 
4.4.2 Transepithelial electrical resistance (TEER) measurements to assess 
Caco-2 cell monolayer integrity before and during treatment 
Transepithelial electrical resistance (TEER) measurements were performed as described in 
section 2.3.5.2, to monitor cell monolayer integrity and formation of TJ. Mean TEER values 
during the pre-treatment period of cell growth and maturation (days 0-21 post-seeding) are 
shown in Figure 4.3. Resistance values consistently increased between day 4 and day 21 post-
seeding, with significant increments between days 7, 11, 14 and 18 (all P < 0.0001), although 
not between days 18 and 21 (P > 0.05). This indicated continuing differentiation and 
maturation of cell monolayers until day 21. 
As shown in Figure 4.4, immediately prior to commencement of the 96 h treatment period 
(day 21), there were no significant differences in TEER measurements between monolayers (P 
= 0.887). Two-way repeated measures ANOVA indicated a significant time by treatment 
interaction during the treatment period (P = 0.003). Subsequent one-way repeated measures 
ANOVA revealed a significant time effect for 5G (P = 0.015), 25G, 50G, 5F and 25F conditions 
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(all P < 0.0001). Separate one-way ANOVA analysis of treatment effects showed significantly 
lower TEER measurements on day 23 for 5G, in comparison with 25F, 50F and the G/F Mix 
condition (all P < 0.05). For the 5F condition, TEER measurements were significantly lower on 
days 23, 24 and 25, compared with all other conditions, except 5G (all P < 0.005). However, 
TEER values for all monolayers remained above the minimum acceptable value of 300 Ω 
throughout the treatment period, indicating monolayer TJ integrity was maintained (Ohashi 
et al. 2009).  
There were no significant differences (all P > 0.18) in the total amount of cell protein between 
treatments (Figure 4.5), which also suggested no serious deleterious effects of any of the 
treatment conditions.            
 
Figure 4.3. TEER measurements of Caco-2 cell monolayers prior to treatment. 
Cells were seeded at 1.61 x 105 cells/cm2 on Transwell® inserts with an area of 4.67 cm2 and cultured 
for 21 days in DMEM complete medium (25 mM glucose) to maximise TAG synthesis and secretory 
capacity. Resistance values (Ω) continued to increase until day 21. Data are mean ± SD for n = 6 
independent experiments. Time differences were analysed by one-way repeated measures ANOVA 
(Bonferroni post hoc); *P < 0.0001 vs day 4, ** P < 0.0001 vs day 7, *** P < 0.0001 vs day 11, **** P < 
0.0001 vs day 14.  
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Figure 4.4. TEER measurements of Caco-2 cell monolayers during treatment with different glucose 
and fructose concentrations. 
Cells were treated from day 21 for 96 h with the glucose (G) and fructose (F) conditions indicated in 
the legend, where numbers indicate the sugar concentration (mM). TEER readings were performed 
each 24 h prior to media change. Data are mean ± SD for n = 6 independent experiments. The red 
dotted line indicates the minimum TEER value for monolayer integrity (300 Ω). Two-way repeated 
measures ANOVA indicated a significant time by treatment interaction (P = 0.003). Main effects of 
time were analysed by one-way repeated measures ANOVA (Bonferroni post hoc); *P = 0.015 time 
effect for 5G, ** P < 0.0001 time effect for 25G, 50G, 5F and 25F. Main effects of treatment were 
analysed by one-way ANOVA (Bonferroni post hoc); † P ≤ 0.005 for 5F vs all conditions except 5G, ‡ P 
< 0.05 for 5G vs 25F, 50F and G/F Mix (12.5 mM Glucose + 12.5 mM Fructose) conditions.  
       
 
 
Figure 4.5. Amount of cell protein following 96 h treatment with different glucose and fructose 
conditions. 
Cells were treated for 96 h with the glucose (G) and fructose (F) conditions indicated, where numbers 
indicate the sugar concentration (mM). Cell monolayers were harvested at the end of the treatment 
period and the total amount of cell protein on each insert measured by BCA assay. Differences 
between groups were tested by one-way ANOVA (NS). G/F Mix, 12.5 mM Glucose + 12.5 mM 
Fructose. 
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4.4.3 Effect of fructose and glucose concentration on intracellular and 
secreted TAG 
The TAG content extracted from cells (intracellular) and from basolateral media (secreted) 
following treatment is shown in Figure 4.6. For all fructose and glucose conditions, the 
intracellular TAG content (nmol/mg cell protein) following treatment was significantly higher 
than the secreted TAG (nmol/mg cell protein) in media (all P < 0.0005). There were no 
significant differences in the intracellular TAG content among the 5G, 25G, 50G and G/F Mix 
conditions (P = 0.60), or among the 5F, 25F, 50F and G/F conditions (P = 0.13). For secreted 
TAG, there were no significant differences among the fructose conditions (P = 0.15). However, 
secreted TAG (mean ± SD) was significantly lower following 50G (50.1 ± 11.9) than after 5G 
(64.8 ± 16.1) (P = 0.042). There were no significant differences when equivalent glucose and 
fructose concentrations were individually-compared (e.g. 5G vs. 5F) by independent-samples 
t-test (two-tailed), for either intracellular or secreted TAG (all P > 0.05).  
 
 
Figure 4.6. Effect of glucose and fructose concentration on the TAG content of cells and basolateral 
media. 
Confluent Caco-2 cells (21 days post-seeding) were incubated for 96 h with different glucose (G) or 
fructose (F) concentrations, in addition to a 0.5 mM mixture of fatty acid micelles to stimulate 
triacylglycerol (TAG) synthesis and secretion. Media were changed each 24 h during treatment and 
basolateral media were collected and pooled to measure the amount of TAG secreted by cells. Cell 
monolayers were harvested at the end of the treatment period and the intracellular TAG content 
extracted. Data are mean ± SD for n = 9-18 independent experiments. The effect of the different 
glucose and fructose conditions on secreted and intracellular TAG were analysed separately by one-
way ANOVA (Tukey’s post hoc); *P = 0.035 for secreted TAG vs 5G.   
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4.4.4 Effect of fructose and glucose concentration on de novo TAG-
palmitate  
4.4.4.1 De novo TAG-palmitate synthesised from [13C2]-acetate 
TAG-palmitate was extracted from cells (intracellular) and basolateral media (secreted) as 
described in section 2.3.5.7, and the [13C]-enrichment measured by GC-MS (section 2.3.5.9). 
The amount of de novo palmitate synthesised from [13C2]-acetate was calculated (pmol/mg 
cell protein) as described in section 2.3.5.11, as a measure of the total DNL capacity of cells 
(Figure 4.7). A measurable amount of de novo palmitate was detected in all samples analysed, 
following all treatment conditions, with a greater amount of de novo palmitate for 
intracellular (cells) than secreted (media) samples (all P < 0.05). There were no significant 
concentration effects among the glucose or fructose conditions, either for secreted or 
intracellular TAG-palmitate, by one-way ANOVA analysis (all P > 0.05). There were also no 
statistically significant differences between equivalent glucose and fructose concentrations by 
independent-samples t-test (all P > 0.05) (Figure 4.7).    
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Figure 4.7. Effect of glucose and fructose concentration on the amount of de novo palmitate 
synthesised from [13C2]-acetate. 
Following treatment for 96 h with different glucose (G) and fructose (F) conditions, the intracellular 
and secreted TAG-palmitate content was extracted and the [13C]-enrichment measured by GC-MS to 
calculate the amount of de novo palmitate (pmol/mg cell protein). Data are mean ± SD for n = 4-5 
independent experiments. The effect of concentration on intracellular and secreted de novo 
palmitate was analysed separately for glucose and fructose treatments by one-way ANOVA (NS). 
Differences between glucose and fructose for each concentration were analysed by separate 
independent-samples t-tests (NS).        
 
 
4.4.4.2 De novo TAG-palmitate synthesised from [13C6]-fructose or [13C6]-glucose 
There was a measurable quantity of [13C]-palmitate within all samples analysed, indicating 
some degree of de novo palmitate synthesis from [13C6]-fructose or [13C6]-glucose for all 
treatment conditions (Figure 4.8). The amount of de novo palmitate was greater for 
intracellular than for secreted samples following all treatments (all P < 0.05), with the 
exception of 5G (P = 0.45).  
For intracellular TAG, the de novo [13C]-palmitate content was significantly higher following 
treatment with 25G (P = 0.004) and 50G (P = 0.006), in comparison to the 5G condition. Among 
the fructose conditions, [13C]-palmitate was significantly greater after treatment with 25F (P = 
0.04), in comparison to the mixture of 12.5 mM glucose and 12.5 mM fructose containing 
[13C6]-fructose tracer (“Mix (F)”). The 50F condition yielded a significantly higher [13C]-
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palmitate than either 5F (P = 0.038) or Mix (F) (P = 0.018) conditions. When cells were treated 
with the sugar mixture, containing either [13C6]-fructose or [13C6]-glucose (“Mix (G)”), a greater 
amount of de novo palmitate was synthesised from [13C6]-glucose (P = 0.006). The 25G 
condition also resulted in significantly more [13C]-palmitate than for 25F (P = 0.034). 
For secreted TAG, the amount of de novo palmitate was greater after treatment with 25F than 
for Mix (F) (P = 0.041), and also higher after 50F than for either 5F (P = 0.014) or Mix (F) (P = 
0.007). Again, comparison of the Mix (F) and Mix (G) conditions revealed a greater amount of 
[13C]-palmitate synthesised from [13C6]-glucose than from [13C6]-fructose (P = 0.015). The 25G 
condition showed a tendency for a higher amount of de novo palmitate than for 25F, although 
this difference did not attain statistical significant (P = 0.072).   
For all treatments, the amount of de novo palmitate synthesised from [13C2]-acetate (Figure 
4.7) was significantly greater than that derived from [13C6]-glucose or [13C6]-fructose (Figure 
4.8) (all P < 0.05), with the exception of 50F intracellular TAG (P > 0.05). 
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Figure 4.8. Effect of glucose and fructose concentration on the amount of de novo palmitate 
synthesised from [13C6]-fructose or [13C6]-glucose. 
Cells were treated for 96 h with different glucose (G) and fructose (F) treatments containing [13C6]-
fructose or [13C6]-glucose (20 % w/v) to trace the synthesis of de novo palmitate (pmol/mg cell 
protein). Data are mean ± SD for n = 4-5 independent experiments. The effect of concentration on 
intracellular and secreted de novo palmitate was analysed separately for glucose and fructose 
treatments by one-way ANOVA (Tukey’s post hoc). For intracellular glucose or fructose groups; * P < 
0.01 vs 5G, ** P < 0.05 vs Mix (Fru), *** P < 0.05 vs Mix (F) and 5F. For secreted glucose or fructose 
groups; † P < 0.05 vs Mix (F), †† P < 0.05 vs 5F and P < 0.01 vs Mix (F). Differences between 
equivalent glucose and fructose concentrations were analysed by independent-samples t-test; a P < 
0.05 vs intracellular 25F, b P < 0.01 vs intracellular Mix (F), c P < 0.05 vs secreted Mix (F). 
Abbreviations: Mix (F), 12.5G + 12.5F ([13C6]-fructose tracer); Mix (G), 12.5G + 12.5F ([13C6]-glucose 
tracer).   
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4.4.5 Effect of fructose and glucose concentration on de novo TAG-glycerol  
The [13C]-enrichment of the glycerol moiety of TAG was analysed by GC-MS as described in 
section 2.3.5.12, to calculate the percentage of TAG-glycerol derived from either [13C6]-
fructose or [13C6]-glucose (section 2.3.5.14). For all treatment conditions, except Mix (F), 
intracellular TAG contained a greater percentage of de novo glycerol than for secreted TAG 
(all P < 0.05).  
For intracellular TAG, there was a significantly higher proportion of [13C3]-glycerol after 
treatment with 25G and 50G, in comparison to 5G (P < 0.05) and Mix (G) (P < 0.0005). Among 
fructose treatments, the [13C3]-glycerol percentage was significantly higher for the 5F, 25F and 
50F conditions, as compared to the Mix (F) treatment (all P < 0.0005). In addition, percentage 
values for 25F and 50F were significantly higher than for 5F (P < 0.005). For the two mixed 
sugar treatments, there was a greater proportion of TAG-glycerol synthesis from [13C6]-
glucose than from [13C6]-fructose (P < 0.0005).          
 
 
Figure 4.9. Percentage of intracellular TAG-glycerol synthesised from [13C6]-fructose or [13C6]-glucose. 
Data are mean ± SD for n = 3-4 independent experiments. The effect of concentration on intracellular 
de novo TAG-glycerol synthesis was analysed separately for glucose (G) and fructose (F) treatments 
by one-way ANOVA (Tukey’s post hoc). For glucose groups; * P < 0.05 vs 5G and P < 0.0005 vs Mix 
(G). For fructose groups; † P < 0.0005 vs Mix (F), †† P < 0.005 vs 5F and P < 0.0005 vs Mix (F). 
Differences between equivalent glucose and fructose concentrations were analysed by independent-
samples t-test;  a P < 0.0005 vs Mix (F). Abbreviations: Mix (F), 12.5G + 12.5F ([13C6]-fructose tracer); 
Mix (G), 12.5G + 12.5F ([13C6]-glucose tracer).   
  
 181 
 
Figure 4.10. Percentage of secreted TAG-glycerol synthesised from [13C6]-fructose or [13C6]-glucose. 
Data are mean ± SD for n = 3-4 independent experiments. The effect of concentration on secreted de 
novo TAG-glycerol was analysed separately for glucose (G) and fructose (F) treatments by one-way 
ANOVA (Tukey’s post hoc). For glucose groups; *P < 0.01 vs. 5G and P < 0.0005 vs Mix (G). For 
fructose groups; † P < 0.05 vs Mix (F), †† P < 0.0005 vs 5F and P < 0.0005 vs Mix (F). Abbreviations: 
Mix (F), 12.5G + 12.5F ([13C6]-fructose tracer); Mix (G), 12.5G + 12.5F ([13C6]-glucose tracer).   
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4.5 Discussion 
4.5.1 Caco-2 cell monolayer integrity during treatment 
Cell viability results from the MTT assay (Figure 4.2) showed that, although the 50F condition 
was lower than the control condition (86 ± 4 %), all of the treatments tested gave a satisfactory 
level of cell viability. TEER measurements during Transwell® experiments (days 21-25) 
appeared to indicate a significant reduction in monolayer integrity for the 5F treatment and, 
to a lesser extent the 5G treatment (Figure 4.4), although this was only significantly different 
to the other conditions 48 h into the treatment period. It is possible that these lower TEER 
values may reflect a decreased metabolic activity of Caco-2 cells habituated to a 25G 
concentration in cell media.  
Although glutamine is considered to be the primary energy substrate for enterocytes in vivo, 
a significant proportion of glucose is also oxidised to provide energy. In the portal-drained 
viscera of fed piglets, enteral (15 %) and arterial (29 %) glucose contributed a combined 44 % 
to the total CO2 production, in comparison to 19 % and 36 % from enteral and arterial 
glutamine, respectively (Stoll et al. 1999). Both glutamine and glucose are also known to be 
the primary respiratory fuels for human enterocytes (Ashy et al. 1988). Therefore, the 
decreased glucose concentration employed during the 5G and 5F treatments, presumably 
restricted the availability of glucose as an energy source.  
Caco-2 cells have been shown to require glucose, in addition to glutamine, in order to sustain 
normal growth, with an increased glutamine concentration having an additional positive effect 
on the number of cells 15 days after seeding (Wirén et al. 1998). In spite of this, current data 
obtained from MTT viability assays clearly demonstrated no serious detrimental effects of 
maintaining Caco-2 cells in 5 mM, 25 mM or 50 mM fructose for 96 h, during a period of rapid 
cell growth (days 8-12 post seeding). These data are supported by the findings of Cheng et al 
(2014), who reported normal cell viability of Caco-2 cells following two days of treatment with 
25F (Cheng et al. 2014).              
Another possible explanation for the decline in TEER measurements for monolayers treated 
with 5F, could be due to the level of expression and function of the essential fructose 
transporter GLUT5. It has been shown that in Caco-2 cells initially grown for 10 days under 
conditions of 25G, changing the CHO source to 25F increased mRNA and protein levels of 
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GLUT5 up until day 30, leading to a three-fold higher level of both (Mesonero et al. 1995). 
Alternatively, switching to hexose-free medium at day 10 significantly reduced GLUT5 mRNA 
and protein levels within 72 h. This effect was reversed by changing to either 25G or 25F at 
day 20, with detectable GLUT5 mRNA levels within 8 h. Levels of GLUT5 are known to be 
increased to a greater extent in Caco-2 cells incubated with fructose, as compared to glucose, 
due to the ability of fructose to enhance GLUT5 mRNA stability through activation of the cyclic 
AMP pathway signalling pathway (Gouyon et al. 2003).   
In the context of the current study, these observations may suggest that cells were able to 
adapt more quickly to either 25F or 50F conditions than to 5F, due to a greater maintenance 
or induction of the GLUT5 transporter. The lowest fructose concentration may have required 
a longer period of adaptation, owing to a less pronounced effect on functional GLUT5 levels. 
Concomitant with the removal of glucose as an energy source, cells may have been more 
reliant on the utilisation of glutamine. Thus, alterations in substrate utilisation for energy 
generation may explain the differences in TEER, particularly for the 5F treatment.  
The ability of Caco-2 cells to utilise glucose and fructose may also partly explain the differences 
in TEER measurements noted here. Caco-2 cells have previously been reported to metabolise 
14C-glucose more than 14C-fructose, which was attributed in part to a more rapid uptake of 
glucose from the medium (Ellwood et al. 1993). In addition, co-incubation with glucose 
reduced the metabolism of 14C-fructose, with a slight inhibition of fructose uptake.        
Interestingly, the apparent decline in monolayer integrity for the 5G (day 23) and 5F (days 23-
25) conditions was not reflected in their ability to synthesise and secrete TAG from an apical 
supply of mixed FA (Figure 4.6), confirming no detrimental effects on the TAG metabolism of 
Caco-2 cells used in Transwell® experiments.          
    
4.5.2 TAG synthesis and secretion by Caco-2 cells 
All treatments employed in the current study resulted in approximately three to four-fold 
higher intracellular than secreted TAG content (Figure 4.6). This finding is consistent with 
values reported elsewhere. Bateman et al (2007) investigated the effect of varying proportions 
of PA and OA (0.5 mM total) on TAG storage and secretion in Caco-2 cells, cultured on 
Transwell® supports for 14 days, and treated for 3 or 4 successive 24 h periods (Bateman et 
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al. 2007). Cellular TAG for all FA combinations was several-fold higher than that secreted into 
the basolateral media. A similar several-fold difference was found in a subsequent study by 
the same group, again utilising Caco-2 cells, to test the impact of FA mixtures that were rich 
in either SFA, MUFA or PUFA (Jackson et al. 2009). This may be expected, as Caco-2 cells are 
known to have a limited ability to secrete newly synthesised TAG within lipoproteins, with 
intracellular TAG accumulation reported to be as much as 13 times higher than in media (Levy 
et al. 1999). This is more extreme than the intracellular/secreted TAG ratio in the current 
study, although remains an important factor in the interpretation of Caco-2 cell findings to a 
broader in vivo context.  
The amounts of secreted and intracellular TAG recovered in the current experiments were 
found to be generally similar to those in the aforementioned studies of Bateman et al (2007) 
and Jackson et al (2009). However, in the latter of these two second studies, intracellular and 
secreted TAG concentrations were up to three-fold and 1.5-fold higher, respectively, than in 
the current study. Several methodological differences may explain this discrepancy, including 
the passage number of the cells used, as well as the analytical technique for measuring TAG. 
The multiple steps involved in the extraction, purification and preparation of TAG for GC-MS 
analysis in the current experiments is likely to have been associated with greater losses of 
material, in contrast to the use of an enzyme-based colorimetric method in the two 
aforementioned studies.      
Surprisingly, a significantly higher secretion of TAG was observed in the current study in 
response to the 5G condition, in comparison to 50G. This greater secretion of TAG in response 
to a lower apical glucose concentration has been reported previously by Pauquai et al (2006), 
in the other only published study to date investigating the influence of an altered CHO 
concentration on Caco-2 TAG metabolism (Pauquai et al. 2006). In post-confluent cells grown 
on inserts and then habituated for two weeks to a low glucose supply in both compartments 
(0 mM glucose apical/5 mM glucose basolateral), treatment for 24 h with OA (0.6 mM) led to 
a two-fold greater TAG secretion (P < 0.05) than for cells maintained in a high glucose supply 
(25 mM glucose apical/25 mM glucose basolateral) for two weeks. An increase in lipoproteins 
of all density ranges was observed, although there was a predominance toward the secretion 
of larger TRL. Levels of MTP activity, as well as the TAG synthesis and apoB production rates, 
were found to be similar between high and low glucose-adapted cells. The increased TRL 
secretion was concluded to be due to the preferential partitioning of newly synthesised TAG 
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towards the ER lumen for lipoprotein formation, as determined by electron microscopy and 
sub-cellular fractionation measurements, although the underlying mechanisms controlling 
this process remain unclear. One may speculate that a trend towards a more ‘absorptive’ 
Caco-2 cell phenotype may also have occurred to some extent in the current study. However, 
glucose was only added to the apical compartment, and a significant difference was only noted 
between 5G and 50G conditions, and not when comparing 5G with 25G.  Also, the current 
study lacked data concerning apoB levels, the density ranges of lipoproteins secreted, MTP 
protein levels and activity, as well as any visual evidence from electron microscopy.  
Only one other comparable study on the combined effects of glucose and fatty acids on Caco-
2 cell TAG metabolism has been conducted to date. In the unpublished PhD work of Lou 
(2013), culturing Caco-2 cells under conditions of either high (25G) or low (5G) glucose, in both 
the apical and basolateral compartments, led to no significant differences in the intracellular 
or secreted TAG concentration. This finding was irrespective of whether media was 
supplemented with 0.5 mM OA or not and agrees with the results of the current study. 
However, the addition of OA to media was associated with a 2.2 to 3.0-fold increase in cellular 
and basolateral TAG for both high and low glucose conditions. These data, taken together with 
those of Jackson et al (2009) and Bateman et al (2007), may suggest that the presence and 
type of FA in the cell medium is a more important determinant of TAG synthesis and secretion 
by Caco-2 cells than the glucose or fructose concentration. 
HepG2 hepatocytes, however, have been shown to exhibit some concentration-dependent 
effects of glucose and fructose on TAG synthesis. Zhao et al (2016) investigated the effect of 
a 24 h incubation with 10 different glucose, fructose or mixed-sugar treatments, in 
combination with a 1:1 mixture of OA (0.5 mM) and PA (0.5 mM). The release of TAG by cells 
was significantly higher in response to the mixed-sugar treatments 10G + 15F and 5G + 20F, in 
comparison to 25G (P < 0.05), with a significantly higher TAG accumulation in cells also for the 
10G + 15F condition (Zhao et al. 2016). A similar enhancement of TAG synthesis was not 
observed for Caco-2 cells in the current study, possibly due to differences in the metabolic 
phenotype of cells isolated from the liver and intestine.  
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4.5.3 De novo lipogenesis in Caco-2 cells 
The current study provides the first known evidence of a DNL capability within Caco-2 cells, 
with acetate, fructose and glucose all capable of being utilised as substrates for the synthesis 
of de novo palmitate. In addition, newly-synthesised [13C]-palmitate was incorporated into 
both cellular TAG stores, as well as into lipoproteins, which were secreted into the basolateral 
compartment.   
For both fructose and glucose there was evidence of a concentration-dependent increase in 
the amount of de novo palmitate recovered from both the intracellular and secreted TAG 
pools. The amount of de novo palmitate derived from [13C2]-acetate was consistently higher 
than that synthesised from either [13C6]-glucose or [13C6]-fructose (all P < 0.05), as would be 
expected considering that acetate is the primary precursor for DNL in humans (Softic et al. 
2016). Interestingly, following treatment with a mixture of the two sugars, a significantly 
higher proportion of TAG was derived from [13C6]-glucose than from [13C6]-fructose, 
suggesting that glucose may be the preferred DNL substrate when both fructose and glucose 
are available.  
No comparable studies using Caco-2 cells are currently available in the literature. However, in 
the previously mentioned study of HepG2 cells by Zhao et al (2016), treatment with either 
10G, 25G, or 10G + 15F, significantly increased mRNA levels of the lipogenic enzymes ACC, FAS 
and SCD,  as compared to cells given 10G and no FA source. Significant differences between 
these three treatments were also seen, in the order 10G +15F > 25G > 10G, thus supporting 
the idea that fructose in combination with glucose may enhance DNL. Consistent with these 
changes in enzyme mRNA levels, significant mRNA differences were also evident for liver X 
receptor-alpha (LXRα), SREBP-1c and ChREBP. These transcription factors promote the 
expression of a wide range of lipogenic genes, with LXRα acting as the ‘master’ lipogenic 
transcription factor controlling the expression of SREBP-1c and ChREBP (Cha et al. 2007). 
Studies in the hamster have demonstrated that SREBP-1c is also a major gene transcript in the 
jejunum and ileum of the small intestine, and that its expression correlates with fatty acid 
synthesis, as measured by the incorporation of [14C]-acetate into cellular lipids (Field et al. 
2001). The expression of SREBP-1c mRNA, as well as the mature protein, has been reported in 
Caco-2 cells (Field et al. 2002). The inhibitory effect of a range of FA on SREBP-1c, FAS and ACC 
expression was also investigated. While treatment with 250 μM of linoleic acid (LA, 18:2), 
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arachidonic acid (AA, 20:4), eicosapentaenoic acid (EPA, 20:5) or docosahexaenoic acid (DHA, 
22:6) significantly suppressed expression of these genes, no such difference occurred for 
stearic acid (SA, 18:0) or OA (18:1). The LXRα agonist T0901317 significantly stimulated 
expression of SREBP-1c, FAS and ACC, with this activity being severely attenuated by 
treatment with EPA, but not with OA. In contrast to a lack of SREBP-1c suppression, OA was 
associated with a 20-25 % reduction in the incorporation of [14C]-acetate and [3H]-water into 
FA, which the authors suggested may be due to OA decreasing either the post-transcriptional 
or post-translational activity of FA synthesis enzymes. In agreement with results from the 
current study, increases in FA synthesis with T0901317 treatment did not alter TAG lipoprotein 
secretion into the basolateral compartment. 
The concentration-dependent changes in de novo palmitate seen in the current study may 
also have been due to greater induction of the transcription factor ChREBP, as noted above 
for HepG2 cells. ChREBP is expressed in the dudodenum, jejunum and ileum of mice, with 
ChREBP KO mice exhibiting a 65 % reduction in hepatic FA synthesis (versus wild-type animals), 
with no concomitant differences in SREBP1 or SREBP2 (Iizuka et al. 2004). It was determined, 
therefore, that both ChREBP and SREBP-1c are essential for hepatic carbohydrate-induced 
DNL. This is supported by a more recent study in mice with a liver-specific deletion of ChREBP, 
which concluded that insulin induction of lipogenic genes is mediated by SREBP-1c, whereas 
glucose’s induction of glycolytic and lipogenic genes acts through ChREBP (Linden et al. 2018).  
In cultured hepatocytes from wild-type mice, ChREBP-dependent expression of ACC and FAS 
is reported to be higher for cells maintained in 25 mM glucose than for 5.5 mM glucose (Ishii 
et al. 2004). Several metabolites are known to induce the function of ChREBP, including 
glucose-6-phosphate, xylulose-5-phosphate and fructose-2,6-bisphosphate, which may be 
derived from the intermediary metabolism of either glucose or fructose (Iizuka 2017).  
Taken together, the above studies suggest the possibility that the concentration dependent 
increases in de novo palmitate observed in the current study, for both glucose and fructose, 
were due to an induction of both SREBP-1c and, possibly, also ChREBP. While the expression 
of ChREBP has not yet been demonstrated in Caco-2 cells, it seems reasonable to assume that 
this cell line is capable of expressing this transcription factor, given the lipogenic capability 
demonstrated here, as well as the evidence for an inter-dependent relationship with SREBP-
1c discussed above.   
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In the current experiments, when cells were supplied with an equimolar mixture of glucose 
and fructose in the apical compartment, a much greater degree of FA synthesis from [13C]-
glucose was noted. This may be explained by differences in the metabolism of fructose and 
glucose already discussed (section 1.4). The more rapid and unregulated phosphorylation of 
fructose may result in a greater channelling of fructose carbons into oxidative energy 
generation, thereby sparing glucose, which can then be utilised for DNL. Human data from the 
previously mentioned study by Chong et al (2007) supports this idea. Ingestion of a fructose 
load, in combination with lipid, led to a significantly higher recovery of tracer as 13CO2 (30.5 
%), compared to when glucose was consumed (24.5 %). Unfortunately, the combined effect 
of co-ingesting glucose and fructose together was not investigated. In non-exercising subjects, 
approximately 45.0 ± 10.7 % (mean ± SD, range 30.5 – 59 %) of a given fructose load was 
oxidised, whereas this increased to 66.0 ± 8.2 % (range 52.2 – 73.6 %) when glucose and 
fructose were administered together, either as free monosaccharides or sucrose (Sun et al. 
2012). However, the relative amounts of each sugar that were oxidised was not determined 
in these studies.  
The differences in palmitate synthesis from [13C6]-fructose and [13C6]-glucose for the G/F Mix 
conditions, could also be explained more simply by a lower uptake and utilisation of fructose 
by Caco-2 cells, as discussed in section 4.5.1.  
              
4.5.4 Fructose and glucose incorporation into TAG-glycerol       
Caco-2 cells in the current experiments derived a considerable amount of the glycerol 
backbone for TAG synthesis from both glucose and fructose, with mean (± SD) utilisation of 
[13C3]-glycerol ranging from 29.2 (± 2.6) % to 58.1 ± (3.8) % for secreted TAG, and from 25.8 (± 
3.6) % to 68.5 (± 0.4) % for intracellular TAG. Glucose has long been considered the major 
source of TAG-glycerol in hepatic metabolism, with glycerol-3-phosphate (G-3-P) derived from 
trioses generated by flux through glycolysis (Jin et al. 2013). This may be expected given that 
the majority of TAG synthesis in the liver occurs via the sequential addition of two fatty acyl 
groups to G-3-P via the monoacylglycerol (G-3-P) pathway (Hall et al. 2012). Caco-2 cells are 
also known to predominantly utilise this pathway for TAG synthesis (Trotter et al. 1993), in 
contrast to enterocytes in vivo, where the 2-MAG pathway of TAG synthesis predominates 
(see section 1.2.2). Therefore, it is perhaps more appropriate to compare data from Caco-2 
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cells regarding sources of TAG-glycerol with studies of hepatic TAG synthesis. In a recent tracer 
study, the relative contributions of [13C6]-glucose, [13C3]-glycerol and [13C3]-lactate to TAG-
glycerol synthesis was assessed using nuclear magnetic resonance imaging (NMR) (Jin et al. 
2013). It was determined that in both fasting and fed rat liver, glucose and free glycerol 
provided the majority of carbons for the glycerol moiety of TAG. In the fed state, over 50 % of 
TAG-glycerol was obtained from glucose, in comparison to approximately 40 % from glycerol, 
with 35 % of glucose having been metabolised through the TCA cycle prior to TAG synthesis. 
The authors concluded that glucose was a major contributor to TAG-glycerol, as previously 
thought, with incorporation occurring via both direct (via glycolysis only) and indirect (via TCA 
cycle) pathways.  
The significant synthesis of TAG-glycerol from [13C6]-fructose in the current study, appears to 
indicate that fructolysis may also make a significant contribution as a carbon source. This is 
supported by in vivo data from humans, where simultaneous consumption of 0.75 g/kg BW 
fructose, in combination with 0.5 g/kg BW oil, led to 38 % of VLDL TAG-glycerol recovered (240 
min post-meal) being derived from fructose (Chong et al. 2007). Conversely, the same study 
found no evidence of [13C6]-glucose tracer incorporation into VLDL TAG-glycerol. It is possible 
that glucose was used for TAG synthesis, but that this may have been directed towards 
intrahepatic storage, rather than secretion into the circulation within VLDL, due to action of 
insulin in suppressing VLDL secretion (Malmstrom et al. 1997). 
In Caco-2 cells incubated for 24 h with 0.5 mM OA and 60 μM [13C3]-glycerol tracer in the apical 
compartment, there was an approximately 2-fold greater tracer incorporation into cellular 
and basolateral TAG-glycerol under conditions of 5 mM glucose, as opposed to 25 mM glucose 
(Lou 2013). This observation appears to contradict data for the current study, where [13C3]-
glycerol within TAG was lower for the 5G than for the 25G condition. It is possible that an 
increased glucose supply may reduce the utilisation of glycerol for TAG synthesis, while 
increasing that derived from glucose carbons. As a result, a consistent rate of TAG synthesis 
may be maintained by cells, while the carbon source for the glycerol backbone may change. 
Given that the work of Lou (2013), in agreement with the current study, did not detect any 
difference in the amount of intracellular or basolateral TAG between high and low glucose 
conditions, this is a reasonable explanation. However, the use of OA alone in Lou’s study, as 
opposed the FA mixture used in the current study, must also be considered, as OA is known 
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to be a more potent stimulator of Caco-2 cell TAG synthesis than FA mixtures (Bateman et al. 
2007). 
                             
4.5.5 Conclusion 
Increasing the glucose or fructose concentration had a minimal effect on the overall synthesis 
and secretion of TAG by Caco-2 cells in the present study, when a sufficient supply of apical 
FA was also present. Nonetheless, Caco-2 cells were clearly able to synthesise de novo 
palmitate from both glucose and fructose carbon sources, with some evidence that DNL is 
dependent on the CHO concentration. These results provide an in vitro demonstration of CHO-
induced DNL in enterocytes, both from glucose and fructose, which further supports the 
limited existing knowledge concerning this pathway in the small intestine (Haidari et al. 2002, 
Theytaz et al. 2014). Cells were also able to significantly utilise both glucose and fructose, the 
latter presumably via fructolysis, to provide the glycerol moiety for TAG synthesis. The 
potential influence of both of these effects on intestinal TAG metabolism clearly warrants 
further study, including CHO effects on transcription factors (LXRα, SREBP-1c, ChREBP) and 
gene expression of enzymes involved in fatty acid synthesis (ACC, FAS).       
In reference to the hypotheses outlined for the current experiments (section 1.8), fructose did 
not increase TAG accumulation within cells or TAG secretion, relative to the same 
concentrations of glucose (hypothesis 1). Fructose did not increase TAG accumulation or 
secretion in a concentration-dependent manner (hypothesis 2), although cells were able to 
utilise fructose as a substrate for DNL (hypothesis 3). The amount of de novo palmitate derived 
from fructose did increase in a concentration-dependent manner (hypothesis 4), although 
glucose appeared to be the preferred substrate when Caco-2 cells were treated with a mixture 
of the two sugars.     
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Chapter 5 General discussion 
5.1 In vivo and in vitro effects of fructose on intestinal TAG metabolism 
and DNL 
Fructose consumption has been reported to raise post-prandial plasma TAG levels in 
comparison to equivalent amounts of glucose (Bantle et al. 2000, Stanhope et al. 2009) or 
CCHO (Abraha et al. 1998, Egli et al. 2013). However, the exact mechanisms for this fructose-
induced hyperTAG remain unclear. The metabolism of fructose is not regulated in response to 
cellular energy requirements, meaning it may provide a large precursor pool of lipogenic 
three-carbon intermediates to drive the process of DNL (Softic et al. 2016). While many studies 
have been conducted to investigate the influence of fructose on TAG metabolism in the liver, 
including hepatic lipogenesis (Schwarz et al. 2015), there is only limited evidence to date 
concerning the effects of fructose on intestinal TAG metabolism (Haidari et al. 2002, Theytaz 
et al. 2014). Considering that an overproduction of intestinal TAG contributes to the 
dyslipidaemia associated with insulin-resistant states (Shojaee-Moradie et al. 2013), and that 
intestinal lipoprotein remnants are known to contribute to the progression of atherosclerosis 
(Weintraub et al. 1996, Pal et al. 2003, Proctor et al. 2003), this area represents a key gap in 
our scientific understanding of the potential deleterious effects of fructose consumption. The 
current work aimed to address this problem through a detailed metabolic investigation of the 
acute effects of a high-fructose load on intestinal (and hepatic) TAG metabolism, including the 
first known attempt to quantify intestinal DNL, as well as steady-state CM-TAG kinetic 
measurements, using stable isotope tracers. This work was complemented by an in vitro cell 
culture study, using Caco-2 cells, to compare the dose-dependent effects of fructose and 
glucose on enterocyte TAG synthesis and secretion. In addition, sugar utilisation for fatty acid 
synthesis and TAG-glycerol synthesis was determined, by tracing the incorporation of [13C6]-
fructose and [13C6]-glucose into the palmitate and glycerol moieties of TAG.  
During post-prandial continuous feeding, high-fructose drinks elicited a significantly higher 
plasma TAG (P < 0.005) and VLDL-TAG (P = 0.003) concentration than when low-fructose drinks 
were consumed. Lipoprotein kinetic analysis revealed the CM-TAG PR was in fact significantly 
lower for the high-fructose visit (P = 0.046), although this was accompanied by an almost 
significantly lower CM-TAG FCR (P = 0.073). No overall significant effect of fructose was 
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observed for the CM-TAG concentration. Kinetic modelling could not explain the greater VLDL-
TAG concentration in response to high-fructose drinks, as no significant differences in VLDL-
TAG PR or FCR were detected. However, the significantly higher TRL apoB48 (P = 0.039) and 
apoB100 (P = 0.013) concentrations during high-fructose feeding indicated a greater 
production and/or accumulation of CM and VLDL particles, respectively, in the post-prandial 
state. These effects on intestinal and hepatic TAG metabolism could most reasonably be 
explained by the significantly lower post-prandial insulin excursion when consuming high-
fructose drinks (P = 0.005), which most likely had several effects on lipid metabolism. Firstly, 
a less pronounced suppression of hepatic VLDL synthesis and secretion may have occurred. 
Secondly, a lower insulin-mediated suppression of the plasma NEFA concentration, which was 
significantly higher during continuous fructose feeding (P = 0.013). The observed effects on 
lipoprotein TAG kinetics suggested a lower induction of endothelial LPL activity by insulin as 
the most likely mechanism, leading to the reduction in catabolism of CM-TAG. It is also 
possible that the lack of difference in VLDL-TAG FCR between high- and low-fructose visits may 
have been due to competition of VLDL-TAG and CM-TAG for hydrolysis by LPL, where CM are 
considered the preferred substrate for LPL (Adiels et al. 2012). Taken together, these 
differential effects of an acute fructose load, versus an equivalent amount of glucose polymer 
(maltodextrin), provide a plausible explanation for the overall exacerbation of post-prandial 
plasma TAG levels seen here. A summary of these findings is presented in Figure 5.1.  
The present work provided the first ever measurements of fasted and post-prandial intestinal 
DNL in vivo, both of which were found to be quantitatively similar to hepatic DNL. There were 
no significant differences in DNL between high- and low-fructose visits, except for an almost 
significantly higher de novo palmitate (μmol/L) in CM-TAG in response to high-fructose drinks 
(P = 0.057). Intestinal and hepatic DNL made a minor contribution to CM-TAG and VLDL-TAG 
concentrations, respectively, in the healthy subjects studied. However, when data from both 
metabolic visits were pooled, highly significant correlations between intestinal and hepatic 
DNL were revealed, for both fasted (P < 0.0001) and post-prandial percentage DNL (P = 0.004), 
as well as fasted (P = 0.0002) and fed (P = 0.002) de novo palmitate concentrations. If a similar 
relationship between rates of hepatic and intestinal DNL occurs in subjects with insulin 
resistance, the intestine may therefore make a significant contribution to plasma TAG levels, 
as hepatic DNL is enhanced several-fold in these individuals (Schwarz et al. 2003, Lambert et 
al. 2014).       
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Figure 5.1. Proposed model for the acute effect of high-fructose drinks on post-prandial TAG 
metabolism in healthy normoinsulinaemic males. 
Consuming hourly high-fructose drinks for 11 h elicited a lower post-prandial glucose concentration 
and less insulin secretion in subjects (n = 5), in comparison to low-fructose drinks. This was concluded 
to have the following effects: 1) a reduced suppression of hepatic VLDL particle synthesis and 
secretion; 2) less suppression of plasma NEFA levels, possibly providing greater hepatic FA availability 
for VLDL synthesis; 3) lower activation of endothelial LPL and therefore a lower CM-TAG FCR. It is also 
possible that the catabolism of VLDL-TAG was inhibited by competition with CM for LPL hydrolysis, 
where CM are the preferred substrate. These combined effects may explain the significantly higher 
VLDL-TAG and significantly greater plasma TAG during steady-state feeding. Red arrows indicate 
differences relative to feeding of low-fructose drinks. Abbreviations: ApoB48, apolipoprotein B48; 
ApoB100, apolipoprotein B100; CM, chylomicron; FA, fatty acids; FCR, fractional catabolic rate; LPL, 
lipoprotein lipase; NEFA, non-esterified fatty acids; PR, production rate; TAG, 
triacylglycerol/triglyceride; VLDL, very low-density lipoprotein.      
 
Results from the in vitro study provide the first known evidence of a DNL capability in Caco-2 
cells, which are a widely-used intestinal cell line. Both fructose and glucose carbons were 
utilised as DNL substrates, with a dose-dependent increase in the amount of de novo 
palmitate in secreted and intracellular TAG for both sugars, although glucose appeared to the 
preferred DNL substrate when cells were treated with a mixture of fructose and glucose. 
Interestingly, a substantial proportion of the glycerol backbone for TAG synthesis was derived 
from fructose (range: 25.8 – 68.5 %) and glucose (range: 33.2 – 69.5 %). A similar utilisation of 
fructose for TAG-glycerol synthesis (38 %) has been reported previously in humans, for TAG 
recovered in the Sf 60 – 400 fraction, following consumption of a 0.75 g/kg BW oral fructose 
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load (Chong et al. 2007). However, in the latter study, no contribution from glucose was 
observed, perhaps due to intrahepatic storage of TAG. Whether the incorporation of fructose 
into the glycerol moiety of TAG may impact on the overall hyperTAG associated with fructose 
consumption requires further investigation. 
 
5.2 Limitations 
There are several limitations in the design of the current work that should be noted. With 
respect to the human study, the small sample size, in combination with the large inter-
individual variation between subjects, may have precluded the detection of significant effects 
for some of the metabolic parameters measured. Moreover, the acute study design may have 
compounded this, due to an insufficient period of exposure to the high- and low-fructose 
treatments. Although the subjects had anthropometric and fasted metabolites measured at 
each metabolic study visit, it is possible that alterations in their diet, physical activity levels 
and other lifestyle factors, during the four-week washout period, may have influenced their 
responses to the high- and low-fructose drinks. While four-day food diaries indicated there 
were no differences in the subjects’ diet immediately prior to each visit, this did not 
necessarily capture their true habitual diet, due to issues of under-reporting or changing the 
foods consumed during this period to appear more acceptable (Ortega et al. 2015). The doses 
of fructose (165 g/d), maltodextrin (176 g/d) and fat (135 g/d) administered to participants 
during metabolic study visits would typically be considered supraphysiological, and may only 
feasibly be consumed occasionally by a small percentage of the population. Only a single 
ultracentrifugation step was used to isolate lipoproteins residing in the Sf > 20 range, which 
includes CM and CMR of all sizes, as well as VLDL1 and VLDL2. Although endogenous (hepatic) 
and exogenous (intestinal) lipoproteins were effectively separated via immunoaffinity 
chromatography, it was not possible to discriminate TRL based on particle size.  
Considering the Caco-2 in vitro study, the differences in the TAG metabolism of this cell type 
in comparison to human enterocytes, as noted in section 4.2.1, limits the interpretation of 
these findings to an in vivo context. The length of time for which cells were grown (21 d) prior 
to experiments was deemed necessary to elicit maximal TAG synthesis and secretion (Chateau 
et al. 2005), although is much longer than the 5-6 day lifespan of enterocytes in vivo, during 
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which the intestinal epithelium is completely renewed (Vallejo et al. 2009). Therefore, the 
Caco-2 cells used for experiments may have exhibited a different metabolic phenotype to 
intestinal enterocytes not only due to their different origin (human adenocarcinoma), but also 
their advanced stage of cell growth and differentiation. For example, Caco-2 cells are known 
to secrete both apoB48- and apoB100-containing lipoproteins, and it is possible in the 
experiments conducted that the TAG kinetics of each may have behaved differently, as has 
been noted when comparing hamster and rat hepatocytes, which predominantly secrete TAG 
within apoB48- or apoB100-containing lipoproteins, respectively (Salter et al. 1998). 
Unfortunately, as these two lipoprotein types were not separated, it is not possible to 
determine whether this was the case. Also, in the Caco-2 cell model used, FFA were presented 
to cells in the form of taurocholate micelles, whereas in vivo the enterocytes of the intestinal 
lumen are also exposed to 2-MAG, providing an exogenous source of glycerol. It is therefore 
possible that the substantial formation of de novo glycerol from glucose and fructose may 
have been due to the lack of a glycerol source in the media for TAG synthesis. This may be 
particularly important as the G-3-P pathway of TAG synthesis predominates in Caco-2 cells, in 
contrast to enterocytes in vivo, which preferentially re-esterify 2-MAG. The kinetics of these 
two pathways may differ significantly, including in their response to the fructose and glucose 
treatment conditions used, meaning a great degree of caution should be taken when 
interpreting the results of the experiments described here in a human context.   
Due to time constraints, no gene expression data were obtained, which would have provided 
further mechanistic insight into the effects of fructose and glucose concentration on Caco-2 
TAG metabolism. It would have been very useful to observe the relative differences in the 
expression of genes for MTT, ACC, FAS and other proteins involved in FA synthesis and 
lipoprotein assembly.        
 
5.3 Future work 
While the current study provides the first reported measurements of the effect of fructose on 
post-prandial intestinal TAG metabolism, including fractional and absolute DNL, there are 
several ways in which this preliminary work could be expanded and developed. Firstly, the 
inclusion of a dietary intervention lasting for several days, weeks or months, as performed by 
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several groups (Stanhope et al. 2009, Egli et al. 2013, Taskinen et al. 2017), would allow the 
effect of chronic fructose consumption to be studied. Ideally, this would involve a greater 
number of subjects than in the present study, and also compare the effects of sucrose, glucose 
and fructose consumption, relative to a CCHO control diet, to determine the effects of each 
sugar type. In terms of the metabolic study protocol, it would be preferable to utilise solid 
meals, rather than liquid test meals, to more closely reflect the real life situation in free living 
individuals. However, changing the feeding regimen may not allow the attainment of a steady 
post-prandial TAG concentration. In the current study, 2H2O was administered to measure 
rates of intestinal and hepatic DNL. It would be desirable in future to utilise labelled [13C6]-
fructose, as done elsewhere (Chong et al. 2007, Egli et al. 2013, Theytaz et al. 2014), to 
determine its direct contribution to DNL. Also, tracing the appearance of ingested [13C6]-
fructose as [13C]-lactate, [13C]-glucose, [13C]-glycerol and/or 13CO2 would offer additional 
information on the relative importance of fructose disposal via different metabolic pathways, 
when consumed in combination with an oral fat load. Finally, the use of multiple 
ultracentrifugation steps to isolate TRL in the ranges Sf 20 – 60, Sf 60 – 400 and Sf > 400, would 
offer a greater insight into the effects of fructose on the TAG kinetics of specific lipoprotein 
subclasses, such as VLDL1 versus VLDL2. 
The in vitro intestinal model developed in the present work could also be employed in future 
studies. It would be interesting to compare the effects of equivalent concentrations of 
fructose and glucose with those of sucrose, to determine the impact of treating cells with 
equimolar amounts of these sugars as either free monosaccharides or bound disaccharide. 
Greater insight into the relative influence of fructose, and other sugars, on intestinal lipid 
metabolism, could be obtained by measuring the expression of key genes encoding proteins 
involved in lipid metabolism (e.g. ACC, FAS, SREBP-1c) and lipoprotein assembly (MTP, 
apoB48). It would be interesting to obtain time course information by varying the treatment 
period of cells, to ascertain whether alterations in the metabolic handling of FA and/or sugars 
changes according to the length of exposure. Importantly, any future studies should measure 
the rates of fructose and glucose uptake by cells, by analysis of apical and basolateral media, 
in order to account for potential differences in the rate of transport into cells.        
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5.4 Conclusion 
The present study demonstrated intestinal DNL for the first time, both in vivo and in Caco-2 
cells. In the healthy males studied, DNL made only a minor contribution to post-prandial 
lipaemia. However, the strong correlations discovered between intestinal and hepatic DNL 
suggest that intestinal lipogenesis may be quantitatively more important in subjects with 
obesity and/or insulin resistance, where hepatic DNL is known to be enhanced (Schwarz et al. 
2003, Lambert et al. 2014). Acute consumption of a high-fructose load exacerbated post-
prandial plasma TAG levels, which was due to differences in TAG metabolism resulting from a 
lower insulin secretion. Although in a small number of subjects, the present findings add to 
the existing evidence demonstrating a specific role for fructose in elevating post-prandial 
plasma TAG, which is a well-established risk factor for CVD (Patsch et al. 1992, Eberly et al. 
2003). The current work therefore supports dietary guidelines for the UK and US, which 
recommend the intake of free sugars be restricted to no more than 5 % and 10 % of total 
dietary calories, respectively, for the prevention of cardiometabolic disease (Prentice 2015, 
USDA 2015).       
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Appendices 
Appendix A – Individual data for human study 
Figure 5.2. Subject FRU10 data excluded from statistical analysis (1) 
 
 199 
Figure 5.3. Subject FRU10 data excluded from statistical analysis (2) 
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Figure 5.4. Individual plasma TAG responses to high- and low-fructose drinks.  
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Figure 5.5. Individual TRL-TAG responses to high- and low-fructose drinks.  
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Figure 5.6. Individual CM-TAG responses to high- and low-fructose drinks.  
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Figure 5.7. Individual VLDL-TAG responses to high- and low-fructose drinks.  
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Figure 5.8. Individual TRL apoB48 responses to high- and low-fructose drinks.  
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Figure 5.9.  Individual TRL apoB100 responses to high- and low-fructose drinks.  
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Figure 5.10. Correlation of intestinal and hepatic DNL in the fasted and post-prandial states including 
subject FRU10. 
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Figure 5.11. Individual plasma glucose responses to high- and low-fructose drinks. 
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Figure 5.12. Individual serum insulin responses to high- and low-fructose drinks. 
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Appendix B – Accepted abstracts 
Abstract accepted for poster presentation at 54th Annual Meeting of the European 
Association for the Study of Diabetes (1-5 October, Berlin) 
 
Both fructose and glucose contribute substantially to intestinal triglyceride synthesis in vitro  
S. Steenson1, K.G. Jackson2, A.M. Umpleby1, F. Shojaee-Moradie1, N. Jackson1, J.A. Lovegrove2, 
B.A. Fielding1; 1Department of Nutritional Sciences, University of Surrey, Guildford, 2Department of 
Food & Nutritional Sciences, University of Reading, Reading, UK.  
Background and aims: Fructose consumption has been associated with postprandial 
hypertriglyceridaemia. The cellular metabolism of fructose is an unregulated process, potentially 
providing excess three-carbon precursors for several metabolic pathways, including the formation of 
glycerol (glyceroneogenesis), which may be utilised for triglyceride (TG) synthesis. While the effects 
of fructose on hepatic TG metabolism have been widely reported, recent evidence suggests that the 
small intestine may in fact be the major site of fructose metabolism. The present study used Caco-2 
cells, a well-characterised intestinal cell line, to determine the concentration dependent effects of 
fructose, and glucose, on TG-glycerol synthesis. Materials and methods: Caco-2 cells (passage 49-
53) were grown for 21 days on Corning Transwell® supports, ensuring maximal differentiation and 
TG synthesis capacity. Cells were treated for 96 h with carbohydrate-free media containing either 5, 
25 or 50 mmol/l fructose or glucose (5, 25 or 50 Fru/Glu), or an equimolar mixture of 12.5 mmol/l 
fructose and 12.5 mmol/l glucose (“Mix”). In addition, a 0.5 mmol/l mixture of fatty acids was added, 
with a composition representing the UK diet. Stable isotope tracers were also added, accounting for 
20% of the total glucose/fructose concentration in each treatment, to measure the proportion of TG-
glycerol carbons derived from either fructose (13C6-fructose) or glucose (13C6-glucose). Following 
treatment, TG was extracted from the cells (intracellular) and media (secreted), hydrolysed to obtain 
the glycerol moiety, and the 13C-enrichment measured via gas chromatography-mass spectrometry. 
Results: A substantial proportion of TG-glycerol was derived from both fructose (range 25-69%) and 
glucose (33-70%) carbons, across all treatment types. Intracellular TG (see figure) contained 
significantly higher de novo TG-glycerol (%) after treatment with 25Fru, 50Fru, 25Glu and 50Glu 
versus either 5Fru or 5Glu, respectively (all p ≤ 0.002). The same pattern was observed for secreted 
TG-glycerol (all p ≤ 0.003). For the “Mix” treatments containing either fructose (Mix [F]) or glucose 
(Mix [G]) isotope tracer, Mix [G] yielded a higher percent intracellular 13C-glycerol than for Mix [F] 
(p < 0.001). Conclusion: The present study further highlights the potential importance of the small 
intestine in fructose metabolism. Glucose appears to be the preferred substrate for TG-glycerol 
synthesis within a sugar mixture. However, fructose is also highly utilised by intestinal enterocytes, 
both for TG directed toward lipoprotein formation and secretion, as well as for storage within 
intracellular lipid droplets. Whether a similar level of TG-glycerol may be derived from fructose in 
vivo, and its possible implications for post-prandial hypertriglyceridaemia, warrant further study in 
human subjects.  
Supported by: BBSRC Food Security DTP  
Disclosure: S. Steenson: None. 
 
(Continues overleaf) 
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